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ABSTRACT

Author: Carreiro, Alicia, L. PhD
Institution: Purdue University
Degree Received: May 2018
Title: Regulation of Intestinal Lipid Storage and Mobilization
Committee Chair: Kimberly K. Buhman
Dietary fat is an energy dense nutrient that also provides essential fatty acids and aids in
the absorption of fat soluble vitamins. The process of dietary fat absorption regulates the amount
and rate at which dietary fat enters circulation, and can therefore contribute to diseases such as
obesity, diabetes and cardiovascular disease when it becomes dysregulated. Triacylglycerol
(TAG), the major form of dietary fat, is efficiently absorbed (>95%) even when high amounts of
fat are consumed. The digestive products of dietary fat are taken up by enterocytes, the
absorptive cells of the small intestine, and rapidly re-synthesized into TAG. This re-synthesized
TAG can either be packed onto chylomicrons and secreted into circulation for delivery to
peripheral tissues, or temporarily stored within cytoplasmic lipid droplets (CLDs). The objective
of this dissertation is to investigate the regulation of enterocyte lipid stores and their contribution
to dietary fat absorption.
First, we determined differences in enterocyte CLD-associated proteins in genetic models
with alterations in intestinal TAG synthesis. Acyl-CoA: diacylglycerol acyltransferase 1 (Dgat1)
and Dgat2 catalyze the final, committed step of TAG synthesis. Mouse models with intestinespecific overexpression of Dgat1 (Dgat1Int) or Dgat2 (Dgat2Int), or a whole body Dgat1
deficiency (Dgat1-/-), have previously been shown to exhibit alterations in intestinal TAG storage
and secretion. We isolated CLDs from enterocytes of these models after an acute dietary fat
challenge and identified proteins present in the enterocyte CLD-enriched fraction using LCMS/MS. We identified a total of 158 proteins, 53 of which were common to all four models
(Dgat1Int, WT, Dgat2Int, and Dgat1-/- mice). In addition, 13% of the proteins identified are
associated with lipid metabolism, and several of these lipid metabolism related proteins were
differentially present among the models. This analysis has identified novel potential regulators of
intestinal lipid storage and mobilization.

xvii
We also assessed differences in enterocyte CLD morphology and protein composition in
models resistant compared to susceptible to high fat diet-induced obesity (DIO). Whole body
Dgat1-/- mice exhibit alterations in intestinal lipid metabolism that are thought to contribute to
their resistance to DIO and insulin resistance. In the current study we found that in response to
chronic high fat feeding Dgat1-/- enterocytes contain a greater number of larger sized CLDs
compared to enterocytes from WT, diet-induced obese mice. In addition, we identified a total of
125 proteins in the enterocyte CLD-enriched fractions from these models, 52 of which were only
identified in the Dgat1-/- model. Furthermore, a greater number of proteins associated with the
mitochondria and fatty acid oxidation were identified in the enterocyte CLD fraction from
Dgat1-/- mice, and this was accompanied by more alterations in enterocyte mitochondrial
morphology in this model. Overall, this study increases knowledge about alterations in
enterocyte CLD metabolism in Dgat1-/- mice that may be contributing to their beneficial DIOresistant phenotype.
Finally, we investigated the effects of oral nutrient exposure and ingestion on intestinal
lipid stores in both humans and mice. Glucose ingestion was shown to mobilize lipid stored in
the intestine from a previous high fat meal in humans. We observed a decrease in enterocyte
CLD number and a greater number of smaller sized CLDs in response to glucose compared to
water ingestion. In addition, we identified a total of 2919 proteins present within human
duodenal biopsy tissues in response to this dietary challenge, 134 of which were differentially
present in response to glucose compared to water ingestion. Consistent with these human studies,
we found that glucose compared to water ingestion (but not oral exposure) also decreases
intestinal lipid stores in mice. Previous studies in humans have shown that sham feeding of fat
and oral glucose ingestion induce a peak in plasma CM-TAG levels, however no detectable
differences in plasma TAG levels were observed in mice in response to an oral fatty acid or
glucose exposure, or to glucose ingestion in the present studies. This work confirms and expands
upon previous work in humans by identifying the specific enterocyte lipid pools mobilized by
glucose ingestion, as well as identifying glucose regulated proteins in the small intestine that
have the potential to contribute to the observed glucose stimulated lipid mobilization.
Taken together, this work identifies novel potential regulators of intestinal lipid storage
and mobilization. Further investigation into their contributions to dietary fat absorption will help

xviii
to provide novel dietary and therapeutic strategies for the management of obesity,
hypertriglyceridemia, and related metabolic diseases.
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CHAPTER 1.

1.1

INTRODUCTION

Dietary fat and its role in health and disease

1.1.1 Structure and composition of dietary fat
Dietary fat is an energy dense nutrient that provides essential fatty acids and is necessary
for efficient absorption of fat soluble vitamins. Approximately 35% of total energy intake comes
from dietary fat in a typical Western diet [1]. Fat in the diet comes from both plant (mainly in the
form of oils) and animal (meat, poultry, fish, and dairy products) sources, and is mainly in the
form of triacylglycerol (TAG). TAG consists of a glycerol backbone to which three fatty acids
(FAs) are esterified. The FAs found within dietary TAG can be classified by chain length as
either short (3-7 C), medium (8-13 C), long (14-20 C), or very long (> 20 C) chain FAs [2]. In
addition, FAs are also classified by their degree of saturation. Saturated FAs do not contain any
double bonds within the carbon chain, monounsaturated FAs contain a single double bond, and
polyunsaturated FAs contain two or more double bonds. Another common method of classifying
FAs is the omega classification, which is based on the location of the first double bond from the
methyl end of the compound [3]. Omega-3 and omega-6 FAs are essential FAs, meaning they
cannot be synthesized in the body and therefore must be obtained from the diet. The diverse FA
species that make up dietary fat can differentially impact its absorption, metabolism, and
contribution to both health and disease.

Portions of this work were published or submitted for publication in:
A.L. Carreiro, K. K. Buhman. Absorption of dietary fat and its metabolism in enterocytes. Submitted
to: Molecular Nutrition: Fats, Elsevier (2018).
C. Xiao, P. Stahel, A.L. Carreiro, K.K. Buhman, G.F. Lewis, Recent Advances in Triacylglycerol
Mobilization by the Gut, Trends Endocrinol Metab, (2018).
T. D'Aquila, Y.H. Hung, A. Carreiro, K.K. Buhman, Recent discoveries on absorption of dietary fat:
Presence, synthesis, and metabolism of cytoplasmic lipid droplets within enterocytes, Biochimica et
biophysica acta, 1861 (2016) 730-747.
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1.1.2 Dietary fat and health
Although dietary fat is an important energy source at all ages, the ability to absorb high
amounts of fat from the diet is particularly important for newborns due to the high fat content in
breast milk or infant formula [4]. In addition to being an energy dense nutrient, dietary fat
provides essential FAs, linoleic and α-linolenic acid [5]. Furthermore, dietary fat allows for
efficient absorption of the fat soluble vitamins A, D, E and K. Like dietary fat, these vitamins are
incorporated into mixed micelles prior to uptake by enterocytes, as well as packaged into
chylomicrons along with TAG for systemic delivery [6].
For years the Dietary Guidelines for Americans, American Heart Association, and
Academy of Nutrition and Dietetics all recommended limiting total fat intake as a means to
decrease cardiovascular disease risk [1]. However, increasing evidence has been accruing over
the last several decades that different types of fat differentially impact health. As a result, the
current Dietary Guidelines no longer suggest limiting total dietary fat intake. Instead it is
recommended to limit saturated fat intake to less than 10% of total energy intake and replace
excess saturated fat in the diet with mono- and polyunsaturated fats [7], which are thought to
have more beneficial impacts on health. In addition, the American Heart Association
recommends that individuals with elevated low-density lipoprotein (LDL) cholesterol levels
further decrease their saturated fat intake to 5-6% of total energy intake [8].
1.1.3 Dietary fat and disease
Since dietary fat is an energy dense food that is also a major contributor to postprandial
plasma TAG levels, it has the potential to contribute to obesity and related metabolic diseases.
High intake of energy dense and nutrient poor but highly palatable foods, which are often high in
saturated and trans fats, is of particular concern. Chronic nutrient overconsumption can lead to
ectopic fat deposition, which can contribute to conditions including fatty liver, insulin resistance
and type 2 diabetes [9-11]. Insulin sensitivity in particular has been shown to be impacted by
dietary fat composition. Saturated fat intake is positively associated with hyperinsulinemia, and
unsaturated, in particular polyunsaturated, fat intake is associated with improved insulin
sensitivity [12]. Furthermore, dietary fat can both acutely and chronically impact fasting and
postprandial plasma TAG levels, which are independent risk factors for cardiovascular disease
when elevated [13, 14].
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Different types of fat have also been shown to differentially impact cardiovascular
disease risk. Reducing saturated fat intake has long been recommended as a means to reduce
LDL cholesterol levels, however it is important to take into consideration the health effects of
replacing saturated fat with other types of fat. In terms of decreasing cardiovascular disease risk,
replacing saturated fat with polyunsaturated fat has been shown to have the most favorable
effect. Some of this may be due to the ability of polyunsaturated FAs to exert beneficial effects
on multiple aspects of lipid metabolism, including decreasing TAG synthesis, increasing fatty
acid oxidation, decreasing de novo lipogenesis, and potentially also increasing apolipoprotein B
degradation [15, 16]. Omega-3 polyunsaturated FAs in particular are used at pharmacological
doses to decrease both fasting and postprandial plasma TAG levels [15, 17]. Replacing saturated
FAs with monounsaturated FAs has been suggested to have a slight beneficial impact on
cardiovascular disease risk, and may have beneficial effects on plasma TAG levels due to their
ability to increase the clearance rate of TAG-rich lipoproteins from circulation [16].
Furthermore, it is also recommended to limit the consumption of trans FAs to 1% of total energy
intake due to their association with an increase in LDL-cholesterol and a decrease in HDL
cholesterol levels, and therefore an increased cardiovascular disease risk [8, 18, 19]. However,
this recommendation is already being met in most countries due to reductions in the use of
partially hydrogenated vegetable oils, and is no longer a major public health concern [20].

1.2

Metabolism of dietary fat within the small intestine
The process of dietary fat absorption is very efficient, with over 95% of fat consumed

being absorbed under normal conditions. The absorption of dietary fat encompasses uptake by,
processing within, and secretion from enterocytes, the absorptive cells of the small intestine. This
process can occur in all three regions of the intestine; however the majority of dietary fat
absorption occurs within the jejunum. The digestive products of dietary fat are taken up by
enterocytes and either packed onto chylomicrons (CMs) for secretion into circulation or stored
within enterocyte cytoplasmic lipid droplets (CLDs) (Figures 1.1 and 1.2).
1.2.1 Systems for investigating dietary fat absorption
Human, animal, and cell systems have been used for investigating the process of dietary
fat absorption. Animal and cell enterocyte models have some important characteristics that differ
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from what is observed in human tissue and may affect CM and/or CLD metabolism and their
contributions to the process of dietary fat absorption. These include established differences in the
mechanism for TAG synthesis, proteins associated with secreted lipoproteins and the size of
lipoproteins secreted. For example, mice are able to synthesize and secrete apoB48-containing
lipoproteins from both the intestine and the liver [21]. This differs from humans, where apoB48
is exclusively synthesized in the small intestine [21]. In addition, mice express a different
complement of TAG synthesis enzymes in the small intestine [22-24]. Caco-2 cells, which are
derived from a human colorectal carcinoma, are a commonly used in vitro model for studying
intestinal lipid metabolism. However these cells exhibit little to no acyl-CoA: monoacylglycerol
acyltransferase (MGAT) activity (see section 1.2.4), which is involved in the predominant TAG
synthesis pathway in human enterocytes in response to dietary fat consumption [25, 26]. In
addition, Caco-2 cells secrete a large proportion of lipid in lipoprotein particles that are smaller
than the CMs secreted from human small intestine and they contain additional lipoproteins [25,
27]. These details are important to note when considering the application of the presented results
to human health and medicine.
1.2.2 Digestion of dietary fat
Although the majority of dietary TAG hydrolysis occurs within the small intestine,
lingual and gastric lipases can also contribute to TAG hydrolysis earlier on during the digestion
process. The relative contributions of these lipases differ at different life stages, with gastric
lipase in particular playing a more crucial role early in life [28]. Dietary fat enters the duodenum
as an emulsion of small lipid globules, which signals the secretion of bile and pancreatic juices.
Pancreatic lipase then hydrolyzes dietary TAG at the sn-1 and sn-3 positions, yielding 2monoacylglycerol (MAG) and free fatty acids (FFAs) [29]. These digestive products are
emulsified by bile acids and incorporated into mixed micelles, which allows them to cross the
unstirred water layer and be taken up by enterocytes at the brush border membrane (apical
surface of enterocytes).
1.2.3 Long chain fatty acid (LCFA) and 2-monoacylglycerol (MAG) uptake and transport in
enterocytes
The unstirred water layer has an acidic pH that initiates the dissociation of mixed
micelles and protonation of FFAs, which, along with MAG, are taken up by enterocytes
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primarily via passive diffusion [30, 31]. However, there is also evidence supporting transportermediated uptake of these digestive products, particularly when present at lower concentrations
(reviewed in [31-33]). Potential FFA transporters include fatty acid binding protein plasma
membrane (FABPpm), fatty acid transport protein 4 (FATP4), and cluster of differentiation 36
(CD36) (reviewed in [32, 33]).
Fatty acid binding proteins (FABPs) transport LCFAs and MAG within enterocytes. Both
FABP1 and FABP2 are expressed in the small intestine, localize to the cytosol, and are increased
in response to high fat feeding [34]. In addition to binding LCFAs, FABP1 can also bind MAG,
lysophospholipids, and prostaglandins [34]. Studies in Fabp1- and Fabp2-deficient mouse
models provide evidence that FABP2 is involved in LCFA uptake and incorporation into TAG,
while FABP1 is thought to direct LCFAs towards oxidation and also bind and direct MAG
toward TAG synthesis (reviewed in [34]). In addition, FABP1 plays a role in CM trafficking
within enterocytes [34]. Human polymorphisms in both FABP1 and FABP2 have been identified
and are associated with elevated plasma TAG levels. The FABP2 polymorphism is also
associated with higher rates of insulin resistance and diabetes (reviewed in [34]). These
observations suggest that FABP1 and FABP2 play important but distinct roles in regulating
intestinal LCFA and MAG trafficking.
For LCFAs to be utilized in enterocyte cellular processes, they are activated to FA-CoAs
by acyl-CoA synthetase activity. Both acyl-CoA synthetase 3 (ACSL3) and ACSL5 are present
in the small intestine and localize to the ER and CLDs in enterocytes [35, 36]. This localization
supports their hypothesized roles of directing FA-CoAs toward TAG and phospholipid (PL)
synthesis (reviewed in [37]). Acsl5-deficient mice retain only 20% of total jejunal ACS activity
and exhibit a decreased rate of intestinal TAG secretion [36], supporting the hypothesis that
Acsl5 is involved in intestinal TAG synthesis.
1.2.4 Intestinal triacylglycerol (TAG) synthesis
In response to a meal, the digestive products of TAG are re-esterified at the ER
membrane and then either incorporated into CMs and secreted or into CLDs and stored (Figure
1.1). TAG is synthesized through one of two pathways in the small intestine: the MGAT
pathway or the glycerol-3-phosphate (G3P) pathway [38, 39]. The MGAT pathway accounts for
approximately 70 - 80% of newly synthesized TAG within enterocytes in the postprandial state
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[40, 41]. The G3P pathway is also present in the small intestine and although it has long been
thought to be only a minor contributor to TAG synthesis in the postprandial state [42], emerging
evidence suggests it may play a more significant role [43].
1.2.4.1 Acyl-CoA: monoacylglycerol acyltransferase (MGAT) pathway
Multiple MGAT enzymes have been identified and are differentially expressed in tissues
and species. The first step of the MGAT pathway for TAG synthesis is the acylation of MAG by
fatty acyl-CoA to produce DAG, which is catalyzed by MGAT activity (reviewed in [39]).
MGAT activity is highest in the proximal small intestine and progressively decreases in distal
regions [44]. Three MGAT isoforms have been identified, but only MGAT2 and MGAT3 are
present in the small intestine [38]. MGAT2 is abundant in the intestine of both mice and humans,
with both mRNA and protein levels reflecting MGAT activity along the length of the small
intestine [44]. MGAT3, on the other hand, is expressed in humans, but not mice, and is highest in
the ileum [23].
The role of Mgat2 in dietary fat absorption has been investigated in mouse models.
Mgat2 protein and mRNA levels increase in response to a high fat diet, suggesting this enzyme
contributes to the increase in MGAT activity that occurs during dietary fat absorption [44]. Two
different Mogat2-deficient mouse models were generated to understand the function of Mgat2 in
intestinal TAG synthesis and dietary fat absorption [45, 46]. Although these mice still synthesize
TAG in enterocytes and secrete CM-sized lipoproteins, they exhibit a reduced postprandial
triglyceridemic response and a decreased TAG secretion rate in response to an oral fat load
compared to wild-type mice [45, 46]. In addition, they remain efficient at absorbing dietary fat
when fed a high fat diet. These results suggest that although other enzymes must be present to
catalyze this activity, the fate of TAG synthesized in enterocytes may be different in Mogat2deficient mice than wild-type mice. In fact, while less TAG is secreted in the Mogat2-deficient
mouse models, more TAG is found in CLDs of jejunal enterocytes in Mogat2-deficient mice fed
a high fat diet than in wild-type mice [45]. Similar effects have been observed in intestinespecific Mogat2-deficient mice [47] and in mice treated with an MGAT2 inhibitor [48]. In
addition, restoring Mogat2 expression specifically in the intestine of Mogat2-deficient mice
normalized the TAG absorption rate [49]. Together these results suggest that MGAT2 is not
critical for absorption, but important for balancing intestinal TAG storage and secretion.
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1.2.4.2 Glycerol-3-phosphate (G3P) pathway
The first step in the G3P pathway is the acylation of G3P, which is catalyzed by glycerol3-phosphate acyltransferase (GPAT) enzymes and yields lysophosphatidic acid [50]. In the small
intestine, two isoforms of GPAT are expressed: GPAT3 (high expression, jejunum) and GPAT4
(moderate expression) [43, 50, 51]. Increased Gpat activity was observed in high fat fed obese
compared to lean Zucker rats [52], suggesting it may play a role in mediating intestinal TAG
metabolism in response to chronic high fat feeding. In addition, Gpat3-deficient mice have
decreased TAG secretion and increased TAG storage in enterocytes following a dietary fat
challenge [43]. The lysophophatidic acid formed during this first reaction is then acylated by
acylglycerolphosphate acyltransferase (AGPAT) enzymes, also known as lysophosphatidic acid
acyltransferases (LPAATs), to form phosphatidic acid. In the small intestine, AGPAT2,
AGPAT4 or AGPAT8 may contribute to the formation of phosphatidic acid. Lipin enzymes, or
phosphatidic acid phosphatases (PAPs), then remove the phosphate group to form diacylglycerol
(DAG). Lipin-3 mRNA is present in the small intestine of mice and humans [53]. The presence
of players in the G3P pathway and results found in Gpat3-deficienct mice highlight that this
pathway may play a more important role in intestinal TAG metabolism than previously
recognized.
1.2.4.3 Final, committed step of both pathways, acyl-CoA:diacylglycerol acyltransferase
(DGAT) activity
Two proteins with DGAT activity have been identified and investigated in intestinal lipid
metabolism. DGAT enzymes catalyze the acylation of DAG, resulting in the formation of TAG
[38, 39]. This reaction is the final, committed step of TAG synthesis, and is the point at which
the MGAT and the G3P pathways converge. Evidence of DGAT activity on both the luminal
(latent activity) and cytosolic (overt activity) sides of the ER in rat liver microsomes suggests
that distinct pools of TAG destined for storage and secretion may be present in lipoproteinproducing cells [54]. Total DGAT activity is highest in the proximal intestine and decreases
distally along the length of the intestine [55]. The two known DGAT enzymes, DGAT1 and
DGAT2, are both integral ER membrane proteins and are both present in the small intestine.
DGAT2 has also been shown to localize to CLDs and associate with mitochondria in other cell
types [56, 57]. Although both of these enzymes catalyze the same reaction, they are members of
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two different gene families, and differ from one another in terms of structure, expression pattern,
and biochemical properties. This suggests that DGAT1 and DGAT2 may play unique roles in
synthesizing TAG for storage versus secretion in enterocytes.
1.2.4.3.1 Acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1)
DGAT1 regulates intestinal TAG metabolism in response to dietary fat. DGAT1 is
ubiquitously expressed with highest levels present in the small intestine compared to other
mouse and human tissues [22, 58, 59]. Whole body Dgat1-deficient mice are resistant to dietinduced obesity and have significantly less TAG storage in all tissues except the intestine, where
TAG storage is significantly higher than in wild-type mice [60, 61]. However, Dgat1-deficient
mice do not have fat malabsorption, as indicated by similar fecal fat compared to wild-type mice.
TAG levels in CLDs in the duodenum and jejunum of Dgat1-deficient mice are high in response
to high fat feeding compared to wild-type mice, but disappear after an overnight fast in both
models [61]. Altered TAG storage likely contributes to the reduced TAG secretion rate and
diminished postprandial triglyceridemic response in Dgat1-deficient mice. These results
highlight how altering the mechanisms of TAG synthesis can influence the dynamics of TAG
storage in CLDs and secretion on CMs from enterocytes in response to dietary fat.
To investigate DGAT1’s effects on intestinal TAG metabolism in relation to whole body
physiology, mice expressing Dgat1 only in the intestine were generated [62]. Expression of
Dgat1 only in the intestine of Dgat1-deficient mice reduces enterocyte TAG storage in CLDs,
and restores the postprandial triglyceridemic response and TAG secretion rate to similar levels
found in wild-type mice. In addition, it restores susceptibility to diet-induced obesity and hepatic
steatosis, despite Dgat1-deficiency in adipose tissue and liver. These results show that DGAT1’s
role in regulating TAG storage and secretion in the intestine impacts whole body TAG
metabolism and energy homeostasis.
Similar to Dgat1-deficient mice, DGAT1 inhibitors have beneficial effects on blood TAG
levels in rodents and humans [63]. In humans, however, the blunted postprandial triglyceridemia
that results from most of these inhibitors is also accompanied by severe gastrointestinal side
effects. It has been suggested that these side effects may be target specific since a DGAT1 loss of
function mutation in humans is associated with congenital diarrheal disorders [64]. Recently,
however, the DGAT1 inhibitor pradigistat has been shown to effectively reduce plasma TAG
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concentrations in both overweight/obese individuals and patients with familial chylomicronemia
syndrome, and has been well tolerated [65, 66]. It’s unclear why this inhibitor does not result in
severe gastrointestinal side effects, but it suggests that DGAT1 inhibitors may still have some
promise in humans for treatment of obesity and related metabolic diseases.
1.2.4.3.2 Acyl-CoA:diacylglycerol acyltransferase 2 (DGAT2)
Residual TAG synthesis in Dgat1-deficient mice led to the cloning of a second enzyme
that also catalyzes the final, committed step of TAG synthesis, DGAT2 [22]. DGAT2 is
expressed ubiquitously, with highest expression in liver and adipose tissue of both humans and
mice [22, 59]. This enzyme is also present in the small intestine of mice and likely contributes to
the maintained efficiency of dietary fat absorption in Dgat1-deficient mice. However, whole
body Dgat2-deficient mice are severely lipopenic and do not survive for more than twenty four
hours [67], which limits interpretation of DGAT2’s function in intestinal lipid metabolism from
this model. Whether or not DGAT2 is present in human intestine is less clear. Gastrointestinal
side effects in humans treated with DGAT1 inhibitors or with a genetic mutation have suggested
that DGAT2 may not be able to compensate for reduced DGAT1 activity in humans; however,
whether or not the gastrointestinal problems are due to dietary fat malabsorption are unclear.
The presence of DGAT2 in mouse intestine suggests that it may play an important role in
synthesizing TAG for secretion on CMs. When mice are fed a high fat diet, Dgat2 mRNA levels
increase in the small intestine [68]. In addition, intestine-specific Dgat2 overexpression in mice
increases the intestinal TAG secretion rate without altering enterocyte CLD storage [69].
Interestingly, intestine-specific Dgat2 overexpression in Dgat1-deficient mice did not restore
TAG secretion or reduce TAG storage in CLDs [62], suggesting that these two enzymes have
distinct, non-redundant functions. Together these results highlight that DGAT2 plays a role in
directing TAG towards secretion in mouse enterocytes in response to dietary fat.
Although DGAT2 was initially identified as an integral ER membrane protein, it has also
been shown to localize to CLDs of several cell types [57, 67, 70]. It has been observed to colocalize with an established CLD-associated protein, perilipin 2 (Plin2, also known as adipocyte
related protein (ADRP) and adipophilin) [56]. DGAT2’s localization to CLDs in response to
increased substrate for TAG synthesis suggests it supports TAG synthesis for CLD expansion
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[71, 72]. Although DGAT2 localization to enterocyte CLDs has not been observed, it is possible
that it plays a similar role in CLD expansion in this cell type.

1.3

Chylomicron (CM) synthesis and secretion
A major fate of re-synthesized TAG in enterocytes is secretion within CMs, the major

lipoprotein secreted from the small intestine in response to dietary fat consumption. These TAGrich lipoproteins consist of a neutral lipid core containing TAG and cholesterol esters (CEs)
surrounded by a phospholipid (PL) monolayer. Pre-CMs are synthesized in the ER lumen
through a two-step process (reviewed in [73, 74], see Figures 1.2 C and 1.3). First, neutral lipids
are packed onto apolipoprotein B48 (APOB48) by microsomal triglyceride transfer protein
(MTP) as APOB48 is co-translationally translocated into the ER lumen, forming primordial CMs.
Next, primordial CMs are expanded via fusion with lipid rich apoB-free particles in the ER
lumen through an unknown mechanism involving MTP, forming pre-CMs.
Pre-CMs are transported from the ER to the Golgi within pre-chylomicron transport
vesicles (PCTVs) (reviewed in [75]) (see Figure 1.3). PCTV formation is ATP dependent and
thought to be the rate limiting step of CM secretion. Budding of PCTVs from the ER is mediated
by a protein complex including VAMP7, CD36, APOB48, and FABP1. FABP1 is normally
present within a cytosolic protein complex containing SAR1B. The phosphorylation of SAR1B
by PKCζ results in dissociation of this complex, allowing FABP1 to bind to the ER and initiate
PCTV budding. SEC24C also associates with the PCTV prior to its detachment from the ER and
targets it to the Golgi. PCTV fusion with the Golgi is mediated by vSNAREs (VAMP7) and
tSNAREs (rbet1, syntaxin5, and vti1a). Within the Golgi (see Figure 1.2 D), pre-CMs undergo
further processing, including the addition of ApoAI and glycosylation of APOB48. The resulting
mature CMs, which contain APOB48, APOC-II, APOC-III, APOA-I, APOA-IV, and APOE [76],
are transported to the basolateral side of the enterocyte within Golgi-derived secretory vesicles
(see Figure 1.2 E), where they are exocytosed into the lamina propria and then reverse
exocytosed into the lymphatic system. Lacteal contraction also plays a role in the drainage of
lipid from enterocytes into the lymph [77], and ultimately CMs enter the circulation via the
thoracic duct [74].

11
Key proteins that regulate CM synthesis and secretion include MTP, APOB, and SAR1B.
The importance of MTP in dietary fat absorption is exemplified by the embryonic lethality of
whole body Mttp deficiency in mice, which is likely due to the inability of fat to be efficiently
transferred to the developing embryo [78]. Furthermore, a conditional intestine-specific Mttp
deletion in mice results in accumulation of TAG and cholesterol within enterocyte CLDs and
significant decreases in TAG and cholesterol absorption [79, 80]. This phenotype is similar to
that observed in humans with defective MTP (discussed in section 1.6.1.1). Whole body ApoBdeficiency is also embryonically lethal in mice, likely due to the need for ApoB in the yolk sac to
mediate lipid transfer from mother to fetus [81]. In addition, intestine-specific ApoB-deficient
mice cannot synthesize CMs and exhibit severe fat malabsorption and failure to thrive, along
with massive lipid accumulation within enterocyte CLDs [82]. This is consistent with the clinical
phenotype resulting from a lack of functional apoB (discussed in section 1.6.1.1). Zebrafish with
a Sar1b deficiency present with a phenotype similar to that of patients with Anderson disease
(discussed in section 1.6.1.1), including accumulation of lipid in enterocyte CLDs and defective
lipid secretion within CMs [83]. Furthermore, mice overexpressing Sar1b exhibit increased TAG
secretion within CMs and are more susceptible to obesity [84]. Together these models highlight
the important functional roles of these proteins in enterocytes and the process of dietary fat
absorption.
1.3.1 Proteins that regulate chylomicron (CM) synthesis and secretion
CM-associated apolipoproteins may affect CM secretion. ApoA-IV associates with and is
secreted on CMs, and has been shown to regulate CM metabolism as well as reverse cholesterol
transport, blood glucose and insulin levels, and satiety (reviewed in [85]). Recently, ApoA-IV
has been shown to localize to CLDs in several enterocyte models [35]. However, whether ApoAIV plays a functional role at the CLD surface is still unknown. ApoA-V is an apolipoprotein
present in the liver, and although it is not known to associate with CMs, it is present in bile and
its biliary secretion increases in response to an acute fat challenge in rats [86]. In addition, ApoAV-deficient mice exhibit an increased rate of intestinal TAG secretion into the lymph and
decreased intestinal TAG storage in response to a constant lipid infusion [87], suggesting this
protein plays a role in regulating intestinal lipid secretion. A third apolipoprotein, ApoC-III,
associates with CMs (and very low-density lipoprotein (VLDL)) and inhibits lipoprotein
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(intestinal and hepatic) clearance from the circulation. It has been thought that ApoC-III
modulates lipoprotein clearance through lipoprotein lipase (LPL) inhibition; however, treatment
with an antisense inhibitor of APOC3 messenger RNA (Volanesorsen, ISIS 304801) reduced CM
TAG and plasma ApoB48 in patients with familial chylomicronemia syndrome who carry
null LPL mutations [88], suggesting an LPL-independent pathway. Interestingly, ApoC-III
overexpression in mice results in a decreased rate of lipid transport in the lymph, accumulation
of lipid species in the intestinal lumen and decreased TAG but increased MAG and FA content in
the intestinal mucosa [89]. These results suggest that ApoC-III impacts CM synthesis and
secretion by regulating lipid uptake and the re-synthesis of TAG within enterocytes. The
potential role of ApoC-III in modulating CM synthesis in humans has not been examined and
cannot be ruled out. Taken together, apolipoproteins impact lipid mobilization from the small
intestine through diverse mechanisms.
Other proteins recently shown to affect CM secretion include carboxylesterase 1 (CES1)
and proprotein convertase subtilisin/kexin type 9 (PCSK9), although it remains unknown
whether they impact enterocyte lipid storage. A deficiency in Ces1 in mice increases the
secretion of CMs that are smaller in size, contain an abnormal protein composition, and are
cleared at a slower rate compared to WT mice [90]. PCSK9 negatively regulates the LDL
receptor by promoting its lysosomal degradation and is highly expressed in the liver and intestine.
Pcsk9 deficiency in mice results in decreased ApoB secretion, increased CM size, and enhanced
CM clearance [91]. PCSK9 treatment of Caco-2 cells increased cellular and secreted ApoB, the
synthesis of TAG-rich lipoproteins, and MTP activity [92]. PCSK9 inhibition with a monoclonal
antibody (alirocumab) in humans did not affect clearance or synthesis of VLDL ApoB or VLDL
TAG, and also had no effect on postprandial plasma TAG or ApoB48 concentrations [93].
Subjects carrying loss-of-function variants of PCSK9 have attenuated levels of fasting and
postprandial TAG, ApoB48 and total ApoB [94]. It remains unknown whether PCSK9 promotes
CM secretion from the intestine.

1.4

Cytoplasmic lipid droplet (CLD) synthesis and mobilization
CLDs are dynamic organelles found in most cell types and consist of a neutral lipid core

surrounded by a PL monolayer with which proteins associate. These organelles were initially
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thought to be inert lipid storage pools, but more recently have been recognized as dynamic
organelles with diverse and likely cell-type specific functions. CLD accumulation within
enterocytes is often viewed as an abnormal occurrence, as it is observed in diseases of defective
CM synthesis and secretion. However, accumulation of CLDs has also been observed in human
enterocytes in response to an acute dietary fat challenge [95]. Furthermore, it is known from
rodent studies that CLDs accumulate in enterocytes in response to both acute (see Figure 1.2 A
and B) and chronic fat challenges [68, 96], and that these CLD stores increase and decrease over
time following fat consumption [97]. Although the exact role of enterocyte CLDs in the process
of dietary fat absorption is unknown, these observations suggest that enterocyte CLDs may act as
a temporary lipid storage pool that serves to indirectly regulate both the amount and rate of lipid
secretion into circulation.
1.4.1 Cytoplasmic lipid droplet (CLD) synthesis and growth
1.4.1.1 Proposed models of cytoplasmic lipid droplet (CLD) synthesis
There are several proposed models of CLD synthesis, including ER budding, bicellar
excision, and vesicle formation (reviewed in [98]). The model with the most current support is
ER budding. In the ER budding model, the accumulation of neutral lipids within the ER
membrane bilayer eventually leads to the budding of a CLD, with the cytosolic ER membrane
leaflet forming its PL monolayer. This budding process may be driven solely by lipid
accumulation, or mediated by proteins that bind to the ER membrane. A model of CLD synthesis
with less support, the bicellar model, involves neutral lipid accumulation in the ER membrane
followed by excision of this lipid along with both surrounding membrane leaflets. The issue with
this model is that it would result in a transient hole in the ER membrane. Another model of CLD
synthesis with less support is the formation of CLDs within bilayer vesicles. This mechanism
would be mediated by vesicle formation machinery of the secretory pathway, and the lipid
accumulation could occur either within the ER or after the vesicle buds. The precise mechanism
of CLD synthesis in the small intestine has not been directly investigated.
1.4.1.2 Proposed models of cytoplasmic lipid droplet (CLD) growth
Once CLDs are formed, they are able to continue to accumulate TAG and increase in size.
One mechanism of CLD growth is through TAG synthesis locally at the CLD surface [57, 98].
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PL synthesis is important for CLD monolayer expansion in this growth mechanism. A second
mechanism for CLD growth is through fusion of CLDs [98, 99]. Although there is not much
known about CLD growth in enterocytes specifically, it may occur through one or both of these
mechanisms.
TAG synthesis is known to occur at the ER membrane, but more recently this process has
been observed at the CLD surface and shown to contribute locally to the growth of CLDs
(reviewed in [98]). For this to occur, TAG synthesis machinery needs to localize to the CLD
surface. One isoform of each of the enzymes involved in the G3P pathway of TAG synthesis
(GPAT4, AGPAT3, PAP, and DGAT2) has been shown to localize to CLDs in either Drosophila
S2 cells, 3T3-L1 adipocytes, or COS7 cells [56, 57, 71]. In addition, specific isoforms of
enzymes that activate FAs to form acyl-CoAs for incorporation into TAG (ACSL1, ACSL3, and
ACSL4) have been identified on CLDs in several cell types (reviewed in [100]). In enterocytes,
TAG synthesis enzymes that have been identified on CLDs are ACSL3, ACSL4, ACSL5,
GPAT3 and MGAT2 in mice and humans (reviewed in [43, 101]). Of these, ACSL3 [102],
ACSL5 [103], and GPAT3 [43] have been validated by confocal or electron microscopy to be
present on CLDs in enterocytes.
During CLD growth, additional PLs are required for expansion of the PL monolayer
surrounding CLDs to prevent their coalescence [104]. Phosphatidylcholine is the most abundant
PL in these structures, and plays an important role in CLD growth [104, 105]. Three pathways
mediate phosphatidylcholine synthesis and are present in most cell types. These pathways
include the de novo, or Kennedy pathway, the phosphatidylethanolamine methyl transferase
(PEMT) pathway (liver cells only), and the Lands Cycle. Enzymes in these pathways associate
with and/or contribute to CLD metabolism in many cell types (reviewed in [106]); however,
knowledge of these pathways in intestinal CLD metabolism is limited.
Another proposed model of CLD growth is through fusion. Soluble NSF attachment
receptor (SNARE) proteins, which facilitate the fusion of vesicles with their target membranes
[107], are also thought to play a role in the fusion of CLDs [99]. Several of these proteins have
been shown to associate with Plin2 in NIH/3T3 cells, and have also been fractionated with CLDs
from these cells ([99], reviewed in [108]). The role of SNARE proteins in enterocyte CLD fusion,
however, has not yet been investigated.
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1.4.2 Cytoplasmic lipid droplet (CLD) mobilization
Lipolysis, or the breakdown of complex lipids (TAG, CEs, and PLs) via hydrolysis of
ester bonds, is the process through which CLDs are catabolized. The dynamic nature of
enterocyte CLD accumulation and depletion in response to dietary fat consumption suggests that
the mobilization of this stored lipid contributes to the process of dietary fat absorption. There are
two major lipolysis pathways through which lipids stored within CLDs are hydrolyzed (see
Figure 1.4). With cytoplasmic lipolysis, lipases present in the cytoplasm associate with CLDs
and sequentially hydrolyze FAs within TAG, ultimately yielding glycerol and FFAs. This
pathway has been well characterized within adipocytes, but the enzymes involved are also
expressed in enterocytes [109]. Lipophagy is a more recently discovered pathway in which CLDs
are degraded via autophagy [110]. FAs released by either pathway can be used for re-synthesis of
complex lipids, oxidation, or act as signaling molecules, but likely mainly provide substrate for
CM synthesis and secretion at later time points.
1.4.2.1 Cytoplasmic lipolysis
Adipose triglyceride lipase (ATGL) catalyzes the initial step of TAG hydrolysis, yielding
DAG and FFAs. Its expression in the small intestine is increased in response to an acute dietary
fat challenge in lean mice, but interestingly reduced in diet-induced obese mice [68]. Intestinespecific Atgl-deficient mice exhibit decreased intestinal TAG hydrolase activity and an
accumulation of TAG in enterocyte CLDs in response to a dietary fat challenge, however
intestinal TAG secretion remains unchanged [111]. Overall these results suggest that TAG
hydrolyzed by ATGL in the intestine is not a major regulator of intestinal TAG secretion.
Comparative gene identification-58 (CGI-58) is the co-activator of ATGL and its binding
is required for ATGL function, but it does not exhibit any hydrolytic activity of its own [112].
The role of CGI-58 within the small intestine was investigated in intestine specific Cgi-58deficient (iCgi-58 deficient) mice, which exhibit massive TAG accumulation within enterocyte
CLDs, even in a fasted state [113]. These mice also exhibit decreased TAG hydrolase activity
and a decreased intestinal TAG secretion rate, suggesting impaired mobilization of this stored
lipid. Furthermore, small but significant decreases in FA absorption and fatty acid oxidation
(FAO) were also observed in iCgi-58-deficient mice. Taken together, these results suggest that
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CGI-58 regulates TAG mobilization from enterocyte CLDs to provide substrate mainly for CM
synthesis but also for FAO.
Hormone sensitive lipase (HSL) catalyzes the hydrolysis of DAG to MAG and FFAs, but
can also hydrolyze TAG, MAG, CEs, and retinyl esters [109]. Intestine-specific Hsl-deficiency
(iHsl-deficiency) in mice decreases intestinal acylglycerol hydrolase activity but almost
completely abolishes cholesterol esterase activity [114]. In addition, iHsl-deficiency does not
have an effect on intestinal TAG secretion, and intestinal TAG and DAG content remains
unchanged even after high fat feeding. There is, however, an accumulation of CE in the intestine
after high fat feeding, along with an increase in plasma cholesterol and a decrease in intestinal
cholesterol biosynthesis [114]. These results suggest that HSL plays a critical role in cholesterol
metabolism in the intestine and only a minor, nonessential role in dietary fat absorption.
Monoglyceride lipase (MGL) catalyzes the final step of cytoplasmic lipolysis,
hydrolyzing MAG to glycerol and FFAs. In addition it is able to hydrolyze the endocannabinoid
2-arachidonylglycerol, and thus its role in endocannabinoid signaling has also been studied.
Development of MGL inhibitors has focused on effects on the endocannabanoid pathway and
their potential for acute/chronic pain and cancer treatment [115]. MGL is present at high levels in
the duodenum and exhibits its highest activity at this location, and in response to high fat feeding
its expression in the small intestine increases [116, 117]. Mice overexpressing Mgl specifically in
the small intestine have an increased susceptibility to diet-induced obesity, due at least in part to
the development of hyperphagia and decreased energy expenditure [118]. These mice also have
decreased intestinal MAG and 2-arachidonylglycerol content and elevated plasma TAG levels in
the fed state compared to wild-type mice. Overall these results support roles of intestinal MGL in
dietary fat absorption and in regulating food intake.
1.4.2.2 Lipophagy
Lipophagy refers specifically to the degradation of CLDs through autophagy [119]. This
process involves the initial formation of an autophagosome around a CLD, followed by fusion of
the autophagosome with the lysosome and subsequent degradation of its contents via lysosomal
hydrolytic enzymes (see Figure 1.4). Evidence that lipophagy is involved in dietary fat
absorption is provided by experiments in Caco-2 cells, in which lipid micelle treatment was
shown to induce autophagy [120]. Furthermore, autophagy inhibition resulted in accumulation of
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TAG within CLDs in these lipid treated cells. These results suggest that lipophagy plays a role in
the hydrolysis and mobilization of TAG within enterocyte CLDs during dietary fat absorption.
Lysosomal acid lipase (LAL) is the lysosomal enzyme responsible for hydrolyzing ester
bonds within TAG and CEs, yielding glycerol, free cholesterol and FFAs. Lal-deficient mice
exhibit a similar phenotype to individuals with Wolman disease (discussed in section 1.6.2),
which includes massive TAG and CE accumulation in the small intestine and liver that increases
with age [121]. However, inhibition of Lal with chloroquine increased intestinal TAG content
but did not have an effect on lipid secretion into the lymph [122]. Overall these results suggest
that LAL’s function is important for maintaining normal TAG storage in the intestine, but
additional studies are needed to determine its contribution to dietary fat absorption.
1.4.2.3 Proteins that regulate cytoplasmic lipid droplet (CLD) storage and mobilization in
enterocytes
Numerous CLD-associated proteins have been identified that have the potential to
regulate CLD metabolism [106]. The first proteins shown to associate with enterocyte CLDs are
members of the perilipin (Plin) family. Plin3 localizes to CLDs in response to an acute dietary fat
challenge in mice, while Plin2 was only found to associate with enterocyte CLDs after chronic
high fat feeding [123]. More recently, Plin2-deficient mice were shown to exhibit decreased
TAG storage in enterocyte CLDs and increased fecal TAG excretion compared to wild-type mice
[124]; however, the specific mechanisms through which Plin2 and Plin3 regulate enterocyte
CLD storage are unknown. CIDEB is a member of a protein family with known roles in CLD
fusion, and localizes to both CLDs and the ER [98, 125]. Cideb-deficient mice exhibit decreased
intestinal TAG secretion, decreased CM size, and increased TAG storage within enterocyte
CLDs [125]. This phenotype and the dual localization of CIDEB suggest it may play a role in
mobilizing TAG stored within enterocyte CLDs to provide substrates for CM secretion.
In mice, the milk protein Mfge8 regulates enterocyte CLD metabolism in response to a
fat challenge [126]. Cell surface Mgfe8 interacts with the αvβ3 and αvβ5 integrins to increase
intracellular TAG hydrolase activity through a PI3 kinase/mTORC2–dependent pathway,
promoting CLD TAG hydrolysis to release FAs for utilization in CM synthesis [126]. Both a
whole-body and an intestine-specific deficiency in the PL remodeling protein Lpcat3 in mice
decreases intestinal TAG secretion and increases intestinal TAG storage, and is accompanied by
fat malabsorption and failure to thrive [127-129]. This severe phenotype suggests a critical role
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of this protein in dietary fat absorption that may, in part, be due to altered membrane
phospholipid composition, including that of CLDs and CMs. TM6SF2 is a gene expressed in
both the liver and the small intestine, and a loss-of-function variant in humans is associated with
liver steatosis and lower fasting lipid levels [130]. CLD accumulation was observed in
enterocytes of Tm6sf2-deficient zebrafish as well as in Caco-2 cells in response to a lipid load
[130], suggesting that TM6SF2 plays an important role in regulating intestinal TAG storage and
secretion.
1.4.2.4 Fate of TAG mobilized from cytoplasmic lipid droplets (CLDs)
1.4.2.4.1 Re-esterification for lipoprotein or membrane synthesis
FAs liberated from CLDs may be re-esterified to form TAG or other complex lipids (CEs
and PLs) for either lipoprotein or membrane synthesis. The synthesis of CLDs is thought to
buffer enterocytes from FA toxicity and control the rate of synthesis and secretion of CMs in
response to high-fat challenges. The hydrolysis and re-esterification of TAG stored in CLDs is
proposed to allow lipids to cross the membrane bilayer of the ER, where they can be re-esterified
into complex lipids destined for alternate fates. Lipoprotein synthesis in the liver requires
lipolysis of stored TAG [131]. In the intestine, it is unclear the extent to which lipolysis is
required for the mobilization of stored TAG for the synthesis of CMs. A radio-labeled tracer
experiment in rats demonstrated that some TAG secreted into lymph from enterocyte stores did
not appear to undergo lipolysis; however, up to fifty percent of TAG in CMs was hydrolyzed and
re-esterified before transport to lymph [132], suggesting that lipoprotein synthesis is a fate of
TAG stored within enterocyte CLDs.
1.4.2.4.2 Fatty acid oxidation (FAO)
FAs liberated from CLDs may be oxidized through mitochondrial β-oxidation to generate
ATP. Although glutamine and glutamate are the major fuel sources in enterocytes [133-135] and
intestinal FAO activity is low in fed and fasted states [136, 137], emerging studies highlight that
regulation of intestinal FAO activity has the capacity to alter enterocyte TAG storage and
secretion. Altering FAO in the intestine may influence systemic FA availability, which could
alter postprandial blood TAG levels and/or energy balance.
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High dietary fat intake is shown to increase intestinal FAO machinery and activity. Mice
chronically fed a high fat diet have higher mRNA levels for multiple FAO genes [68, 138] and
higher FAO activity [139] in the intestine compared to mice fed a low fat diet. This increase in
FAO may be important for supplying the enterocytes with energy needed for absorption of large
quantities of dietary fat. On the other hand, an increased capacity for FAO in the intestine may
limit systemic FA availability and reduce postprandial blood TAG levels and weight gain.
Recent reports of genetic and lifestyle factors regulating intestinal FAO support this hypothesis.
Mice that are resistant to high fat diet-induced obesity (A/J mice) have a greater increase in
intestinal FAO than mice that are susceptible to obesity (C57BL/6J mice) when fed a high fat
diet [139]. Endurance exercise also significantly increases mRNA levels of FAO genes in
intestine of obese rats [140]. In addition to limiting systemic FA availability, activation of
intestinal FAO has been shown to exert a satiety effect in rodent models (reviewed in [141]).
Together these results show that increasing intestinal FAO can have beneficial systemic effects.
Several dietary factors, pharmaceutical compounds, and molecular targets that activate
intestinal FAO have been identified and investigated. For example, dietary supplementation of
polyunsaturated FAs (docosahexanoic acid, eicosapentanoic acid, and α-linolenic acid) [142-144]
and 1,3-DAG [145-147] were found to induce intestinal FAO and contribute to
hypotriglyceridemic and anti-obesity effects. The induction of intestinal FAO by polyunsaturated
FAs occurs through the activation of transcription factors (PPAR) or cellular molecules (AMPactivated protein kinase [148, 149]) involved in lipid catabolism. 1,3-DAG was shown to be a
less preferable substrate for DGAT enzymes compared to 1,2-DAG (generated from normal
lipolysis of TAG ) [150], and thus may generate more FAs through hydrolysis to activate FAO.
In addition, fenofibrate, a synthetic PPARα agonist for clinically treating hypertriglyceridemia,
was found to lower postprandial blood lipid levels, in part by activating intestinal FAO in high
fat-fed, obese mice [151].
Several mouse models with altered intestinal TAG storage and secretion discussed
previously also exhibit changes in intestinal FAO machinery and/or activity. Rodent models with
reduced TAG secretion and increased TAG storage in enterocytes, including Mogat2- deficiency,
pharmacological inhibition of DGAT1, and intestine specific Mttp-deficiency, have increased
FAO. Mogat2-deficient mice have higher mRNA levels of FAO genes in enterocytes than wildtype mice [46, 49]. Pharmacological inhibition of DGAT1 results in higher levels of proteins
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involved in FAO and ketogenesis in enterocytes of high-fat fed rats and stimulates FAO activity
in enterocyte cell models [152]. iMttp–deficient mice have enhanced FAO activity in enterocytes
[79]. On the other hand, a model with increased TAG secretion and similar TAG storage (mice
with intestine-specific Dgat2 overexpression) was found to have decreases in mRNA levels of
FAO genes in enterocytes in response to a chronic high fat diet [69]. The changes in intestinal
FAO in models with altered expression of genes involved in TAG synthesis and CM assembly
may either be an adaptive response to or the cause of the altered dietary fat absorption observed
in these models.
1.4.2.4.3 Signaling
The FAs or lipids released from enterocyte CLDs have the potential to serve as signaling
molecules that regulate intestinal and/or systemic physiology. These FAs or lipids may serve as
ligands for transcription factors, or substrates for synthesizing specialized, bioactive lipids that
regulate diverse cellular functions. In the small intestine, FAs and lipids act as ligands for
transcription factors such as LXR, HFN4α and PPARα (reviewed in [106]). In addition,
arachidonic acid is the major FA precursor for synthesizing eicosanoids (such as prostaglandins,
leukotrienes, and other related molecules) and endocannabinoids (anandamide and 2arachidonoylglycerol). Eicosanoids and arachidonic acid metabolites in the intestine have been
shown to mediate inflammatory processes and play a role in inflammatory bowel disease [153,
154]. Furthermore, endocannabinoids have been shown to activate the endocannabinoid system
by binding to their receptors in the intestine and other cell types, resulting in protective effects
against inflammation [155, 156], regulation of food intake [157], and regulation of energy
homeostasis [158]. Therefore, the dynamic CLD storage in enterocytes may be important in the
regulation of lipid-mediated signaling pathways.

1.5

Other factors that regulate cytoplasmic lipid droplet (CLD) metabolism and mobilization in
enterocytes

1.5.1 High fat diet-induced obesity (DIO)
Chronic high-fat diet consumption in mice results in DIO and alters intestinal CLD
metabolism. Diet-induced obese mice have a reduced TAG secretion rate in response to dietary
fat compared to lean mice [68, 159]. In the fed state, diet-induced obese mice have abundant
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TAG storage in CLDs within enterocytes, but after a six hour fast this TAG storage is
significantly reduced. In diet-induced obese mice given an acute dietary fat challenge, mRNA
levels of genes involved in lipolysis (Atgl and Hsl) are significantly reduced compared to before
the challenge [68]. This is a response to dietary fat that does not occur in lean mice. These results
suggest that DIO induces adaptations in CLD metabolism resulting in decreased mobilization of
enterocyte TAG stores and decreased TAG secretion.
1.5.2 Glucose
Dietary glucose mobilizes TAG stored in enterocytes from a previous meal in humans
[95]. Individuals were subjected to a dietary fat pre-load five hours before drinking either water
or a glucose solution. One hour after drinking the water or glucose solution, jejunual biopsies
were collected and analyzed for neutral lipid content. The results demonstrated that individuals
who drank the glucose solution had significantly less neutral lipid storage in enterocytes
compared to those who drank water. In addition, plasma TAG concentrations peaked after
glucose but not water consumption. These results indicate that TAG from a previous meal can be
stored in enterocytes for several hours, and subsequent glucose consumption is capable of
mobilizing this stored TAG from the small intestine.
1.5.3 Oral fat exposure
Oral exposure to dietary fat induces a cephalic phase response in CM-TAG secretion that
is derived from TAG stored in the intestine from a previous meal in humans [160]. Individuals
were subjected to a dietary fat pre-load containing a radiolabeled FA during the evening meal.
Breakfast the following morning consisted of an additional fat load containing a different label in
capsule form to avoid activation of taste receptors. Individuals were then sham fed either a low
fat or high fat cream cheese. Plasma lipoprotein analysis showed that some of the TAG within
the CM fraction was derived from the previous night’s meal. These results indicate that oral fat
exposure can promote the mobilization of TAG stored in the intestine from a previous meal.
Additionally, the high fat sham feeding induced a greater postprandial triglyceridemic response
compared to low fat sham feeding. These results suggest that a cephalic phase response to dietary
fat can initiate the mobilization and secretion of TAG from enterocytes.
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1.5.4 Other factors
Several additional factors have been shown to have effects on the storage and
mobilization of lipid from the small intestine. These include but are not limited to hormones, gut
peptides, transcription factors, and the gut microbiota (reviewed in [106]). Future work is needed
to determine the mechanisms through which these factors, as well as those discussed above, exert
their effects on intestinal lipid metabolism.

1.6

Clinical conditions of altered dietary fat absorption

1.6.1 Disorders of defective chylomicron (CM) metabolism
Alterations in CM metabolism present clinically as abnormal levels of CMs in the blood
in a fasting and/or postprandial state. These abnormal plasma CM levels can be due to defects in
CM synthesis and secretion and/or impaired CM clearance from circulation. Conditions resulting
in very low as well as very high plasma CM levels will be discussed.
1.6.1.1 Hypochylomicronemia
Abetalipoproteinemia is an autosomal recessive disorder caused by defects in MTP, and
it results in almost no APOB-containing lipoproteins in the plasma, along with very low plasma
TAG and cholesterol levels (reviewed in [161]). Symptoms of severe diarrhea, fat malabsorption,
and failure to thrive are usually detected early in life, and treatment includes reduced fat intake,
as well as supplementation of essential FAs and fat soluble vitamins [161]. Vitamin A and E
supplementation in particular are important to start at an early age to prevent neurological and
retinal disabilities.
Familial hypobetaliproteinemia is an autosomal co-dominant disorder caused by
mutations in the gene encoding APOB, resulting in the synthesis of truncated forms of APOB
(reviewed in [161]). These patients exhibit steatorrhea, essential FA and fat soluble vitamin
deficiencies, hypocholesterolemia, and low plasma ApoB levels. Individuals with familial
hypobetalipoproteinemia are recommended to consume a low fat diet supplemented with
essential FAs and fat soluble vitamins.
CM retention disease (also known as Anderson disease) is an autosomal recessive
disorder due to a defect in SARA2 (gene encoding SAR1B) (reviewed in [161]). SAR1B
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regulates pre-CM trafficking from the ER to the Golgi. In this disease, CMs can be made, but
they cannot be transported to the Golgi and are thus “retained” within the ER. These patients
exhibit steatorrhea and failure to thrive.
1.6.1.2 Hyperchylomicronemia
Hyperchylomicronemia is characterized by extreme hypertriglyceridemia, the abnormal
presence of CMs in the blood in the fasting state, and an additional clinical symptom such as
eruptive xanthomas, lipemia retinalis, swelling of the spleen, persistent abdominal pain, or acute
pancreatitis [162]. There are genetic causes of hyperchylomicronemia, but in most cases the
disorder is polygenic and results from a combination of genetic and environmental factors
(reviewed in [162]). Familial hyperchylomicronemia (Type 1 hyperlipidemia) is very rare and
caused by homozygous or double heterozygous loss of function mutations in lipoprotein lipase
(LPL). In the blood, LPL normally hydrolyzes TAG within CMs so that the released FAs can be
taken up by peripheral tissues. Polygenic hyperchylomicronemia (Type 5 hyperlipidemia) occurs
when an LPL mutation is present along with one or more additional mutations in genes involved
in CM clearance (ex: APOA5, APOE, ANGPTL3). Additional environmental factors such as
obesity, uncontrolled diabetes, excess alcohol consumption or use of certain medications are
commonly associated with this condition. Other forms of hyperchylomicronemia include
dysbetalipoproteinemia, which is most commonly due to mutations in APOE, and autoimmune
hyperchylomicronemia, which is due to the production of anti-LPL antibodies. Overall, there are
multiple causes of hyperchylomicronemia, but they all involve reduced CM clearance.
1.6.2 Disorders of defective cytoplasmic lipid droplet (CLD) metabolism
Mutations in intracellular lipase enzymes have been identified that impair intestinal lipid
metabolism. A rare autosomal recessive mutation in CGI-58, the cofactor of ATGL, causes
Chanarin-Dorfman Syndrome (neutral lipid storage disease), which is characterized by
accumulation of lipid in multiple tissues, including the intestine [163]. Furthermore, LAL
deficiency in humans causes one of two autosomal recessive disorders [164]. Wolman disease
results from a complete loss of LAL, and affected individuals present with vomiting, diarrhea, fat
malabsorption, and failure to thrive early in life. These patients also accumulate large amounts of
neutral lipids in tissues, including the liver and intestine. Cholesterol ester storage disease results
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from partial loss of LAL, and causes symptoms similar to non-alcoholic fatty liver disease
(NAFLD), but in some cases is asymptomatic. Overall, these disorders suggest that both
cytoplasmic and lysosomal lipolysis play roles in regulating dietary fat absorption.
1.6.3 Obesity
Obesity, clinically defined by a BMI ≥ 30, is continuing to increase in prevalence and can
result from a combination of dietary, environmental and genetic factors. It is also often
accompanied by other co-morbidities such as Type 2 diabetes, hypertriglyceridemia, and
increased cardiovascular disease risk [165]. There is evidence of alterations in dietary fat
absorption in obese compared to lean individuals; however whether physiological or molecular
alterations are drivers and/or the result of obesity is still uncertain. Elevated postprandial plasma
TAG levels are often observed in obese individuals [165], and in diet-induced obese mice the
postprandial peak in plasma TAG levels is both delayed and elevated compared to lean controls
[68]. In addition, the rate of TAG secretion from the intestine is decreased in response to an
acute dietary fat challenge in diet-induced obese mice, and TAG accumulates within their
enterocytes in the fed state [68, 159]. Taken together, these results suggest that the process of
dietary fat absorption is altered in obesity.
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Figure 1.1 Overview of dietary fat absorption within enterocytes
Dietary triacylglycerol (TAG) is hydrolyzed in the intestinal lumen to free fatty acids (FFAs) and
2-monacylglycerol (MAG), which are taken up by enterocytes and re-synthesized into TAG at
the ER lumen, primarily through the MAG pathway. Re-synthesized TAG is either incorporated
into chylomicrons (CMs) and secreted into the lymph and then circulation for delivery to
peripheral tissues, or incorporated into and temporarily stored within enterocyte cytoplasmic
lipid droplets (CLDs). Yellow spheres represent TAG/TAG-rich lipid particles.
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Figure 1.2 Transmission electron micrographs of enterocytes during dietary fat absorption
A) Ultrastructural image of mouse enterocytes two hours after a 200 µl oral olive oil gavage.
Several pools of TAG can be observed, including TAG within cytoplasmic lipid droplets (CLDs)
(3, B), the ER (4, C), the Golgi (5, D), Golgi-derived secretory vesicles (6, E), and the
intercellular space (7, E(*)).
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Figure 1.3 Mechanism and proteins involved in CM synthesis
Microsomal triglyceride transfer protein (MTP) packs neutral lipids onto apolipoprotein B48
(ApoB48) as it translocates into the ER lumen to form primordial chylomicrons (CMs).
Primordial CMs then fuse with an APOB-free lipid particle to form a pre-CM. Pre-CMs are then
transported to the Golgi within pre-CM transport vesicles (PCTVs), where they undergo further
processing prior to secretion from enterocytes. Yellow spheres represent TAG/TAG-rich lipid
particles.
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Figure 1.4 Mechanisms and proteins involved in enterocyte CLD catabolism
Triacylglycerol (TAG) stored within enterocyte cytoplasmic lipid droplets (CLDs) can be
mobilized through either cytoplasmic TAG lipolysis or lipophagy. Cytoplasmic TAG lipolysis
involves the sequential cleavage of fatty acids (FAs) from TAG by cytoplasmic enzymes that
associate with CLDs. Lipophagy involves the engulfment of a CLD (or a piece of a CLD) by an
autophagosome, which then fuses with the lysosome. Within the lysosome, lysosmal acid lipase
(LAL) hydrolyzes TAG (and other complex lipids), releasing free fatty acids (FFAs) into the
cytoplasm. The released FFAs from either pathway can be used for complex lipid synthesis,
synthesis of signaling molecules, or fatty acid oxidation. Yellow sphere represents a CLD.
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CHAPTER 2.
DGAT1 AND DGAT2 ALTER PROTEINS ASSOCIATED
WITH ENTEROCYTE CYTOPLASMIC LIPID DROPLETS IN
RESPONSE TO DIETARY FAT

2.1

Abstract
Enterocytes, the absorptive cells of the small intestine, mediate efficient absorption of

dietary fat (triacylglycerol, TAG). The digestive products of dietary fat are taken up by
enterocytes, re-esterified into TAG, and packaged on chylomicrons (CMs) for secretion into
blood or temporarily stored within cytoplasmic lipid droplets (CLDs). Altered enterocyte TAG
distribution impacts susceptibility to high fat diet associated diseases, but molecular mechanisms
directing TAG toward these fates are unclear. Two enzymes, acyl CoA: diacylglycerol
acyltransferase 1 (Dgat1) and Dgat2, catalyze the final, committed step of TAG synthesis within
enterocytes. Mice with intestine-specific overexpression of Dgat1 (Dgat1Int) or Dgat2 (Dgat2Int),
or lack of Dgat1 (Dgat1-/-), were previously found to have altered intestinal TAG secretion and
storage. We hypothesized that varying intestinal Dgat1 and Dgat2 levels alters TAG distribution
in subcellular pools for CM synthesis as well as the morphology and proteome of CLDs. To test
this we used ultrastructural and proteomic methods to investigate intracellular TAG distribution
and CLD-associated proteins in enterocytes from Dgat1Int, Dgat2Int, and Dgat1-/- mice 2 hours
after a 200 µl oral olive oil gavage. We found that varying levels of intestinal Dgat1 and Dgat2
altered TAG pools involved in CM assembly and secretion, the number or size of CLDs present
in enterocytes, and the enterocyte CLD proteome. Overall, these results support a model where
Dgat1 and Dgat2 function coordinately to regulate the process of dietary fat absorption by
preferentially synthesizing TAG for incorporation into distinct subcellular TAG pools in
enterocytes.

This work was published in Biochim Biophys Acta - Molecular and Cell Biology of Lipids.
Y.H. Hung, A.L. Carreiro, K.K. Buhman, Dgat1 and Dgat2 regulate enterocyte triacylglycerol
distribution and alter proteins associated with cytoplasmic lipid droplets in response to dietary fat,
Biochimica et biophysica acta, 1862 (2017) 600-614.
Y.H. Hung and A.L. Carreiro equally contributed to the work. Y.H. Hung conducted the transmission
electron microscopy experiments and A.L. Carreiro conducted the proteomic analysis experiments.
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2.2

Introduction
The highly efficient absorption of dietary fat (triacylglycerol, TAG) is mediated by

enterocytes, the absorptive cells of the small intestine. This process is important in the promotion
of health as well as in contributing to disease when dysregulated [1]. Within this process, TAG is
first hydrolyzed to fatty acids and monoacylglycerol in the intestinal lumen. These digestive
products are then taken up by enterocytes and rapidly re-synthesized into TAG at the ER
membrane. The resulting TAG is packaged in chylomicrons (CMs) for secretion into blood or in
cytoplasmic lipid droplets (CLDs) for temporary storage within enterocytes [2]. The number and
size of CLDs increase and then decrease over time in response to dietary fat consumption [3],
suggesting that the stored TAG is hydrolyzed at later time points and either re-esterified into
TAG at the ER membrane and used for CM synthesis or used for other cellular functions. The
mechanism(s) through which TAG is partitioned for CMs and CLDs in enterocytes is unclear.
The partitioning of TAG for CM and CLD synthesis may be mediated by specific TAG
synthesis enzymes. Acyl CoA: diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 both
catalyze the final, committed step of TAG synthesis (the acylation of diacylglycerol with a fatty
acyl-CoA); however, they share no sequence homology, are members of different gene families
and exhibit different biochemical, cellular, and physiological functions [4]. Although both
DGAT1 and DGAT2 are expressed ubiquitously, they have different tissue expression patterns
[5, 6]. Within the cell, both DGAT1 and DGAT2 localize to the ER, but DGAT2 has also been
identified on CLDs and mitochondria-associated membranes [7, 8]. DGAT activity occurs on the
lumenal and cytosolic sides of the ER membrane[9]. Topological studies demonstrate that the
active site of DGAT1 may be present on either side of the ER membrane as the protein has dual
topology [10], while the active site of DGAT2 is oriented toward the cytoplasm [11]. However,
additional studies investigating the roles of DGAT1 and DGAT2 in hepatocytes suggest that this
partitioning may be more complex [12-15]. Furthermore, the distinct physiological roles of
Dgat1 and Dgat2 have been demonstrated in knockout mouse models. Dgat1-/- mice are viable
and resistant to diet-induced obesity [16]. Dgat2-/- mice die within a few hours, likely due to
extremely low whole body TAG content and an impaired skin barrier [17]. Together, these
differences suggest that Dgat1 and Dgat2 have non-redundant roles, but their specific cellular
functions remain unclear.
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Targeted studies investigating the role of Dgat1 and Dgat2 in intestinal lipid metabolism in
mice indicated that these enzymes synthesize TAG for specific cellular fates within enterocytes
and contribute to whole body physiology. Dgat1-/- mice secrete TAG in smaller-sized CMs at a
reduced rate and exhibit increased TAG storage in enterocyte CLDs compared to wild-type (WT)
mice [18]. This intestine phenotype was shown to be critical for their resistance to diet-induced
obesity and hepatic steatosis by using a mouse model where Dgat1 was only expressed in the
intestine [19]. Mice with intestine-specific overexpression of Dgat1 (Dgat1Int) secrete TAG from
the intestine at a similar rate within similar sized CMs compared to WT mice [20]. Interestingly,
we were barely able to detect TAG accumulation in enterocytes of Dgat1Int mice by coherent
anti-Stokes Raman scattering microscopy, but by biochemical analysis TAG levels were similar
to WT mice [19, 20]. This result suggested that using a more sensitive technique to detect
intracellular distribution of TAG, such as transmission electron microscopy (TEM) would be
necessary to understand the role of Dgat1 and Dgat2 in synthesizing TAG for specific
intracellular fates. Mice with intestine-specific overexpression of Dgat2 (Dgat2Int) have higher
intestinal TAG secretion rates but unchanged CM size and similar TAG accumulation in
enterocytes compared to WT mice [20]. The higher TAG secretion rate seen in Dgat2Int mice
contributes to postprandial hypertriglyceridemia and an increased susceptibility to hepatic
steatosis [20]. Together, these differences suggest that Dgat1 and Dgat2 have non-redundant
roles in dietary fat absorption, but their specific cellular functions in this process requires further
investigation.
A major difference within enterocytes of mice with varying levels of Dgat1 and Dgat2 is
the storage of TAG within CLDs. Emerging evidence suggests that proteins present on CLDs
play important roles in regulating CLD morphology and potentially the balance between TAG
storage and secretion [2]. Both targeted and global proteomic approaches have been used to
identify proteins associated with enterocyte CLDs that are important in their metabolism [21-25].
These proteins include enzymes involved in lipid synthesis, lipolysis and CM metabolism, as
well as other diverse cellular pathways. This localization of these proteins may exert regulatory
effects on CM and CLD metabolism directly or indirectly. Determining the differences in
proteins that associate with enterocyte CLDs in models with varying levels of Dgat1 and Dgat2
(Dgat1Int, Dgat2Int, and Dgat1-/- mice) will provide further insight into the mechanism through
which Dgat1 and Dgat2 synthesize TAG for secretion and storage within enterocytes.
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Based on our previous observations in the intestinal phenotypes of mouse models with
varying Dgat1 and Dgat2 levels, we hypothesize that varying intestinal Dgat1 and Dgat2 levels
alters TAG distribution in subcellular pools for CM synthesis as well as the morphology and
proteome of CLDs. To test this hypothesis, enterocytes from the proximal region of the small
intestine of mouse models with varying levels of Dgat1 and Dgat2 (Dgat1Int, Dgat2Int, and
Dgat1-/-) were analyzed 2 hours after a 200 μl oral olive oil gavage. An ultrastructural
examination of enterocytes by TEM and a proteomic analysis of isolated CLDs using LCMS/MS were performed. Identifying differences in subcellular TAG distribution and the proteins
associated with CLDs in enterocytes from mouse models with varying Dgat levels will illustrate
unique cellular contributions of Dgat1 and Dgat2 to the process of dietary fat absorption.

2.3

Materials and Methods

2.3.1 Diet and animals
All procedures were approved by the Purdue Animal Care and Use Committee. Mice
with intestine-specific overexpression of Dgat1 (Dgat1Int), intestine-specific overexpression of
Dgat2 (Dgat2Int) and whole body Dgat1 deficient (Dgat1-/-) mice were generated as previous
described [16, 19, 20]. Male Dgat1Int, Dgat2Int and Dgat1-/- mice, 4-6 months of age were used in
this study. The mice were housed in a specific pathogen-free barrier facility with a 12 hour
light/dark cycle (6AM/6PM) and fed a low-fat, rodent chow diet (PicoLab 5053, Lab Diets,
Richmond, IN). On the day of the experiment the mice were fasted for 4 hours at the beginning
of the light cycle and administered 200 μl of olive oil by oral gavage. No food was available after
the gavage.
2.3.2 Intestinal TAG secretion
Intestinal TAG secretion in these models of altered intestinal Dgat expression was
assessed previously in our lab [19, 20]. Mice were fasted for 4 h starting at the beginning of the
light cycle and administered 500 mg/kg Tyloxapol (T0307, Sigma-Aldrich, St. Louis, MO) via
IP injection to block lipase activity in circulation. At 30 min post-Tyloxapol injection, mice were
given a 200 μl oral olive oil gavage and blood was collected via the submandibular vein at 2 and
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4 h post gavage. Plasma TAG concentration was determined using the Wako L-Type TG M
determination kit (Wako Chemicals USA).
2.3.3 Transmission electron microscopy (TEM)
Mice were anesthetized using inhaled isoflurane 2 h after a 200 μl oral olive oil gavage.
We performed whole mouse perfusion fixation by cardiac infusion of 2% glutaraldehyde and 2%
paraformaldehyde in 0.1M sodium cacodylate (pH 7.4). The small intestine was harvested and
divided into five equal length segments and labeled S1–S5 (proximal to distal) in relation to the
stomach, with S2-3 representing the jejunum. Small pieces of the jejunum were stored in freshly
prepared 2% glutaraldehyde in 0.1 M sodium cacodylate, pH 7.4 for at least 2 h at 4°C. Tissues
were diced into 1 x 5 mm pieces then fixed with 1% osmium tetroxide in 0.1 M sodium
cacodylate, pH 7.4, for 1 h at room temperature. Tissues were then washed repeatedly in distilled
deionized water. Dehydration was completed with a graded series of ethanol and specimens were
embedded in Embed 812 resin. Thick sections (0.5 μm) were stained with 1% toluidine blue and
examined by light microscopy to confirm tissue orientation. Thin sections (80 nm) were cut on a
Leica UC6 ultramicrotome and stained in 2% uranyl acetate and lead citrate. Images were
acquired on a Tecnai T20 transmission electron microscope (FEI, Hillsboro, OR) equipped with
a LaB6 source and operating at 100 kV. The quantitative measurements with acquired
micrographs were made using ImageJ software (NIH, USA). Sixty intact enterocytes from the
middle area of villi in each group were examined for quantitative measurements (20 cells/mouse;
3 mice/group). All the enterocytes selected for quantitative measurements had TAG present in
the subcellular pools for both secretion (ER lumen and Golgi/secretory vesicles (SVs)) and
storage (CLDs). The identification of these subcellular TAG pools is based on previously
published electron microscopy work [26-30]. The TAG for secretion was assessed by measuring
areas of expanded, TAG-containing ER vesicles and Golgi/SVs within an individual cell. The
TAG for storage was assessed by counting the number of CLDs and measuring the diameter of
CLDs within an individual cell. The amount of TAG stored in CLDs within an individual cell
was indicated by the sum of the areas of identified CLDs. The area of a CLD was estimated from
its diameter by applying the equation of (mean number of CLDs) x π x (mean radius)2.
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2.3.4 Enterocyte isolation
The proximal third of the small intestine was excised 2 h after a 200 μl oral olive oil
gavage and enterocytes were isolated as previously described [21, 24, 31]. Briefly, intestinal
tissue was washed in cold tissue buffer (Hank’s Balanced Salt Solution containing 25 mM
HEPES and 1% fetal bovine serum), then incubated in isolation buffer (Calcium and magnesium
free Hanks’s Balanced Salt Solution with 1.5 mM EDTA) for 15 minutes at 37°C with rotation.
The sample was vortexed briefly and the supernatant, which contained isolated enterocytes, was
obtained. This isolation process was repeated, the supernatants were combined, and isolated
enterocytes were pelleted.
2.3.5 CLD isolation
CLDs were isolated from enterocytes using a previously validated sucrose gradient
ultracentrifugation protocol that was modified for mouse enterocytes [24, 32, 33]. Enterocytes
were lysed using ice cold lysis buffer containing sucrose (175 mM sucrose, 10 mM HEPES and
1 mM EDTA) and disrupted by passing through a 27 gauge 1 inch needle eight times. The 2 mls
of cell lysate was transferred to a centrifuge tube and overlaid with 6 mls of sucrose free lysis
buffer. The sample was centrifuged at 20,000 x g at 4°C for 2 h. Following the centrifugation,
the sample was frozen at -80°C and then sliced into seven fractions of approximately 1 cm in
length, with the top fraction containing isolated CLDs. A sample from the CLD enriched fraction
was negatively stained with 2% w/v aqueous uranyl acetate and imaged using a Technai T20
transmission electron microscope (FEI, Hillsboro, OR). Protein concentrations of these fractions
were determined using a BCA assay.
2.3.6 Protein digestion and LC-MS/MS analysis
CLD fractions were delipidated using 2:1 chloroform:methanol, followed by protein
precipitation using ice cold acetone. In preparation for the digest, samples were denatured using
8M urea and 10 mM DTT for 1 h at 37°C, followed by alkylation (using a 2% 2-iodoethanol,
97.5% acetonitrile, 0.5% TEP solution). Peptides were digested using Trypsin/Lys-C Mix
(Promega, Madison, WI, USA) using the Barocycler NEP2320 (Pressure Biosciences, Inc.,
South Easton, MA, USA) at 50°C under 20,000 psi for 120 cycles (2 h). One cycle consisted of
50 seconds at 20,000 psi followed by 10 seconds at atmospheric pressure. The digestion was

47
quenched using trifluoroacetic acid. Injection volumes were adjusted to load 1 µg of sample onto
the column for nanoLC-MS/MS analysis.
Peptides were separated on a nanoLC system (1100 Series LC, Agilent Technologies,
Santa Clara, CA). The peptides were loaded on the Agilent 300SB-C18 enrichment column for
concentration and the enrichment column was switched in-line with the analytical column after 5
min. Peptides were separated with the C18 reversed phase ZORBAX 300SB-C18 analytical
column (0.75 μm × 150 mm, 3.5um) from Agilent. The column was connected to an emission tip
from New Objective and coupled to the nano electrospray ionization (ESI) source of the high
resolution hybrid ion trap mass spectrometer LTQ Orbitrap XL (Thermo Scientific). The
peptides were eluted from the column using acetonitrile (ACN)/0.1% formic acid (mobile phase
B). For the first 5 minutes, the column was equilibrated with 95% purified H2O /0.1% formic
acid (mobile phase A) followed by the linear gradient of 5% B to 40% B in 65 minutes at
0.3ul/min and from 40% B to 95% B in an additional 10 minutes. The column was washed with
95% of ACN/0.1% formic acid and equilibrated with 95% purified H2O/0.1% formic acid before
the next sample was injected. A blank injection was run between samples to avoid carryover and
keep the system clean.
The LTQ-Orbitrap mass spectrometer was operated in the data dependent positive
acquisition mode at a resolution of 30,000. Each full MS scan was followed by eight MS/MS
scans where these abundant molecular ions were selected and fragmented by collision induced
dissociation using a normalized collision energy of 35%.
2.3.7 Proteomic data analysis
The MS and MS/MS peak list files were analyzed using MaxQuant Version 1.5.2.8 [34].
To identify proteins, the MS/MS spectra were searched against the UniProt protein database,
which combines the SwissProt (manually annotated and reviewed) and TrEMBL (automatically
annotated and not reviewed) databases [35]. The following settings were used for conducting the
search: trypsin and Lys-C digestion enzymes with a maximum of two missed cleavages, fixed
modification of ethanolyl addition to cysteine, and variable modifications of N-terminal
acetylation and oxidation of methionine. The MS tolerance was set at 4.5 ppm with a maximum
of five modifications. A false discovery rate of 0.01 was used for protein and peptide
identifications, and the spectra were searched against a reverse decoy database. The minimum
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peptide length was set at seven amino acids, and a minimum score of 40 was required for
modified peptides. The MS/MS match tolerance was set at 40 ppm for protein identification, and
at least one unique/razor peptide was required for identification.
The MaxQuant output was analyzed using the bioinformatics statistical analysis program
Perseus 1.5.1.6. Potential contaminants, such as keratin, were removed, and then LFQ intensities
transformed log2(x). Protein intensities falling below the level of detection were assigned a value
of 12.0941. Only proteins identified in at least 4 of 6 biological replicates were considered
present in a particular genotype and used for the analysis of relative protein levels across
genotypes. The identified proteins were grouped into broad clusters based on Gene Ontology
(GO) terms for biological process or molecular function using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) v 6.7 and the analysis tool in STRING version
10.0. Protein-protein interactions were visualized using STRING version 10.0 using the
confidence view (medium confidence, score 0.400).
2.3.8 qPCR
Total RNA was extracted from jejunal mucosa with RNA STAT60 (Tel-Test,
Friendswood, TX) and then DNase treated with a Turbo DNA-free Kit (Ambion, Austin, TX).
cDNA was synthesized from 1µg DNase-treated RNA using the AffinityScript QPCR cDNA
Synthesis Kit (Stratagene, La Jolla, CA). Total DNA was extracted from tissues using DNeasy
Blood & Tissue Kit (Qiagen, Valencia, CA). SYBR green qPCR was performed using the
Mx3000P QPCR System (Stratagene) and Brilliant III SYBR Green Master Mix (Stratagene).
Primers used for determination of relative mRNA levels were produced by Integrated DNA
technologies (Coralville, IA) and validated for efficiency and correct product size in cDNA from
mouse intestinal mucosa (see Table 2.1). Mitochondrial content was assessed by determining the
ratio of mitochondrial DNA to nuclear genomic DNA. Primers for mitochondrial specific gene
are forward 5’-CCCATTCGCGTTATTCTT-3’ and reverse 5’AAGTTGATCGTAACGGAAGC-3’. Primers for nuclear specific gene are forward 5’TGGTAAAGCAAAGAGGCCTAA-3’ and reverse 5’-AGAAGTAGCCACAGGGTTGG-3’.
The level of each gene was calculated with the comparative Ct method using WT mice as the
reference group.

49
2.3.9 Statistical analysis
Values of quantitative data were reported as means ± standard error of the mean (SEM).
Statistical analyses of data were performed in SAS (SAS Institute, Inc., Cary, NC). One‐way
analysis of variance (ANOVA) with Tukey’s HSD post hoc test was used for multiple
comparisons. Type 3 tests of fixed effects and Kolmogorov-Smirnov tests were used for
characterization of CLD size distribution. A p value < 0.05 denotes a statistically significant
difference.

2.4

Results

2.4.1 Varying levels of intestinal Dgat1 and Dgat2 alters intracellular TAG distribution in
enterocytes
Multiple subcellular TAG pools were identified in enterocytes of WT mice 2 hours after a
200 l oral olive oil gavage using TEM (Figure 2.1 A), and the ultrastructural morphology of
these TAG pools were consistent with previously published work [26-30]. The subcellular TAG
pools present in the lumen of the ER, Golgi and Golgi-derived SVs) are involved in CM
synthesis and secretion, highlighting the complexity of this process. CMs are first assembled and
expanded in the lumen of the ER (Figure 1A-③, B and C), then transported to the Golgi (Figure
2.1 A-④ and D) and carried by SVs (Figure 1A-⑤ and E) to the basolateral side of enterocytes
for secretion. CM-sized lipid particles were also present in the intercellular space between
adjacent enterocytes (Figure1A-⑥ and E), showing that CMs were being secreted into the
lymph. In addition, CLDs (Figure1A-⑦ and F), which serve as a temporary TAG storage pool,
were present in enterocytes. The subcellular location of TAG pools for secretion and storage
were also distinct. TAG in the lumen of the ER was usually found in the apical region of
enterocytes beneath the microvilli, whereas TAG in the Golgi and SVs was usually found in the
central region of enterocytes just above the nucleus. CLDs of various sizes were primarily found
in the cytoplasmic area above the nucleus and occasionally on the basolateral side of enterocytes.
In addition, enterocyte CLDs were observed to have physical interactions with multiple
organelles including the ER, nucleus, degradative vacuoles (possibly lysosomes) and
mitochondria (data not shown).
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To investigate the role of individual Dgats in directing synthesized TAG into specific
subcellular pools, an ultrastructural examination of enterocytes from jejunum segments of WT,
Dgat1Int, Dgat2Int and Dgat1-/- mice was performed 2 hours after a 200 l oral olive oil gavage.
No abnormal villus morphology was observed in any of the mouse models, as assessed using
light microscopy (data not shown). The pattern of TAG distribution along the villi was similar
among the mouse models, with the greatest TAG content in the tip and the least in the crypt (data
not shown). The abundance of intracellular TAG in the tip area made it difficult to clearly
observe membrane structures in this region. Thus, the enterocytes in the middle area of villi,
which were structurally intact and contained moderate amounts of intracellular lipids, were
further examined.
Varying levels of intestinal Dgat1 and Dgat2 altered TAG distribution within enterocytes
(Figure 2.2). Among these models, almost all enterocytes presented with TAG in at least one of
the pools involved in the secretion process (ER lumen, Golgi, and/or SVs); however, not every
enterocyte contained TAG stored in CLDs. Thus, more than fifty enterocytes representing the
middle area of villi from each mouse were viewed to determine CLD presence. We found that
when Dgat1 levels were increased (Dgat1Int mice), the percentage of enterocytes containing
CLDs was significantly lower than in WT, Dgat2Int and Dgat1-/- mice (data not shown).
2.4.2 Varying levels of intestinal Dgat1 and Dgat2 alters the distribution of TAG in subcellular
pools for CM synthesis and secretion
In our previous studies, the intestinal TAG secretion rates of WT, Dgat1Int, Dgat2Int and
Dgat1-/- mice were assessed by administering an IP injection of Tyloxapol (to block TAG
clearance from circulation) and then measuring plasma TAG levels in response to an oral olive
oil gavage. We found that Dgat1Int, Dgat2Int and Dgat1-/- mice had unchanged, increased and
decreased rates of intestinal TAG secretion compared to WT mice, respectively (Figure 2.3 A)
[19, 20].
To determine whether subcellular TAG pools involved in CM synthesis and secretion are
altered by varying the levels of intestinal Dgat1 and Dgat2, we imaged enterocytes 2 hours after
a 200 μl oral olive oil gavage using TEM and quantified the area of TAG in the lumen of the ER,
as well as in the Golgi/SVs within individual cells from these models. In Dgat1Int mice, the mean
area of TAG in the ER is significantly greater than in WT mice (Figure 3 B-D), while the mean
area of TAG in Golgi/SVs is similar (Figure 2.3 E). In Dgat2Int mice, the mean area of TAG in
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the Golgi/SVs is significantly greater than in WT mice (Figure 2.3 B and E), while the mean area
of TAG in the ER is similar (Figure 2.3 D). In Dgat1-/- mice the mean area of TAG in the ER and
Golgi/SVs trended lower than in WT mice (Figure 2.3 D and E). Taken together, varying
intestinal levels of Dgat1 and Dgat2 alters subcellular pools of TAG in the ER and Golgi/SVs as
well as TAG secretion rate.
2.4.3 Varying levels of intestinal Dgat1 and Dgat2 alters enterocyte CLD morphology
We also identified alterations in CLD morphology in models with varying levels of
intestinal Dgat1 and Dgat2. We found that enterocytes of WT, Dgat1Int, Dgat2Int, and Dgat1-/mice all contained CLDs of various sizes. However, Dgat1Int and Dgat1-/-, but not Dgat2Int mice,
had significantly altered CLD size distributions compared to WT mice (Figure 2.4 A and B). In
WT and Dgat2Int mice the majority of CLDs were 1-3 µm in diameter. Dgat1Int mice had a right
skewed distribution in CLD size, with CLDs smaller than 1 µm in diameter observed most
frequently. On the other hand, Dgat1-/- mice exhibited the widest range of CLD sizes and were
the only model that could synthesize CLDs greater than 7 µm in diameter (maximum ~10µm in
diameter).
We further analyzed changes in CLD morphology within individual cells containing
CLDs. In Dgat1Int mice, the mean number, diameter and total area of CLDs is similar to WT
mice (Figure 2.4 C, D, and E). In Dgat2Int mice, the mean diameter of individual CLDs is similar
to WT mice (Figure 2.4 D); however, the mean number and total area of CLDs per cell are
significantly greater than in WT mice (Figure 2.4 C and E). In Dgat1-/- mice, the mean number of
CLDs is similar to WT mice (Figure 2.4 C); however, the mean diameter and total area of CLDs
per cell are significantly greater than in WT mice (Figure 2.4 D and E). Even though varying
levels of intestinal Dgat1 and Dgat2 alters the size or the number of CLDs per cell, intestinal
mRNA levels of proteins involved in CLD metabolism or morphology (Plin2, Plin3, and Seipin)
[21, 36] were similar in Dgat1Int, Dgat2Int and Dgat1-/- compared to WT mice 2 hours after a 200
l oral olive oil gavage (Figure 2.4 F).
2.4.4 Varying levels of intestinal Dgat1 and Dgat2 alters the enterocyte CLD proteome
Since proteins associated with CLDs have been shown to regulate their synthesis and
catabolism, we hypothesized that varying intestinal levels of Dgat1 and Dgat2 alters the proteins
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that associate with enterocyte CLDs. These alterations may contribute to the altered subcellular
TAG distribution in enterocytes of these models. To determine this, CLDs were isolated from
enterocytes of WT, Dgat1Int, Dgat2Int, and Dgat1-/- mice 2 hours after a 200 μl oral olive oil
gavage using density gradient ultracentrifugation [24, 32, 33]. This method enriches for CLDs,
as demonstrated by immunoblotting of the obtained fractions for representative CLD, cytosolic,
and membrane proteins [24]. A challenge in isolating CLDs from cells that make both CLDs and
lipoproteins is the potential for ER lumenal lipids and lipoproteins to contaminate the CLD
fraction. To minimize this, CLDs were isolated at a much lower speed than those used to isolate
ER lumenal lipids or CMs [37-39]. In addition, using negative stain electron microscopy we
observed that the isolated CLDs in WT, Dgat1Int, and Dgat2Int mice were similar in size, while
the isolated CLDs from Dgat1-/- mice spanned a greater size distribution, with the presence of
small as well as larger CLDs compared to the other models (Figure 2.5 A). This result is
consistent with the ultrastructural observation in Figure 2.4A and the images also suggest a lack
of broader contamination in the CLD enriched fraction.
Proteins present in the CLD fraction were identified using high resolution tandem mass
spectrometry. A total of 158 proteins were identified in at least 4 of 6 biological replicates of at
least one of the four mouse models. Of these 158 proteins, 53 of them were present in all four
models (Figure 2.5 B, Table 2.2), and the remainder were unique to one, two, or three genotypes
(Figure 2.5 B, Table 2.3). For further characterization, the gene functional classification tool
DAVID and the protein analysis tool STRING were used to classify proteins into broad
categories based on gene ontology (GO) terms for biological process or molecular function.
Since several proteins had multiple functions that fell under more than one of the broad
classifications, their functions were further investigated by performing individual protein
searches using the UniProt database. The available information about the function of the protein
was used to determine the most appropriate broad classification (Tables 2.2 & 2.3, Function
column).
The 53 proteins common among the four mouse models are involved in multiple
biological processes (Figure 2.5 C). The majority of these common proteins are involved in
carbohydrate metabolism (19%), cell stress response (19%), or lipid metabolism (15%). The
relative abundances of these common proteins were also compared among the genotypes, and
four proteins were found to be differentially expressed among the models (Figure 2.5 D).
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Hemoglobin subunit beta-1 (Hbbt), which was classified as a cell stress response-related protein
[40], had significantly higher relative levels in Dgat2Int enterocyte CLD fractions compared to
Dgat1-/- fractions. In addition, heterogeneous nuclear ribonucleoproteins A2/B1 (Hnrnpa2b1),
which is involved regulating transcription/translation, was expressed at higher levels in Dgat1-/mice compared to all the other genotypes. Furthermore, 40S ribosomal protein SA (Rpsa), which
also plays a role in translation [41], was expressed at higher levels in Dgat1-/- compared to
Dgat1Int mice. Additionally, the carbohydrate metabolism-related protein malate dehydrogenase
(Mdh1) [42] was expressed at higher levels in Dgat1-/- compared to Dgat1Int mice.
To better understand the role of CLDs in intestinal lipid metabolism in these models with
varying levels of intestinal Dgat1 and Dgat2, further analysis was performed on all of the
identified proteins with biological process or molecular function GO terms related to lipid
metabolism. Overall, 13% of all of the proteins identified in this study were associated with
lipid/lipoprotein metabolism. The majority of these proteins have been previously identified as
CLD-associated proteins in various cell types, and those identified in enterocyte models are
highlighted (Table 2.4, Previously Identified column). In addition, just under half of these lipid
metabolism related proteins were common to WT, Dgat1Int, Dgat2Int, and Dgat1-/- mice, while
the remainder were unique to one, two, or three of these models (Table 2.4). A few of these
differentially expressed proteins, including Dgat1, Lambda-crystallin homolog (Cryl1), and
Aminopeptidase B (Rnpep), were identified for the first time as being associated with CLDs in
these models. Predicted interactions between the identified lipid metabolism proteins were
visualized by performing a STRING analysis. The STRING network shows several protein
clusters, including one large cluster containing proteins involved in fatty acid modification as
well as TAG and CM synthesis (Figure 2.5 E).
2.4.5 Varying levels of intestinal Dgat1 and Dgat2 impacts enterocyte mitochondrial biology
Fatty acid oxidation (FAO) takes place mainly within mitochondria and has the potential
to reduce the availability of fatty acids for TAG synthesis and incorporation into CMs and CLDs
[43-45]. Therefore, we determined mRNA levels of genes involved in FAO and the ratio of
mitochondrial DNA to genomic DNA (indicator of mitochondrial content) in enterocytes of WT,
Dgat1Int, Dgat2Int, and Dgat1-/- mice 2 hours after a 200 μl oral olive oil gavage. We found
similar mRNA levels of FAO genes (Cpt1 and Acox) in mice with varying intestinal Dgat1 and
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Dgat2 levels (Figure 6A). In Dgat2Int mice, however, mitochondrial content was significantly
lower than that observed in all the other mouse models (Figure 2.6 B). In addition, we frequently
observed round, swollen-looking mitochondria in Dgat1-/- mice by TEM (Figure 2.6 C and D).
Taken together, varying levels of intestinal Dgat1 and Dgat2 affects enterocyte mitochondrial
morphology and content without affecting mRNA levels of FAO genes in response to acute fat
challenges.

2.5

Discussion
In the present study, we investigated whether varying intestinal Dgat1 and Dgat2 levels

alters TAG distribution in subcellular pools for CM synthesis as well as the morphology and
proteome of CLDs. The multi-step and dynamic nature of this process makes it challenging to
determine distinct roles of Dgat enzymes in CM and CLD synthesis; however the results
presented here highlight that Dgat1 and Dgat2 play non-redundant, but coordinated roles in
dietary fat absorption. A proposed model for the roles of Dgat1 and Dgat2 in enterocytes during
dietary fat absorption was generated based on these as well as previous results (Figure 2.7).
Overall, we found that Dgat1 preferentially synthesizes TAG that supports the synthesis of TAGrich CMs, whereas Dgat2 preferentially synthesizes TAG that is incorporated into nascent CMs
and CLDs.
2.5.1 Varying levels of intestinal Dgat1 and Dgat2 alters the distribution of TAG in subcellular
pools for CM synthesis and secretion
Consistent with earlier ultrastructural studies of enterocytes after consumption of dietary
fat [26-29], we observed TAG present along the secretory pathway (in the ER, Golgi and SVs) in
enterocytes from WT mice as well as mice with altered intestinal Dgat levels. CMs are first
synthesized in ER lumen by a two-step process that involves two distinct pools of TAG:
apolipoprotein B (ApoB)-containing nascent CMs and ApoB-free lumenal lipid droplets (LLDs)
[46] (Figure 2.7 B). ApoB-containing nascent CMs are generated by incorporation of a small
amount of TAG onto ApoB, the main structural protein of CMs. ApoB-free LLDs are used in the
second step of CM synthesis for expansion of nascent CMs, yielding TAG-rich pre-CM particles.
ApoB-free LLDs were initially identified in mice deficient in ApoB by TEM [30], and have a
distinct appearance similar to what was observed predominantly in the Dgat1Int mice in this
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study (Figure 2.3 B and C). ApoB-containing nascent CMs are challenging to visualize due to
their poor lipidation, however only particles containing ApoB are able to be transported from the
ER to the Golgi for secretion [47]. Pre-CM particles are transported to the Golgi by pre-CM
transport vesicles and ultimately to SVs for exocytosis from the basolateral side of enterocytes
into lymph [48]. By quantitatively assessing TEM images we observed alterations in TAG
distribution within these subcellular locations in enterocytes of mouse models with varying
intestinal Dgat1 and Dgat2 levels (Figure 2.3). The proposed roles of Dgat1 and Dgat2 in
synthesizing TAG for CM synthesis and secretion are discussed below.
We propose that Dgat1 drives the synthesis of TAG for incorporation into ApoB-free
LLDs based on the results from Dgat1Int and Dgat1-/- mice (Figure 2.7). First, the accumulation
of TAG in the ER in Dgat1Int enterocytes suggests more ApoB-free LLDs than ApoB-containing
particles are produced when Dgat1 is overexpressed (Figure 2.2 and 2.3). Although the
presence/absence of ApoB on these particles was not assessed, the result mimics the
accumulation of LLDs seen in enterocytes of mice with intestine-specific deficiency of ApoB
[30] and in response to pharmaceutical inhibition of protein synthesis [26], where only LLDs can
be synthesized. However, the greater amount of TAG present in the ER lumen in Dgat1Int
enterocytes has little effect on the amount of TAG reaching the Golgi/SVs within enterocytes,
the size of CMs in the blood, or intestinal TAG secretion rate, since these are all similar to WT
mice [20]. This suggests the presence of other mechanisms that determine which or how many
ApoB-free LLDs are able to fuse with ApoB-containing nascent CMs within the ER. Second,
significant reductions in the size of CMs secreted into the blood are seen in Dgat1-/- compared to
WT mice [20]. This was supported by a trend, but not significant reduction in TAG content in
the ER and Golgi/SVs within enterocytes of Dgat1-/- compared to WT mice in this study (Figure
2.3 D and E). This suggests that the absence of Dgat1 leads to a defect in LLD synthesis that
prevents the synthesis of TAG-rich CMs. Taken together, our results support a role of Dgat1 in
synthesizing TAG that is incorporated into LLDs, which determines the availability of TAG for
nascent CM expansion and contributes to the synthesis of TAG-rich CMs.
We propose that Dgat2 drives the synthesis of TAG for incorporation into ApoB-containing
nascent CMs, as supported by the results from Dgat2Int and Dgat1-/- mice (Figure 2.7). First,
since lipid particles must acquire ApoB before being transported from the ER to Golgi, the
increased TAG content in the Golgi/SVs in Dgat2Int enterocytes suggests that Dgat2 is involved
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in synthesizing TAG for incorporation into ApoB-containing nascent CMs. In addition, TAG
present in the Golgi/SVs within enterocytes positively correlates with CM secretion from
enterocytes [26, 29, 30], so the increased TAG content in the Golgi/SVs of Dgat2Int enterocytes
is also consistent with the increased intestinal TAG secretion rate in this model [20]. This
increased TAG secretion in Dgat2Int mice is likely due to an increased number of CMs being
secreted since there are no differences in CM size compared to WT mice [20]. Second, mice
lacking Dgat2 die within a few hours of birth [17, 49]. This supports an essential role of Dgat2 in
the synthesis and secretion of ApoB-containing lipoproteins from enterocytes for dietary fat
absorption and survival. Furthermore, Dgat1-/- mice, which only express Dgat2, have nascent
CMs present in the Golgi of enterocytes and are capable of secreting CMs into blood [18]. Taken
together, these results suggest that Dgat2 plays an important role in driving the synthesis of
ApoB-containing nascent CMs that fuse with LLDs synthesized by Dgat1, and together these
enzymes regulate the rate of intestinal TAG secretion.
2.5.2 Varying levels of intestinal Dgat1 and Dgat2 alters enterocyte CLD morphology
Varying levels of intestinal Dgat1 and Dgat2 affects the number and size of CLDs in
enterocytes after dietary fat is consumed, which may in part be due to their contribution to CM
synthesis and secretion. The CLD morphology observed in enterocytes of Dgat1Int and Dgat1-/mice (Figure 2.4 and 2.7) support the hypothesis that Dgat1 restricts and Dgat2 promotes CLD
expansion reported in other models [12, 50]. In primary hepatocytes, which express both Dgat1
and Dgat2, inhibition of Dgat2 reduced CLD size whereas inhibition of Dgat1 increased CLD
size [12]. In addition, the overexpression of Dgat2 in HEK293T cells resulted in increased CLD
size [50]. This observation is thought to be due to the localization of Dgat2 to CLDs and its
ability to synthesize TAG directly at the CLD surface [50, 51]. Although we did see larger CLDs
in Dgat1-/- mice, we did not see an increase in CLD size when Dgat2 was overexpressed in the
intestine. We hypothesize that this is due to the combination of high endogenous levels of Dgat1
and high transgenic levels of Dgat2, which is different than in the liver or other cell types that
have been used to assess the roles of these enzymes. In this situation the presence of high
amounts of Dgat1 can direct synthesized TAG to LLDs and thus restrict CLD expansion. In
addition, high amounts of Dgat2 can synthesize TAG for incorporation into both nascent CMs
and CLDs, which may also limit CLD expansion.
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2.5.3 Varying levels of intestinal Dgat1 and Dgat2 alters the enterocyte CLD proteome
Consistent with other CLD proteomic studies, proteins involved in diverse cellular
functions were found to be associated with enterocyte CLDs among the mouse models.
Interestingly, the greatest percentage of the proteins identified in all four mouse models were
classified as playing roles in carbohydrate metabolism or cell stress response (Figure 2.5 C). It is
unknown whether or not these proteins play functional roles at the CLD surface, are being
sequestered at this location to regulate their function/activity in the cell, or are contaminants
resulting from the lipid droplet isolation procedure. However, proteins involved in these
processes have been identified in CLD proteomics studies from multiple cell types [22-24, 5256].
Several proteins associated with lipid and lipoprotein metabolism were found to associate
with CLDs in the current study, and some were differentially expressed among mice with altered
intestinal Dgat levels. We have selected a few of these proteins to highlight below. They include:
Cideb, ApoAIV, Dgat1, Cryl1, and Rnpep. Among them, only the localization of Cideb and
ApoAIV to CLDs has been validated using additional methods (Western blot or
immunofluorescence) [22, 24, 57, 58]. Although validation of the localization of the other
proteins to enterocyte CLDs is still needed, the findings suggest that these lipid related proteins
may be uniquely contributing to the altered susceptibilities to obesity and related metabolic
diseases in these mouse models.
Interestingly, we found that Cideb uniquely associates with enterocyte CLDs in Dgat1-/mice, while ApoAIV was identified in all of the models except Dgat1-/- mice. Cideb is a member
of the CIDE protein family, which has been shown to regulate CLD size in multiple cell types
[59, 60]. Cideb has been show to localize to CLDs in mouse liver and when exogenously
expressed in Caco-2 cells [58]. Cideb-deficient mice exhibit a decreased TAG secretion rate,
decreased CM size, and increased TAG storage within enterocyte CLDs, suggesting Cideb is
important for CM lipidation. Since Dgat1-/- and Cideb-deficient mice exhibit a similar phenotype,
this suggests that Cideb localization to CLDs may prevent it from promoting CM lipidation at
the ER membrane. Consistent with previous studies that validated the localization of ApoAIV to
enterocyte CLDs [22, 24], ApoAIV was identified on enterocyte CLDs of WT, Dgat1Int, and
Dgat2Int mice in the current study. However ApoAIV was not identified on enterocyte CLDs of
Dgat1-/- mice, which exhibit decreased TAG secretion. Since ApoAIV is known to play a role in
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regulating CM metabolism, it is possible that ApoAIV plays a functional role at the CLD surface
that promotes CM secretion. Taken together, the differential association of these proteins that
regulate CM metabolism with enterocyte CLDs in Dgat1-/- mice compared to the other models
suggests that they may contribute to the altered TAG storage and secretion in this model.
Dgat1 was only found to associate with CLDs in enterocytes of Dgat1Int mice. Dgat1 is
thought to localize exclusively to the ER membrane and has not previously been identified in
other CLD proteomic studies. However, other TAG synthesis enzymes that were initially thought
to be ER resident proteins (Mgat2 [18], Dgat2 [7, 50], and several glycerol-3-phosphate pathway
enzymes [7]) have also been found to localize to CLDs and play a role in local CLD growth.
Since Dgat1 is a multi-spanning integral membrane protein [61], it is unlikely that it directly
associates with the CLD monolayer, and thus may only be identified in Dgat1Int mice due to its
overexpression. However we cannot rule out the possibility that Dgat1associates with CLDs
through an alternative domain or mechanism, as is the case for Dgat2 [50]. Alternatively, it could
be misfolded or non-functional at the CLD surface and targeted to CLDs for degradation (as is
the case for apoB [62]) as a way to regulate Dgat1 activity at the ER.
Two lipid related proteins, Cryl1 and Rnpep, were only found to associate with enterocyte
CLDs in models with a higher than normal ratio of Dgat2 to Dgat1 (Dgat2Int and Dgat1-/- mice).
Cryl1 shares sequence homology with 3-hydroxyacyl-CoA dehydrogenase, an enzyme that
catalyzes the third reaction of fatty acid beta oxidation [18, 63]. Human CRYL1 mRNA is
expressed at low levels in the small intestine and Cryl1 has been detected at moderate levels in
mouse large intestine [64], but very little is known about its role in intestinal lipid metabolism.
Therefore, further investigation of this protein’s function in enterocytes is needed. In addition to
exhibiting aminopeptidase activity, Rnpep also hydrolyzes the lipid mediator leukotriene A4
(LTA4) [65], resulting in the formation of the pro-inflammatory LTB4 [66]. Interestingly, we also
identified Leukotriene A-4 hydrolase (Lta4h) associated with enterocyte CLDs in all except the
Dgat1Int model, and this protein has also been identified in other CLD proteomics studies (see
Table 4.4). The presence of these enzymes at the CLD surface suggests that an acute high dietary
fat load has the potential to induce an inflammatory response, consistent with previous studies
[67].
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2.5.4 Varying levels of intestinal Dgat1 and Dgat2 impacts enterocyte mitochondrial biology
The changes in mitochondrial biology observed in enterocytes of Dgat2Int and Dgat1-/compared to WT mice have the potential to contribute to the alterations in intestinal TAG
metabolism observed in these models. We found that Dgat2Int mice have significantly reduced
mitochondrial content, but similar mRNA levels of genes involved in FAO in response to an
acute fat challenge. Interestingly, we previously found that Dgat2Int mice have reduced mRNA
levels of FAO genes in a fed state after chronic high fat diet feeding [20]. We are uncertain why
we observed differences in the chronic high fat diet fed state but not after an acute high fat
challenge. However, these results highlight the potential for FAO to alter the availability of fatty
acids for TAG synthesis and incorporation into CMs and CLDs. In addition, we found that
Dgat1-/- mice have altered mitochondrial morphology but no change in mitochondrial content in
enterocytes. The poor membrane integrity of mitochondria in Dgat1-/- enterocytes indicates
possible impaired mitochondrial function, which may contribute to or result from the abnormal
TAG storage in CLDs observed in this model. Although FAO was not directly measured in these
studies, these observations suggest that regulation of FAO is important in these models. Future
studies are needed to further assess the role of FAO in intestinal TAG metabolism.
2.5.5 Intestinal DGAT1 and DGAT2 in mice versus humans
Although it is known that DGAT1 is the major intestinal DGAT enzyme in both mice and
humans, it is still unclear whether or not DGAT2 plays an important physiological role within
this tissue in humans. Dgat2 is present at significantly lower levels compared to Dgat1 in the
intestine of mice, and whether DGAT2 is expressed in human intestine is questionable [6]. One
of the reasons for this is that a DGAT1 loss of function mutation has been identified in humans
and observed to cause congenital diarrheal disorder resulting in severe outcomes [68, 69].
Dgat1-/- mice, on the other hand, have no obvious increase in fecal fat or diarrhea, and their
intestine phenotype contributes to their beneficial resistance to diet induced obesity [16, 18, 19].
In addition, gastrointestinal side effects observed in humans with DGAT1 mutations are also
observed in humans treated with DGAT1 inhibitors, leading to the conclusion that these effects
may be target specific. More recently, however, the DGAT1 inhibitor pradigastat has been well
tolerated in overweight/obese individuals and patients with familial chylomicronemia syndrome
[70, 71], suggesting these inhibitors may still be beneficial for some patients. Although mice and
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humans may differ in terms of the relative contributions of DGAT1 and DGAT2 to dietary fat
absorption, knowledge gained from investigating the altered intestinal lipid metabolism in
models with varying intestinal levels of Dgat1 and Dgat2 in mice will contribute to novel
knowledge of additional players in the process of dietary fat absorption that may be significant in
human health and disease.
2.5.6 Conclusion
Overall, the results from this study show that Dgat1 and Dgat2 have non-redundant roles
in intestinal lipid metabolism that are required for proper regulation of dietary fat absorption.
The ultrastructural analyses of enterocytes suggest that Dgat1 preferentially synthesizes TAG for
incorporation into ApoB-free LLDs, promoting CM expansion. The results also support that
Dgat2 preferentially synthesizes TAG for incorporation into ApoB-containing nascent CMs and
CLDs. The defect in CM synthesis and secretion due to the deficiency of Dgat1 highlights the
importance of the coordinated functions of Dgat1 and Dgat2 in the process of dietary fat
absorption. Furthermore, varying levels of intestinal Dgat1 and Dgat2 impacts the proteins that
associate with CLDs, which may play a role in regulating both TAG storage and secretion.
Further investigation of these identified proteins may lead to the identification of novel
regulators of dietary fat absorption, which have the potential to serve as therapeutic targets for
the treatment of obesity, diabetes, and cardiovascular disease.
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Table 2.1 Primers used for qPCR
Gene
Cpt1α
Acox1
Plin2
Plin3
Seipin
β-actin

Primer Sequences
F 5’-TGTGGTGTCCAAGTATCTGGCAGT-3’
R 5’- AACACCATAGCCGTCATCAGAAC-3’
F 5’- ATATTTACGTCACGTTTACCCCGG-3’
R 5’-GGCAGGTCATTCAAGTACGACAC-3’
F 5’-AAGAGGCCAAACAAAAGAGCCAGGAGACCA-3’
R 5’- ACCCTGAATTTTCTGGTTGGCACTGTGCAT-3’
F 5’-ATGGAATCCGTGAAACAGGGTGTG-3’
R 5’-TGAGAGGTCCTGGAAGGAGTGAAT-3’
F 5’- TTTGGCTTCGCTGAACAGAAGCAG-3’
R 5’-ATAGCTGAAGAGCACGATGACGCT-3’
F 5’-AGGCCCAGAGCAAGAGAGGTA-3’
R 5’-GGGGTGTTGAAGGTCTCAAACA-3’
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Table 2.2 CLD-associated proteins common among all genotypes

Protein
Alpha-enolase
ATP synthase subunit alpha, mitochondrial
ATP synthase subunit beta, mitochondrial
Bifunctional ATP-dependent dihydroxyacetone
kinase/FAD-AMP lyase (cyclizing)
Fructose-bisphosphate aldolase B
Glyceraldehyde-3-phosphate dehydrogenase
Malate dehydrogenase, cytoplasmic
Malate dehydrogenase, mitochondrial
Pyrethroid hydrolase Ces2e
Pyruvate kinase PKM
78 kDa glucose-regulated protein
Apoptosis-associated speck-like protein
containing a CARD
Bifunctional 3-phosphoadenosine 5phosphosulfate synthase 2
Bifunctional epoxide hydrolase 2
Glutathione S-transferase Mu 3
Glutathione S-transferase P 1
Hemoglobin subunit beta-1
Protein disulfide-isomerase
Superoxide dismutase [Cu-Zn]

Gene
Eno1
Atp5a1
Atp5b

UniProt ID
P17182
Q03265
P56480

Function
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism

Dak
Aldob
Gm3839
Mdh1
Mdh2
Ces2e
Pkm
Hspa5

Q8VC30
Q91Y97
P16858
P14152
P08249
Q8BK48
P52480
P20029

Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Cell Stress Response

Pycard

Q9EPB4

Cell Stress Response

Papss2
Ephx2
Gstm3
Gstp1
Hbbt1
P4hb
Sod1
Tpm1
Actg1
Anxa2
Tuba1c
Tubb4b
Vil1
Ces2c
Apoa1
Hsd17b11
Fabp2
Fabp1

O88428
P34914
P19639
P19157
A8DUK4
P09103
P08228
G5E8R0
P63260
B0V2N7
P68373
P68372
Q62468
Q91WG0
Q00623
Q9EQ06
P55050
P12710

Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization
Lipid Metabolism
Lipid Metabolism
Lipid Metabolism
Lipid Metabolism
Lipid Metabolism

O08601
Q9DCN2
Q9DBG5
P30275
G5E850
Q99L04

Lipid Metabolism
Lipid Metabolism
Lipid Metabolism
Mitochondria/Redox
Mitochondria/Redox
Mitochondria/Redox

Actin, cytoplasmic 2
Annexin
Tubulin alpha-1C chain
Tubulin beta-4B chain
Villin-1
Acylcarnitine hydrolase
Apolipoprotein A-I
Estradiol 17-beta-dehydrogenase 11
Fatty acid-binding protein, intestinal
Fatty acid-binding protein, liver
Microsomal triglyceride transfer protein large
subunit
Mttp
NADH-cytochrome b5 reductase 3
Cyb5r3
Perilipin-3
Plin3
Creatine kinase U-type, mitochondrial
Ckmt1
Cytochrome b5
Cyb5a
Dehydrogenase/reductase SDR family member 1 Dhrs1
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Table 2.2 continued
Histone H2A type 1-H
Histone H2B type 1-P
Histone H4
Heat shock protein HSP 90-beta
14-3-3 protein zeta/delta
Alpha-actinin-4
Annexin A4
Clathrin heavy chain
40S ribosomal protein SA
Elongation factor 1-alpha 1
Elongation factor 1-delta
Heterogeneous nuclear ribonucleoproteins
A2/B1

Hist1h2ah
Hist1h2bp
Hist1h4a
Hsp90ab1
Ywhaz
Actn4
Anxa4
Cltc
Rpsa
Eef1a1
Eef1d

Q8CGP6
Q8CGP2
P62806
P11499
P63101
P57780
P97429
Q5SXR6
P14206
P10126
D3Z7N2

Calmodulin

Calm1

P62204

Galectin-2

Lgals2

Q9CQW5

Hnrnpa2b1 O88569

Galectin-4
Lgals4
Heat shock cognate 71 kDa protein
Hspa8
Sodium/potassium-transporting ATPase subunit
alpha-1
Atp1a1

Nucleosome Assembly
Nucleosome Assembly
Nucleosome Assembly
Protein Folding
Protein Localization/Transport
Protein Localization/Transport
Protein Localization/Transport
Protein Localization/Transport
Translation
Translation
Translation

Q8K419
P63017

Translation
Other (Calcium Mediated
Signaling)
Other (Carbohydrate Binding,
Unknown Function)
Other (Carbohydrate Binding,
Unknown Function)
Other (Protein Metabolism)

Q8VDN2

Other (Ion Transport)
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Table 2.3 CLD-associated proteins unique to one, two, or three genotypes

Protein
Cytochrome b-c1 complex subunit 1,
mitochondrial
Guanine deaminase
Diacylglycerol O-acyltransferase 1

Gene
Dgat1Int

UniProt ID Function

Q9CZ13
Q9R111
Q9Z2A7

Carbohydrate Metabolism,
Mitochondria/Redox
Carbohydrate Metabolism
Lipid Metabolism

P48758

Carbohydrate Metabolism

Q9CZS1
P00405

Carbohydrate Metabolism
Carbohydrate Metabolism

Ddost
Oat
Ces2g
Peroxisomal multifunctional enzyme type 2
Hsd17b4
V-type proton ATPase catalytic subunit A
Atp6v1a
Zymogen granule membrane protein 16
Zg16
T-complex protein 1 subunit delta
Cct4
Dgat1-/4-trimethylaminobutyraldehyde dehydrogenase Aldh9a1
6-phosphogluconate dehydrogenase,
decarboxylating
Pgd
Aldehyde dehydrogenase family 16 member A1 Aldh16a1
Glutamine--fructose-6-phosphate
aminotransferase [isomerizing] 1
Gfpt1
Glycerol-3-phosphate dehydrogenase [NAD(+)],
cytoplasmic
Gpd1

O54734
P29758
E9PV38
P51660
P50516
Q8K0C5
G5E839

Carbohydrate Metabolism
Carbohydrate Metabolism
Hydrolase
Lipid Metabolism
Nucleotide Biosynthesis
Protein Localization/Transport
Protein Metabolism

Q9JLJ2

Carbohydrate Metabolism

Q9DCD0
D3Z0B9

Carbohydrate Metabolism
Carbohydrate Metabolism

P47856

Carbohydrate Metabolism

E0CXN5

Isocitrate dehydrogenase [NADP] cytoplasmic
Cell death activator CIDE-B

Idh1
Cideb

O88844
O70303

Nucleophosmin
Peroxiredoxin-1
Peroxiredoxin-2
Peroxiredoxin-5, mitochondrial
Adenylyl cyclase-associated protein 1
Destrin
Cytochrome P450 2D26

Npm1
Prdx1
Prdx2
Prdx5
Cap1
Dstn
Cyp2d26

Q5SQB0
B1AXW5
Q61171
G3UZJ4
P40124
Q9R0P5
Q8CIM7

Carbohydrate Metabolism
Carbohydrate Metabolism,
Cell Stress Response
Cell Stress Response
Cell Stress Response,
Cytoskeletal Organization
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cytoskeleton Organization
Cytoskeletal Organization
Mitochondria/Redox

Carbonyl reductase [NADPH] 1
Aldehyde dehydrogenase X, mitochondrial
Cytochrome c oxidase subunit 2
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase 48 kDa subunit
Ornithine aminotransferase, mitochondrial

Uqcrc1
Gda
Dgat1
WT
Cbr1
Dgat2Int
Aldh1b1
Mtco2
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Table 2.3 continued

Bifunctional purine biosynthesis protein PURH Atic
Q9CWJ9
J3QPS8
Eukaryotic translation initiation factor 5A-1
Eif5a
P60335
Poly(rC)-binding protein 1
Pcbp1
P62320
Small nuclear ribonucleoprotein Sm D3
Snrpd3
Int
Dgat1 , WT
P62242
40S ribosomal protein S8
Rps8
Int
Int
Dgat1 , Dgat2
Beta-1,4 N-acetylgalactosaminyltransferase 2
B4galnt2 Q09199
P24270
Catalase
Cat
P58021
Transmembrane 9 superfamily member 2
Tm9sf2
Int
WT, Dgat2
Heat shock protein HSP 90-alpha
Hsp90aa1 P07901
WT, Dgat1-/P06151
L-lactate dehydrogenase A chain
Ldha
Q9CZ44
NSFL1 cofactor p47
Nsfl1c
F8WGL3
Cofilin-1
Cfl1
Q04447
Creatine kinase B-type
Ckb
D3Z6A6
Glutathione S-transferase
Gsta2
P62264
40S ribosomal protein S14
Rps14
D3YV43
40S ribosomal protein S3
Rps3
E9Q9C6
Fcgbp
Int
-/Dgat2 , Dgat1
P62259
14-3-3 protein epsilon
Ywhae
P62843
40S ribosomal protein S15
Rps15
F6YVP7
40S ribosomal protein S18
Rps18
Dgat1Int, WT, Dgat2Int
Nucleobindin-1
Apolipoprotein A-IV
Retinal dehydrogenase 1;Aldehyde
dehydrogenase, cytosolic 1
Protein disulfide-isomerase A3
Protein disulfide-isomerase A6
Myosin-14
Myosin-9
Cytochrome P450 2B10

Nucb1
Apoa4

H3BK79
P06728

Aldh1a1 O35945
Dgat1Int, Dgat2Int, Dgat1-/P27773
Pdia3
Q3TML0
Pdia6
K3W4R2
Myh14
Q8VDD5
Myh9
Cyp2b10 Q9WUD0

Nucleotide Biosynthesis,
Mitochondria/Redox
Protein Localization/Transport
RNA Processing
RNA Processing
Translation
Carbohydrate Metabolism
Cell Stress Response
Unknown Function
Protein Localization/Transport
Carbohydrate Metabolism
Cell Stress Response
Cytoskeleton Organization
Kinase, Transferase
Transferase
Translation
Translation
Unknown Function
Protein Localization/
Transport
Translation
Translation
Calcium Ion Binding,
Unknown Function
Lipid Metabolism
Lipid Metabolism
Cell Stress Response
Cell Stress Response
Cytoskeletal Organization
Cytoskeletal Organization
Lipid Metabolism

66
Table 2.3 continued
Q8JZR0
Long-chain-fatty-acid--CoA ligase 5
Acsl5
Q99KI0
Aconitate hydratase, mitochondrial
Aco2
Q9CQX2
Cytochrome b5 type B
Cyb5b
Synaptic vesicle membrane protein VAT-1
homolog
Vat1
Q62465
P53994
Ras-related protein Rab-2A
Rab2a
P17742
Peptidyl-prolyl cis-trans isomerase A
Ppia
P97351
40S ribosomal protein S3a
Rps3a
P47963
60S ribosomal protein L13
Rpl13
P14148
60S ribosomal protein L7
Rpl7
Int
WT, Dgat2 , Dgat1-/P70695
Fructose-1,6-bisphosphatase isozyme 2
Fbp2
P40142
Transketolase
Tkt
B2M1R6
Heterogeneous nuclear ribonucleoprotein K
Hnrnpk
Q543K9
Purine nucleoside phosphorylase
Pnp
Q02053
Ubiquitin-like modifier-activating enzyme 1
Uba1
Q3V0K9
Plastin-1
Pls1
P24527
Leukotriene A-4 hydrolase
Lta4h
Guanine nucleotide-binding protein subunit
beta-2-like 1
Gnb2l1
P68040
Q01853
Transitional endoplasmic reticulum ATPase
Vcp
Leukocyte elastase inhibitor A
Serpinb1a Q9D154
P58252
Elongation factor 2
Eef2

Lipid Metabolism
Mitochondria/Redox
Mitochondria/Redox
Mitochondria/Redox
Protein Localization/Transport
Protein Metabolism
Translation
Translation
Translation
Carbohydrate Metabolism
Carbohydrate Metabolism
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cytoskeletal Organization
Lipid Metabolism
Protein Localization/Transport
Protein Localization/Transport
Protein Metabolism
Translation
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Table 2.4 CLD-associated proteins involved in lipid/lipoprotein metabolism

Protein

Gene

Acylcarnitine hydrolase
Ces2c
ATP synthase subunit alpha,
mitochondrial
Atp5a1
ATP synthase subunit beta,
mitochondrial
Atp5b
NADH-cytochrome b5
reductase 3
Cyb5r3
Bifunctional epoxide hydrolase
2
Ephx2
Fatty acid-binding protein, liver Fabp1
Fatty acid-binding protein,
intestinal
Fabp2
Estradiol 17-betadehydrogenase 11*
Hsd17b11
Microsomal triglyceride
transfer protein large subunit* Mttp

Previously Identified Dgat1Int

WT

Dgat2Int Dgat1-/-

[24, 55]

✓

✓

✓

✓

[24, 52, 54-56, 72, 73]
[22, 24, 52, 54-56, 72,
73]
[22-24, 52, 54, 55, 7274]

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

[24, 54, 55]
[24, 54, 55]

✓
✓

✓
✓

✓
✓

✓
✓

[24, 55]

✓

✓

✓

✓

[22, 24, 53-56, 72-77]

✓

✓

✓

✓

[22-24, 55]
[22-24, 53, 55, 56, 7275, 78-81]

✓

✓

✓

✓

✓

✓

✓

✓

[24, 55]

✓

✓

✓

✓

✓

Perilipin-3*

Plin3

Retinal dehydrogenase 1

Aldh1a1

Apolipoprotein A-IV*
Long-chain-fatty-acid--CoA
ligase 5*

Apoa4

[22, 24, 55, 73]

✓

Acsl5

✓

✓

✓

Cytochrome b5 type B

Cyb5b

[23, 24, 55]
[52, 54, 55, 72-75, 77,
79, 81]

✓

✓

✓

Cytochrome P450 2B10

Cyp2b10

[24]

✓

✓

✓

Leukotriene A-4 hydrolase

Lta4h

✓

✓

Aminopeptidase B

Rnpep

✓

✓

Lambda-crystallin homolog
Diacylglycerol Oacyltransferase 1
Peroxisomal multifunctional
enzyme type 2

Cryl1

✓

✓

✓

✓

Dgat1
Hsd17b4

[55, 72, 73]

✓

Cell death activator CIDE-B* Cideb
Cytochrome P450 2D26

Cyp2d26

✓

[24, 55]

✓

*Proteins validated as being associated with CLDs using immunohistochemistry &/or Western blot
[22-24] represent enterocyte models
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Figure 2.1 Identification of subcellular TAG pools within enterocytes by TEM
(A) An ultrastructural overview of enterocytes from the jejunum of WT mice 2 hours after a 200
l oral olive oil gavage. At this time point during dietary fat absorption, TAG is found in several
subcellular pools involved in either CM or CLD synthesis. CMs are assembled and further
expanded in the ER lumen ③, then transported to the Golgi ④ and Golgi-derived SVs ⑤, and
finally secreted from enterocytes into the lymph ⑥. CLDs serve as temporary TAG storage
pools in enterocytes ⑦. (B) TAG present in the lumen of the ER is surrounded by smooth ER
membrane. (C) The smooth ER containing TAG (black arrows) is continuous with the rough ER
membrane, which can be distinguished by the presence of ribosomes (white arrows). (D) TAG is
present within stacks of the Golgi apparatus. (E) CMs are carried within SVs (black arrow) and
secreted into the intercellular space (*). (F) CLDs are surrounded by a phospholipid monolayer.
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Figure 2.2 Varying levels of intestinal Dgat1 and Dgat2 alters intracellular TAG distribution in
enterocytes
Representative TEM images of enterocytes from the jejunum of Dgat1Int, WT, Dgat2Int and
Dgat1-/- mice 2 hours after a 200 l oral olive oil gavage. Representative CLD (*), TAG in ER
lumen (black arrows), and TAG in Golgi/SVs (white arrows) are highlighted. Scale bar = 2 μm
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Figure 2.3 Varying levels of intestinal Dgat1 and Dgat2 alters the distribution of TAG in
subcellular pools for CM synthesis and secretion
(A) TAG secretion was assessed by measuring plasma TAG levels in Dgat1Int, WT, Dgat2Int and
Dgat1-/- mice given an IP injection of Tyloxapol at 0, 2 and 4 hours after a 200 l oral olive oil
gavage (n = 6-16 mice/group). (B) Representative TEM images of the area above the nucleus in
enterocytes from Dgat1Int and Dgat2Int mice 2 hours after a 200 l oral olive oil gavage. A
greater amount of TAG was found in the ER lumen of Dgat1Int enterocytes, whereas a greater
amount of TAG was found in Golgi/SVs of Dgat2Int enterocytes. Representative CLD (*), TAG
in ER lumen (black arrows), and TAG in Golgi/SVs (†) are highlighted. (C) TEM images
highlighting distinct, small CLDs (*) and TAG within the ER lumen (black arrow) in enterocytes
of Dgat1Int mice 2 hours after a 200 µl olive oil oral gavage. (D) Mean area of TAG in the ER
lumen and (E) mean area of TAG in Golgi/ SVs per cell were quantified using ImageJ. The value
of each bar is the average of three biological replicates (20 cells/mouse, n=3 mice/group). Data
are represented as mean ± SEM. Different letters denote significant differences, p < 0.05 (oneway ANOVA, Tukey HSD test), N.S = not significant.
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Figure 2.4 Varying levels of intestinal Dgat1 and Dgat2 alters enterocyte CLD morphology
(A, B) Size distribution of CLDs within enterocytes of mice 2 hours after a 200 l oral olive oil
gavage. All of the CLDs identified from 60 enterocytes (20 enterocytes/mouse, n=3 mice/group)
were examined by TEM and the diameter of CLDs were determined using ImageJ. Data is
reported as % of all the CLDs measured per group. * denotes a statistically significant difference,
p < 0.05 (Kolmogorov-Smirnov tests). (C) Mean number of CLDs and (D) mean size of CLDs
per cell (diameter) were determined. (E) The amount of TAG stored in CLDs is estimated by the
equation of (mean number of CLD) x π x (mean radius)2. The value of each bar is the average of
three biological replicates (20 cells/mouse, n=3 mice/group). (F) qPCR analysis of mRNA levels
of genes involved in CLD metabolism. WT mice were the reference group, with their mRNA
levels set as 1 (n=3-5 mice/group). Different letters denote significant differences, p < 0.05 (oneway ANOVA, Tukey HSD test), N.S = not significant.

72

Figure 2.5 Varying levels of intestinal Dgat1 and Dgat2 alters the enterocyte CLD proteome
CLDs were isolated from enterocytes of Dgat1Int, WT, Dgat2Int, and Dgat1-/- mice 2 hours after a
200μl oral olive oil gavage. (A) Negative stain EM of the intestinal CLD-enriched fraction from
a representative sample for each mouse model. Scale bar = 0.5 μm. (B) Overlap of CLDassociated proteins for each mouse model, identified by proteomics. (C) Biological functions of
CLD-associated proteins common to all four mouse models, classified based on GO terms (for
biological process & molecular function). (D) Differentially expressed CLD-associated proteins
common among all mouse models. Different letters denote significantly different relative protein
levels (p < 0.05). (E) String map of all proteins with a GO term/functional classification related
to lipid/lipoprotein metabolism. Black circles indicate proteins identified in all four genotypes
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Figure 2.6 Varying levels of intestinal Dgat1 and Dgat2 impacts enterocyte mitochondrial
biology
(A) qPCR analysis of mRNA levels of genes involved in FAO. (B) qPCR analysis of the ratio of
mitochondrial DNA to nuclear DNA for the assessment of mitochondrial content. WT mice was
the reference group, with its DNA level set as 1 (n=3-4 mice/group). Different letters denote
significant differences, p < 0.05 (one-way ANOVA, Tukey HSD test), N.S = not significant. (C)
Representative TEM images of mitochondria (black arrow) within enterocytes of WT and Dgat1/mice 2 hours after a 200 µl oral olive oil gavage. (D) Representative TEM images of normal
mitochondria (left) and round, swollen mitochondria (right) found in Dgat1-/- mice 2 hours after
a 200 µl oral olive oil gavage.
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Figure 2.7 Summary of results and proposed model of cellular roles of Dgat1 and Dgat2 in
synthesizing TAG for CM and CLDs within enterocytes
(A) Results summary: In Dgat1Int mice, greater amounts of TAG in the ER lumen, similar
amounts of TAG in Golgi/SVs, a trend toward smaller CLDs, and a similar intestinal TAG
secretion rate were found compared to WT mice. In Dgat2Int mice, similar amounts of TAG in
the ER lumen, greater amounts of TAG in Golgi/SVs, an increased number of CLDs, and a
higher intestinal TAG secretion rate were observed compared to WT mice. In Dgat1-/- mice, a
trend towards less TAG in the ER lumen and Golgi/SVs and an increase in CLD size were found
in enterocytes compared to WT mice. Dgat1-/- mice also secrete TAG from the intestine at a
slower rate within smaller sized CMs compared to WT mice. Some of the CLD-associated
proteins are present in all genotypes, whereas others, such as ApoAIV and Cideb, are unique to
certain genotype(s) and may be contributing to the altered subcellular distribution of TAG
observed in these models. (B) Proposed model: A proposed model of coordinated, non-redundant
roles of Dgat1 and Dgat2 in CM synthesis was generated by combining the results of the current
study with previous knowledge of the CM synthesis pathway. CM assembly in enterocytes
requires two distinct pools of TAG within the lumen of the ER: ApoB-containing nascent CMs
and ApoB-free LLDs. In this model, Dgat1 is proposed to preferentially synthesize TAG for
incorporation into ApoB-free LLDs, which determines the availability of TAG for nascent CM
expansion and thus the size of CMs. Dgat2 is proposed to preferentially synthesize TAG for
incorporation into ApoB-containing nascent CMs, which likely regulates the rate of intestinal
TAG secretion. In addition, TAG storage in CLDs and its subsequent catabolism provides
substrates for re-synthesis of TAG at the ER membrane that may contribute to CM synthesis and
secretion at later times. Based on the results from the current study, Dgat1 is proposed to restrict
CLD growth in enterocytes by preferentially synthesizing TAG that is delivered into the ER
lumen, thus limiting TAG storage in CLDs. Dgat2, on the other hand, is proposed to
preferentially increase TAG storage in CLDs, which may provide fatty acids for re-synthesis of
TAG at the ER membrane for incorporation into CMs at later time points. Differential
associations of proteins with enterocyte CLDs in these models may serve to regulate the
localization and activity of proteins involved in dietary fat absorption.
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CHAPTER 3.
ALTERATIONS IN ENTEROCYTE CYTOPLASMIC
LIPID STORES IN MICE RESISTANT (DGAT1-/-) TO DIET-INDUCED
OBESITY

3.1

Abstract
Whole body Dgat1 deficient (Dgat1-/-) mice are resistant to high fat diet-induced obesity

(DIO) and glucose intolerance with no evidence of quantitative fat malabsorption. This
resistance is due in part to changes in dietary fat absorption, including a blunted postprandial
triglyceridemic response and a reduced rate of intestinal triacylglycerol (TAG) secretion
compared to high fat fed wild-type (WT) mice. Although high fat fed Dgat1-/- mice have an
abnormal accumulation of TAG within enterocytes that is consistent with the reduced intestinal
TAG secretion rate, the specific alterations in intestinal cytoplasmic lipid droplet (CLD)
metabolism and morphology in response to chronic high fat feeding are unknown. We
hypothesized that chronically high fat fed Dgat1-/- mice exhibit alterations in enterocyte CLD
morphology and protein composition that may contribute to their beneficial DIO resistant
phenotype. To investigate this we used transmission electron microscopy (TEM) to assess CLD
morphology in enterocytes of WT and Dgat1-/- mice after 12 weeks of high fat feeding, and also
isolated CLDs from enterocytes and identified proteins in the CLD-enriched fraction using LCMS/MS. We found that enterocytes from chronically high fat fed Dgat1-/- mice contained a
greater number of larger sized CLDs compared to WT mice. In addition, label-free quantification
resulted in the identification of 125 proteins in the enterocyte CLD-enriched fraction that span
diverse cellular processes, including lipid metabolism. Several of the identified proteins were
differentially present in the enterocyte CLD fraction from Dgat1-/- compared to WT mice, and
over a third of these proteins were only identified in the Dgat1-/- model. Interestingly, more
proteins associated with mitochondria and involved in fatty acid oxidation were identified in the
enterocyte CLD fraction from Dgat1-/- compared to WT mice, and this was accompanied by
more mitochondria with altered morphology within Dgat1-/- enterocytes. Further investigation
into the identified proteins will contribute to molecular knowledge of the regulation of enterocyte
CLD stores, as well as the role of CLDs in the process of dietary fat absorption. This knowledge
can be used to identify potential therapeutic targets for the treatment of obesity, type 2 diabetes,
and cardiovascular disease.
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3.2

Introduction
The highly efficient process of dietary fat absorption is essential for health but can also

contribute to disease when it becomes dysregulated [1]. The major form of dietary fat,
triacylglycerol (TAG), is hydrolyzed in the intestinal lumen and its digestive products (2monoacylglycerol and free fatty acids) are taken up by enterocytes, the absorptive cells of the
small intestine. These digestive products are re-esterified into TAG at the ER membrane and
either packed within chylomicrons (CMs) for secretion into circulation or temporarily stored
within the cell in cytoplasmic lipid droplets (CLDs). The exact role of CLDs within enterocytes
is unknown, but the storage of TAG within these organelles is thought to be involved in
regulating both the rate and amount of TAG secreted into circulation, particularly when high
amounts of dietary fat are consumed.
Acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) plays an important role in intestinal
TAG synthesis and dietary fat absorption. DGAT1 is one of two known DGAT enzymes that
catalyze the acylation of DAG with a fatty acyl-CoA to form TAG, and this enzyme is present at
high levels in the small intestine of both humans and mice. In response to an acute dietary fat
challenge, low fat fed Dgat1 deficient (Dgat1-/-) mice exhibit a blunted postprandial
triglyceridemic response and a decreased intestinal TAG secretion rate compared to wild-type
(WT) mice [2]. In response to chronic high fat feeding Dgat1-/- mice are resistant to diet-induced
obesity and type 2 diabetes [2-5], and a lack of Dgat1 specifically in the small intestine is critical
for this beneficial phenotype [2].
A consistent observation in Dgat1-/- compared to WT mice in response to either an acute
high fat challenge or chronic high fat feeding is an increased accumulation of TAG in the small
intestine. We recently showed that low fat fed Dgat1-/- mice accumulate TAG within large
enterocyte CLDs that have an altered protein composition compared to WT mice in response to
an acute high fat challenge [6]. Although the specific mechanisms through which enterocyte
CLD stores are regulated are still unknown, it is likely that proteins associated with these
organelles play a role in regulating their metabolism. Proteins associated with CLDs have been
identified in several enterocyte models, and include proteins with known roles in intestinal lipid
and lipoprotein metabolism [7]. Thus the regulation of enterocyte CLD stores by CLD-associated
proteins may indirectly regulate CM secretion. In response to chronic high fat feeding, we have
determined biochemically that there is an increase in intestinal TAG content in Dgat1-/-

84
compared to WT mice, which is consistent with the higher amounts of intestinal TAG stores
observed using coherent anti-stokes raman scattering (CARS) imaging in this model [2]. This
work suggests that the increased intestinal TAG storage in Dgat1-/- mice contributes to their
reduced intestinal TAG secretion rate and resistance to diet-induced obesity, however additional
work is needed to confirm alterations in enterocyte CLD storage in this model in response to
chronic high fat feeding, as well as to identify and further investigate the potential molecular
regulators of this process.
The goal of the current study was to investigate potential alterations in enterocyte CLD
morphology and protein composition in chronically high fat fed Dgat1-/- compared to WT mice
that may contribute to their beneficial DIO resistant phenotype. To assess this, we fed WT and
Dgat1-/- mice a 60% high fat diet for 12 weeks and then harvested the small intestine in the fed
state. We performed an ultrastructural analysis of enterocyte CLDs from these models using
transmission electron microscopy (TEM), as well as a proteomic analysis of the enterocyte CLD
fraction. Comparing this DIO resistant model to mice susceptible to DIO will allow for the
identification of novel potential therapeutic targets for the treatment of obesity, type 2 diabetes,
and cardiovascular disease. In addition, this comparison will help increase knowledge about the
role and regulation of CLDs within enterocytes and their contribution to dietary fat absorption.

3.3

Materials and Methods

3.3.1 Diet and animals
All procedures were approved by the Purdue Animal Care and Use Committee. Whole
body Dgat1 deficient (Dgat1-/-) mice were generated as previously described [3]. Male WT and
Dgat1-/- mice were house in a specific pathogen-free barrier facility with a 12 hour light/dark
cycle (6AM/6PM) and fed a low-fat rodent chow diet (PicoLab 5053, Lab Diets, Richmond, IN)
containing 13.2% kcal from fat, 24.7% from protein, and 62.1% kcal from carbohydrate postweaning. At 5-6 weeks of age, mice were switched to a high fat diet (D12492, Research Diets,
New Brunswick, NJ) containing 60% kcal from fat, 20% from protein, and 20% from
carbohydrate. The mice were maintained on this diet for 12 weeks, with body weights assessed
weekly and body composition measured using an EchoMRI 500 (EchoMRI™, Houston, TX) at
the end of the 12 weeks.
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3.3.2 Postprandial plasma TAG levels
After 9 weeks of high fat feeding, a subset of mice were fasted for 4 h at the beginning of
the light cycle, then administered a 200 μl oral olive oil gavage. Blood was collected from the
submandibular vein at t = 0, as well as at 1, 2 and 4 h post gavage. Plasma TAG concentrations
were determined using the Wako L-Type TG M Assay (Wako Diagnostics, USA).
3.3.3 Intestinal TAG secretion
After 9 weeks of high fat feeding, a subset of mice were fasted for 4 h at the beginning of
the light cycle, then administered an IP injection of 500 mg/kg tyloxapol (T0307, Sigma-Aldrich,
St. Louis, MO). At 30 minutes post tyloxapol injection, mice were administered a 200 μl oral
olive oil gavage. Blood was collected from the submandibular vein at t = 0, as well as at 2 and
4 h post gavage. Plasma TAG concentrations were determined using the Wako L-Type TG M
Assay (Wako Diagnostics, USA).
3.3.4 Transmission electron microscopy (TEM)
After 12 weeks of high fat feeding, mice were fasted for 2 h at the beginning of the light
cycle and then anesthetized using inhaled isoflurane. Whole mouse perfusion fixation was
performed by cardiac infusion of 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium
cacodylate, pH 7.4. The small intestine was divided into 6 regions, and a segment from region 2,
representing the proximal jejunum, was harvested and stored in 2% glutaraldehyde in 0.1 M
sodium cacodylate, pH 7.4 for at least 2 h at 4°C. Intestinal tissues were diced into 1 x 5 mm
pieces, and then fixed with 1% osmium tetroxide in 0.1 M sodium cacodylate, pH 7.4, for 1 h at
room temperature. Tissues were then washed repeatedly in distilled deionized water.
Dehydration was completed with a graded series of ethanol and specimens were embedded in
Embed 812 resin. Thick sections (0.5 μm) were stained with 1% toluidine blue and examined by
light microscopy to confirm tissue orientation. Thin sections (80 nm) were cut on a Leica UC6
ultramicrotome and stained with 2% uranyl acetate and lead citrate. Images were acquired on a
Tecnai T20 transmission electron microscope (FEI, Hillsboro, OR) equipped with a LaB6 source
and operating at 100 kV. The quantitative measurements with acquired micrographs were made
using ImageJ software (NIH, USA). Intact enterocytes from the middle region of villi that
contained CLDs were examined for quantitative CLD measurements (16-20 cells/mouse; 3
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mice/group), as well as for mitochondrial analyses (15 cells/mouse; 3 mice/group). For the CLD
analysis, the number of CLDs per enterocyte were counted, and their diameters and areas were
measured. For the mitochondrial analysis, the number of mitochondria per enterocyte were
counted, as well as the number of close interactions between CLDs and mitochondria. In addition,
mitochondrial morphology was assessed.
3.3.5 Enterocyte isolation
After 12 weeks of high fat feeding, the proximal third of the small intestine was excised
after a 2 h fast starting at the beginning of the light cycle. Enterocytes were isolated as previously
described [8-10]. Briefly, intestinal tissue was washed in cold tissue buffer (Hank’s Balanced
Salt Solution containing 25 mM HEPES and 1% fetal bovine serum), then incubated in isolation
buffer (calcium and magnesium free Hanks’s Balanced Salt Solution with 1.5 mM EDTA) for 15
minutes at 37°C with rotation. The sample was vortexed briefly and the supernatant, which
contained isolated enterocytes, was obtained. This isolation process was repeated, the
supernatants were combined, and isolated enterocytes were pelleted.
3.3.6 CLD isolation
CLDs were isolated from enterocytes using a previously validated sucrose gradient
ultracentrifugation protocol that was modified for mouse enterocytes [10-12]. Enterocytes were
lysed using ice cold lysis buffer containing sucrose (175 mM sucrose, 10 mM HEPES and 1 mM
EDTA) and disrupted by passing through a 27 gauge 1 inch needle eight times. The 2 ml of cell
lysate was transferred to a centrifuge tube and overlaid with 6 ml of sucrose free lysis buffer. The
sample was centrifuged at 20,000 x g at 4°C for 2 h. Following the centrifugation, the sample
was frozen at -80°C and then sliced into seven fractions of approximately 1 cm in length, with
the top fraction containing isolated CLDs. A sample from the CLD enriched fraction was
negatively stained with 2% w/v aqueous uranyl acetate and imaged using a Technai T20
transmission electron microscope (FEI, Hillsboro, OR). Protein concentrations of these fractions
were determined using a BCA assay.
3.3.7 Protein digestion and LC-MS/MS analysis
CLD fractions were delipidated using 2:1 chloroform:methanol, followed by protein
precipitation using ice cold acetone. In preparation for the digest, samples were denatured using
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8 M urea and 10 mM DTT for 1 h at 37°C, followed by alkylation (using a 2% 2-iodoethanol,
97.5% acetonitrile, 0.5% TEP solution). Peptides were digested using Trypsin/Lys-C Mix
(Promega, Madison, WI, USA) using the Barocycler NEP2320 (Pressure Biosciences, Inc.,
South Easton, MA, USA) at 50°C under 20,000 psi for 120 cycles (2 h). One cycle consisted of
50 seconds at 20,000 psi followed by 10 seconds at atmospheric pressure. The digestion was
quenched using trifluoroacetic acid. Injection volumes were adjusted to load 1 µg of sample onto
the column for nanoLC-MS/MS analysis.
Peptides were separated on a nanoLC system (1100 Series LC, Agilent Technologies,
Santa Clara, CA). The peptides were loaded on the Agilent 300SB-C18 enrichment column for
concentration and the enrichment column was switched in-line with the analytical column after 5
min. Peptides were separated with the C18 reversed phase ZORBAX 300SB-C18 analytical
column (0.75 μm × 150 mm, 3.5 μm) from Agilent. The column was connected to an emission
tip from New Objective and coupled to the nano electrospray ionization (ESI) source of the high
resolution hybrid ion trap mass spectrometer LTQ Orbitrap XL (Thermo Scientific). The
peptides were eluted from the column using acetonitrile (ACN)/0.1% formic acid (mobile phase
B). For the first 5 minutes, the column was equilibrated with 95% purified H2O /0.1% formic
acid (mobile phase A) followed by the linear gradient of 5% B to 40% B in 65 minutes at
0.3 μl/min and from 40% B to 95% B in an additional 10 min. The column was washed with 95%
of ACN/0.1% formic acid and equilibrated with 95% purified H2O/0.1% formic acid before the
next sample was injected. A blank injection was run between samples to avoid carryover and
keep the system clean.
The LTQ-Orbitrap mass spectrometer was operated in the data dependent positive
acquisition mode at a resolution of 30,000. Each full MS scan was followed by eight MS/MS
scans where these abundant molecular ions were selected and fragmented by collision induced
dissociation using a normalized collision energy of 35%.
3.3.8 Proteomic data analysis
The MS and MS/MS peak list files were analyzed using MaxQuant Version 1.5.2.8 [13].
To identify proteins, the MS/MS spectra were searched against the UniProt protein database,
which combines the SwissProt (manually annotated and reviewed) and TrEMBL (automatically
annotated and not reviewed) databases [14]. The following settings were used for conducting the
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search: trypsin and Lys-C digestion enzymes with a maximum of two missed cleavages, fixed
modification of ethanolyl addition to cysteine, and variable modifications of N-terminal
acetylation and oxidation of methionine. The MS tolerance was set at 4.5 ppm with a maximum
of five modifications. A false discovery rate of 0.01 was used for protein and peptide
identifications, and the spectra were searched against a reverse decoy database. The minimum
peptide length was set at seven amino acids, and a minimum score of 40 was required for
modified peptides. The MS/MS match tolerance was set at 40 ppm for protein identification, and
at least one unique/razor peptide was required for identification.
The MaxQuant output was analyzed using the bioinformatics statistical analysis program
Perseus 1.5.1.6. Potential contaminants, such as keratin, were removed, and then LFQ intensities
transformed log2(x). Protein intensities falling below the level of detection were assigned a value
of 11.7665. Only proteins identified in at least 4 of 6 biological replicates were considered
present in a particular genotype and used for the analysis of relative protein levels across
genotypes. The identified proteins were grouped into broad clusters based on Gene Ontology
(GO) terms for biological process or molecular function using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) v 6.7 and the analysis tool in STRING version
10.5. Protein-protein interactions were visualized using STRING version 10.5 using the
confidence view (medium confidence, score 0.400).
3.3.9 qPCR
Total RNA was extracted from mucosa from the proximal third of the small intestine
using TRIzol (Invitrogen, Carlsbad, CA) and then DNase treated with a Turbo DNA-free Kit
(Ambion, Austin, TX). cDNA was synthesized from 1µg DNase-treated RNA using the
AffinityScript QPCR cDNA Synthesis Kit (Stratagene, La Jolla, CA). SYBR green qPCR was
performed using the Mx3000P QPCR System (Stratagene) and Brilliant III SYBR Green Master
Mix (Stratagene). Primers used for determination of relative mRNA levels (see Table 3.1) were
produced by Integrated DNA technologies (Coralville, IA) and validated for efficiency and
correct product size using cDNA from mouse intestinal mucosa. Ces2c, Ces2e, and Ces2g
primers were also previously used and validated in [15]. β-actin was used as a reference gene.
The level of each gene was calculated using the comparative Ct method, with WT mice as the
reference group.
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3.3.10 Statistical analysis
Values of quantitative data are reported as mean ± standard error of the mean (SEM).
Student’s t tests were used to compare values between the two groups. Kolmogorov Smirnov
tests were performed using SAS version 9.4 to compare CLD diameter distributions. A p value <
0.05 indicates a statistically significant difference.

3.4

Results

3.4.1 Chronically high fat fed Dgat1-/- mice exhibit a decreased postprandial plasma TAG
response and a decreased intestinal TAG secretion rate in response to an acute dietary fat
challenge compared to WT mice
After nine weeks of high fat feeding, postprandial plasma TAG levels were assessed in
WT and Dgat1-/- mice in response to a 200 µl oral olive oil gavage (Figure 3.1 A). Chronically
high fat fed Dgat1-/- mice exhibited a decreased postprandial triglyceridemic response compared
to high fat fed WT mice. In addition, the rate of intestinal TAG secretion was assessed in a
separate subset of animals by administering tyloxapol, a lipoprotein lipase inhibitor, prior to the
oral olive oil gavage. Dgat1-/- mice also exhibited a decreased intestinal TAG secretion rate
compared to WT mice after nine weeks of chronic high fat feeding (Figure 3.1 B). These results
are consistent with the blunted postprandial triglyceridemic response and decreased intestinal
TAG secretion rate we previously observed in low fat fed Dgat1-/- compared to WT mice [2, 16].
Furthermore, body weights of WT and Dgat1-/- mice were assessed weekly in response to
high fat feeding, and Dgat1-/- mice gained significantly less weight than WT mice (Figure 3.2 A).
In addition to this, body composition was assessed at the end of the 12 week period, and the
percent body fat of Dgat1-/- mice was also significantly lower than that of WT mice (Figure 3.2
B). Together these results further confirm the previously reported resistance to high fat dietinduced obesity in Dgat1-/- mice [2-5].
3.4.2 Chronically high fat fed Dgat1-/- mice exhibit an altered enterocyte CLD size distribution
compared to WT mice
We have previously observed alterations in enterocyte CLD stores in low fat fed Dgat1-/compared to WT mice in response to an acute dietary fat challenge [6], which likely contributes
to the decreased intestinal TAG secretion rate in this model. To determine whether enterocyte
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CLD morphology is also altered in Dgat1-/- compared to WT mice after chronic high fat feeding,
enterocytes from these models were imaged using TEM and CLDs were analyzed using ImageJ.
After 12 weeks of high fat feeding, jejunal tissues were harvested in the fed state (after a 2 h fast
at the beginning of the light cycle) and processed for TEM. Overall villus morphology was
examined using light microscopy, and appeared normal in both models (data not shown).
Enterocytes located in the middle region of at least three villi were analyzed per mouse. The
presence of CLDs within enterocytes was assessed in 60-80 cells per mouse, and there was no
significant difference in the percent of enterocytes containing CLDs between WT and Dgat1-/mice (data not shown). Among enterocytes containing CLDs, there was no difference in the
number of CLDs within individual enterocytes between the groups (Figure 3.3 B). However
there was a significant difference in CLD size distribution, with Dgat1-/- enterocytes containing a
greater number of CLDs that were larger in size compared to WT enterocytes (Figure 3.3 C).
3.4.3 Chronically high fat fed Dgat1-/- mice exhibit alterations in enterocyte CLD-associated
proteins compared to WT mice
Since proteins that associate with CLDs have the potential to regulate their metabolism,
we identified and compared proteins present in the enterocyte CLD fraction from chronically
high fat fed WT and Dgat1-/- mice to further investigate potential differences in enterocyte CLD
storage in these models. We isolated enterocyte CLDs from these models after 12 weeks of high
fat feeding using sucrose density gradient ultracentrifugation [10-12]. Enrichment of CLDs in
this fraction was determined using negative stain electron microcopy (Figure 3.4 A). In addition,
CLD enrichment, as well as a lack of gross contamination of the enterocyte CLD-enriched
fraction, was previously confirmed for this method by Western blotting for representative CLD,
cytosolic, and membrane proteins [17]. In order to minimize potential contamination of the CLD
fraction with ER lumenal lipids and lipoproteins, we used an ultracentrifugation speed that is
much lower than those used to isolate ER lumenal lipid droplets and chylomicrons [18-20].
Using high resolution tandem mass spectrometry we identified a total of 125 proteins in
the enterocyte CLD-enriched fraction of at least 4 out of 6 mice from at least one model (Table
3.2), with 73 of these proteins common to both WT and Dgat1-/- mice and 52 only identified in
the Dgat1-/- CLD-enriched fraction (Figure 3.4 B). These proteins are involved in a variety of
biological processes, with 14% classified as lipid metabolism related proteins (Figure 3.4 C).
Among the 73 proteins identified in both models, 21 were present at relatively different levels in
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the enterocyte CLD fraction from Dgat1-/- compared to WT mice (Figure 3.5). These
differentially present proteins were involved in a variety of cellular processes, one of which is
lipid metabolism, and the majority of these proteins were present at relatively higher levels in
Dgat1-/- compared to WT mice. Among these differentially present proteins were several
carboxylesterase 2 (Ces2) family members: Ces2c, Ces2e and Ces2g, which were present at
relatively higher levels in the Dgat1-/- compared to the WT enterocyte CLD-enriched fraction. To
investigate this further we assessed mRNA levels of these genes in intestinal mucosa from WT
and Dgat1-/- mice after 12 weeks of high fat feeding (Figure 3.6). However, we found that
mRNA levels of these Ces2 family members were similar between the two genotypes.
Since Dgat1-/- mice exhibit altered intestinal lipid (CLD) storage and secretion compared
to WT mice in response to chronic high fat feeding, we looked further at the lipid metabolism
related proteins identified in the enterocyte CLD-enriched fraction. All of the lipid metabolism
related proteins identified in our study have been identified previously in other CLD proteomic
studies (Table 3.3), with a few of them also validated to localize to CLDs using additional
methods. Interestingly, 9 of the lipid metabolism related proteins identified in the current study
were present in the enterocyte CLD-enriched fractions from both WT and Dgat1-/- mice, while
the other 10 were only identified in Dgat1-/- mice. In order to assess potential structural and
functional relationships between the identified lipid metabolism related proteins, we performed a
STRING analysis (Figure 3.7). From this analysis we identified a cluster of proteins associated
with mitochondria and peroxisomes, several of which are involved in fatty acid oxidation
(highlighted in Table 3.3). In addition, these particular proteins were either only identified in or
present at relatively higher levels in the Dgat1-/- enterocyte CLD-enriched fraction.
3.4.4 Chronically high fat fed Dgat1-/- enterocytes have similar CLD-mitochondria contact but
altered mitochondrial morphology compared to WT mice
Since we found a greater number of mitochondrial/fatty acid oxidation related proteins in
the enterocyte CLD-enriched fraction from chronically high fat fed Dgat1-/- compared to WT
mice, we hypothesized that there may be differences in CLD-mitochondria contact and/or
mitochondrial morphology in these models. To assess this, we performed a TEM analysis of
mitochondria within jejunal enterocytes from WT and Dgat1-/- mice after 12 weeks of high fat
feeding. There was no difference in the number of mitochondria per enterocyte between WT and
Dgat1-/- mice (Figure 3.8 A). In addition, close associations between mitochondria and CLDs
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were observed in enterocytes from both WT and Dgat1-/- mice (Figure 3.8 B), with no difference
in the percent of mitochondria in contact with CLDs between the two genotypes (Figure 3.8 C).
A range of mitochondrial morphology was observed within both WT and Dgat1-/- enterocytes.
Some mitochondria had normal looking morphology, while others were classified as having
partially altered (swelling but most cristae still intact) or altered (matrix clearing, few/disrupted
cristae) morphology (Figure 3.8 D). A greater percentage of mitochondria within enterocytes
from chronically high fat fed Dgat1-/- mice exhibited partially altered or altered morphology
compared to WT enterocytes (Figure 3.8 E).

3.5

Discussion
In the present study we investigated potential alterations in enterocyte CLD morphology

and protein composition in chronically high fat fed Dgat1-/- compared to WT mice that may
contribute to their beneficial DIO-resistant phenotype. Enterocytes from chronically high fat fed
Dgat1-/- mice contain a similar number of CLDs compared to high fat fed WT mice, but a greater
number of these CLDs are larger in size (results are summarized in Figure 3.9). Consistent with
this increase in CLD storage, chronically high fat fed Dgat1-/- mice exhibit a decreased intestinal
TAG secretion rate compared to high fat fed WT mice. In addition to these alterations in
intestinal TAG storage and secretion, the protein composition of the enterocyte CLD-enriched
fraction was altered in Dgat1-/- mice, with a greater number of total proteins as well as a greater
number of proteins involved in lipid metabolism identified compared to WT mice. These
proteins have the potential to play a functional role at the enterocyte CLD surface, however they
could also be targeted to CLDs as a way to regulate their activity/function at another cellular
location, because they are damaged and need to be degraded, or because they are contaminants
from the CLD isolation procedure. Thus validation of the differential localization to enterocyte
CLDs in chronically high fat fed WT and Dgat1-/- mice is still needed, along with further
investigation as to whether or not these proteins play functional roles at this location.
In this study, we found that in response to chronic high fat feeding, Dgat1-/- mice exhibit
alterations in both enterocyte CLD storage and intestinal TAG secretion compared to WT mice.
These results are consistent with what has been observed previously in low fat fed Dgat1-/- mice,
however the differences in CLD size are not as dramatic as those seen between low fat fed WT
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and Dgat1-/- mice in response to an acute dietary fat challenge [2, 6]. This may be due, in part, to
the fact that enterocyte CLDs in the present study were analyzed in response to chronic high fat
feeding, as opposed to in low fat fed mice in response to an acute high fat challenge. In addition,
an increase in CLD size has been observed in chronically high fat fed obese compared to low fat
fed lean WT mice [21], which could further contribute to the less dramatic difference in
enterocyte CLD size observed between chronically high fat fed WT and Dgat1-/- mice.
Since we observed differences in both enterocyte CLD storage and intestinal TAG
secretion in chronically high fat fed Dgat1-/- compared to WT mice, we expected to see
differences in proteins involved in the mobilization of TAG from CLDs in these models.
Lipolysis is one pathway through which TAG within CLDs can be mobilized; however we did
not identify any of the classical lipases (ATGL, CGI-58, HSL, and MGL) in the enterocyte CLD
fraction from either model in this study. Although these enzymes have been identified in
previous CLD proteomics studies using enterocyte models [10, 22, 23] and they are known to be
present within enterocytes, their activity alone does not quantitatively account for the amount of
TAG from CLDs that is hydrolyzed to provide substrate for CM secretion [24-27]. It is possible
that these lipases were not identified in the present study because they are present at levels below
the level of detection of the mass spec, and the fact that these lipases are exchangeable CLDassociated proteins may also add to the difficulty of detecting them at a single time point. It may
also be the case that other enzymes or pathways, such as lipophagy [28], play more of a role in
mobilizing TAG stored within enterocyte CLDs.
One family of enzymes identified in this study that has the potential to act as TAG
hydrolases are carboxylesterase 2 family members. These enzymes have well-defined roles in
xenobiotic clearance and pharmacologic prodrug activation, but emerging evidence also supports
a role of these proteins in lipid metabolism [15]. In fact, Ces2 was recently shown to exhibit
TAG hydrolase activity and play a role in regulating lipid metabolism in the liver [29]. In the
present study we found that carboxylesterase 2c, 2e, and 2g were all present at relatively higher
levels in the enterocyte CLD-enriched fraction from chronically high fat fed Dgat1-/- compared
to WT mice. Since this model has greater amounts of TAG stored within enterocyte CLDs, this
suggests that these proteins may not be functional at the CLD surface, and may instead be
localized there as a way to prevent them from exerting their normal function at the ER. To
determine if these proteins were identified at relatively different levels in the enterocyte CLD
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fractions as a result of alterations in their presence within enterocytes, we assessed Ces2 mRNA
levels in intestinal mucosa from these models. We found no differences in mRNA levels of these
genes, suggesting that the altered presence of these proteins in the enterocyte CLD fraction may
either be due to altered post-translational modifications of these proteins or the result of
differential localization in Dgat1-/- compared to WT enterocytes. Future studies are needed to
further assess carboxylesterase 2 protein levels and localization within enterocytes once suitable
antibodies become available.
Another interesting finding from the proteomic analysis was that a few of the lipid
metabolism related proteins we identified in the current study were identified for the first time in
the CLD-enriched fraction from an enterocyte model. One particular newly identified protein of
interest, which was only present in the Dgat1-/- enterocyte CLD-enriched fraction, was aspartate
aminotransferase, mitochondrial (Got2). This enzyme plays an essential role in the malateaspartate shuttle within the mitochondria, and interestingly has also been shown to be identical to
fatty acid binding protein plasma membrane (FABPpm) [30]. Its localization to the cell surface
of multiple cell types, including enterocytes has been confirmed using immunofluorescence, and
a model for its role in long chain fatty acid uptake in the liver has been proposed [30]. It is
possible that this protein plays a functional role at the CLD surface, however since it is known to
localize to either the mitochondria or the plasma membrane, its localization to CLDs may serve
to prevent it from functioning at other cellular locations. Further investigation into this protein’s
function within enterocytes, as well as validation of its localization to enterocyte CLDs in
chronically high fat fed Dgat1-/- mice, is still needed.
It was also interesting that the lipid metabolism related proteins associated with the
mitochondria, including several involved in fatty acid β-oxidation, were either present at
relatively higher levels or only identified in the Dgat1-/- enterocyte CLD-enriched fraction. Two
of these proteins, peroxisomal 3-ketoacyl-CoA thiolase A (Acaa1a) and mitochondrial 3ketoacyl-CoA thiolase (Acaa2), were identified for the first time in the CLD-enriched fraction
from an enterocyte model in the present study. These enzymes catalyze the final step of fatty
acid β-oxidation [31] and were found to be present at relatively higher levels (ACAA1A) or only
identified (ACAA2) in the Dgat1-/- enterocyte CLD-enriched fraction, respectively. We initially
hypothesized that a greater number of these mitochondrial proteins may be identified in the
CLD-enriched fraction from Dgat1-/- compared to WT enterocytes because there is a greater
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amount of CLD-mitochondria contact in this model. However we did not observe a difference in
CLD-mitochondria contact within enterocytes from these models using TEM. We did, on the
other hand, find that enterocytes from chronically high fat fed Dgat1-/- mice contained more
mitochondria with altered morphology. This finding is consistent with our previous observations
of altered mitochondrial morphology in chow fed Dgat1-/- compared to WT mice in response to
an acute dietary fat challenge [6].
There are several potential reasons why there would be more proteins associated with the
mitochondria and fatty acid oxidation in chronically high fat fed Dgat1-/- compared to WT mice.
First, it is possible that the increased size of enterocyte CLDs in chronically high fat fed Dgat1-/mice allows a greater number of proteins to associate with the CLD surface, and this just
happens to include more mitochondrial proteins. Alternatively, there may be more damaged
mitochondrial proteins within enterocytes of chronically high fat fed Dgat1-/- mice (which would
be consistent with the altered mitochondrial morphology in this model) that are being targeted to
the CLD surface prior to degradation, as shown previously with other proteins such as ApoB-100
[32, 33]. Another potential explanation could be that CLDs are serving as a temporary storage
site for mitochondrial proteins. A recent study in yeast identified a role for CLDs in transporting
a subset of mitochondrial proteins to and from the mitochondria in response to multiple forms of
cell stress [34]. In this particular study a specific domain was identified in several pro- and antiapoptotic proteins that allowed them to localize to both CLDs as well as the mitochondria.
Although we did not identify any of these particular proteins in the present study, we have
observed an increase in reactive oxygen species within low fat fed Dgat1-/- enterocytes in
response to an acute high fat challenge [35], so it is possible that there is also increased oxidative
stress in this model in response to chronic high fat feeding, but this still needs to be assessed.
In conclusion, we found that Dgat1-/- mice, which are resistant to DIO, contain a greater
number of larger sized CLDs within enterocytes and exhibit a decreased intestinal TAG secretion
rate compared to WT, DIO mice. These alterations in Dgat1-/- mice are accompanied by
differences in proteins identified in the enterocyte CLD-enriched fraction, which include a
greater number of mitochondrial/fatty acid oxidation associated proteins. In addition, alterations
in mitochondrial morphology were observed in Dgat1-/- enterocytes, which have the potential to
contribute to and/or result from the alterations in intestinal lipid storage and secretion in this
model. These adaptations that occur within enterocytes of chronically high fat fed mice in the
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absence of Dgat1 may contribute to their beneficial, DIO resistant phenotype. Further
investigation into the proteins identified in the enterocyte CLD-enriched fractions in this study,
in particular the proteins that were differentially present in Dgat1-/- and WT mice, can help to
increase knowledge about the role and regulation of CLDs within enterocytes, as well as identify
potential novel therapeutic targets for the treatment and prevention of obesity, type 2 diabetes,
and cardiovascular disease.
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Table 3.1 Primers used for qPCR
Gene
β-actin
Ces2c
Ces2e
Ces2g

Primer Sequences
F 5’-AGGCCCAGAGCAAGAGAGGTA-3’
R 5’-GGGGTGTTGAAGGTCTCAAACA-3’
F: 5’-GCTGAATGCTGGGTTCTTCG-3’
R: 5’-GCTGCCTTGGATCTGTCCTGT-3’
F: 5’-CTTGTCTTTGGCTACCAGTTCG-3’
R: 5’-TTGCTCCTCTTCCTCAGTGTAAGG-3’
F: 5’-TCTCTGAGGTGGTTTACCAAACG-3’
R: 5’-CCTCTCAGACAGCGCACCAG-3’
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Table 3.2 Proteins identified in the enterocyte CLD fraction from chronically high fat fed WT
and Dgat1-/- mice
WT and Dgat1-/Uniprot
Accession
P17182

Protein Name

Gene
Name
Eno1

Carbohydrate Metabolism

Dak

Carbohydrate Metabolism

Aldob
Mdh2
Ganab
Pgam1
Pklr
Pkm

Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism

Pycard

Cell Stress Response

Ephx2
Ckmt1
Hsp90b1
Hsp90ab1
Hbbt1
Prdx6
Sod1
Uba1
Vil1
Actg1
Actr2
Actn4
Cltc
Eppk1
Flnb
Myh9
Myh14

Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization
Cytoskeleton Organization

Slc9a3r1

Cytoskeleton Organization

Tuba1c
Tubb4b

Cytoskeleton Organization
Cytoskeleton Organization
DNA Binding/Nucleotide
Metabolism
DNA Binding/Nucleotide
Metabolism
DNA Binding/Nucleotide
Metabolism
DNA Binding/Nucleotide
Metabolism
Lipid metabolism
Lipid Metabolism
Lipid Metabolism

P68373
P68372

Alpha-enolase
Bifunctional ATP-dependent
dihydroxyacetone kinase/FAD-AMP lyase
(cyclizing)
Fructose-bisphosphate aldolase B
Malate dehydrogenase, mitochondrial
Neutral alpha-glucosidase AB
Phosphoglycerate mutase 1
Pyruvate kinase
Pyruvate kinase PKM
Apoptosis-associated speck-like protein
containing a CARD
Bifunctional epoxide hydrolase 2
Creatine kinase U-type, mitochondrial
Endoplasmin
Heat shock protein HSP 90-beta
Hemoglobin subunit beta-1
Peroxiredoxin-6
Superoxide dismutase [Cu-Zn]
Ubiquitin-like modifier-activating enzyme 1
Villin-1
Actin, cytoplasmic 2
Actin-related protein 2
Alpha-actinin-4
Clathrin heavy chain
Epiplakin
Filamin-B
Myosin-9
Myosin-14
Na(+)/H(+) exchange regulatory cofactor
NHE-RF1
Tubulin alpha-1C chain
Tubulin beta-4B chain

A2A9X5

5(3)-deoxyribonucleotidase, cytosolic type

Nt5c

P03958

Adenosine deaminase

Ada

O88428

Bifunctional 3-phosphoadenosine 5phosphosulfate synthase 2

Papss2

Q8CGP6

Histone H2A type 1-H

Hist1h2ah

H3BKA1
Q91WG0
E9PYF1

3-ketoacyl-CoA thiolase A, peroxisomal
Acylcarnitine hydrolase
Aminopeptidase B

Acaa1a
Ces2c
Rnpep

Q8VC30
Q91Y97
P08249
Q8BHN3
Q9DBJ1
E9Q509
P52480
Q9EPB4
P34914
P30275
P08113
P11499
A8DUK4
Q6GT24
P08228
Q02053
Q62468
P63260
P61161
P57780
Q5SXR6
Q8R0W0
Q80X90
Q8VDD5
K3W4R2
P70441

Biological Process
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Table 3.2 continued
P56480
Q8CIM7
P24527

G3X9Y6
P48758
G3UXX3

ATP synthase subunit beta, mitochondrial
Cytochrome P450 2D26
Leukotriene A-4 hydrolase
Microsomal triglyceride transfer protein
large subunit
Perilipin-3
4-trimethylaminobutyraldehyde
dehydrogenase
Aconitate hydratase, mitochondrial
Aldehyde dehydrogenase family 16 member
A1
Aldo-keto reductase family 1, member C19
Carbonyl reductase [NADPH] 1
Sepiapterin reductase

P62259

14-3-3 protein epsilon

Ywhae

B0V2N7

Annexin

Anxa2

S4R2A9

Protein transport protein Sec31A

Sec31a

Q01853

Transitional endoplasmic reticulum ATPase

Vcp

Q8QZR5
Q504P4
O70435
H3BK43
P63325
P97351
P14206
P47911
P97429
D3Z7N2
E9Q561

Alanine aminotransferase 1
Heat shock cognate 71 kDa protein
Proteasome subunit alpha type-3
S-formylglutathione hydrolase
40S ribosomal protein S10
40S ribosomal protein S3a
40S ribosomal protein SA
60S ribosomal protein L6
Annexin A4
Elongation factor 1-delta
Eukaryotic initiation factor 4A-I

Gpt
Hspa8
Psma3
Esd
Rps10
Rps3a
Rpsa
Rpl6
Anxa4
Eef1d
Eif4a2

O88312

Anterior gradient protein 2 homolog

Agr2

Q04447
Q8K419
P19639

Creatine kinase B-type
Galectin-4
Glutathione S-transferase Mu 3

Ckb
Lgals4
Gstm3

Q9CZ44

NSFL1 cofactor p47

Nsfl1c

Q8BK48

Ces2e
Atp1a1

E9PV38

Pyrethroid hydrolase Ces2e
Sodium/potassium-transporting ATPase
subunit alpha-1
Carboxylic ester hydrolase

E9Q9C6

Fc fragment of IgG-binding protein

Fcgbp

Q9Z1A1

TFG protein

Tfg

O08601
Q9DBG5
Q9JLJ2
Q99KI0
D3Z0B9

Q8VDN2

Atp5b
Cyp2d26
Lta4h

Lipid Metabolism
Lipid Metabolism
Lipid Metabolism

Mttp

Lipid Metabolism

Plin3

Lipid Metabolism

Aldh9a1

Oxidation/Reduction

Aco2

Oxidation/Reduction

Aldh16a1

Oxidation/Reduction

Akr1c19
Cbr1
Spr

Oxidation/Reduction
Oxidation/Reduction
Oxidation/Reduction
Protein
Localization/Transport
Protein Localization/
Transport
Protein Localization/
Transport
Protein Localization/
Transport
Protein/AA Metabolism
Protein/AA Metabolism
Protein/AA Metabolism
Protein/AA Metabolism
Transcription/Translation
Transcription/Translation
Transcription/Translation
Transcription/Translation
Transcription/Translation
Transcription/Translation
Transcription/Translation
Other (intestinal mucus
production)
Other (kinase, transferase)
Other (cell-cell Interaction)
Other (transferase)
Other (ER & golgi
formation)
Other (hydrolase)
Other (plasma membrane
ATPase)
Other (hydrolase)
Other (intestinal mucus
layer, structural)
Other (regulation of IKB/NF
kappa b signaling)

Ces2g
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Table 3.2 continued
D3Z2H9
Uniprot
Accession

Tropomyosin 3, related sequence 7
Dgat1-/- Only
Protein names

Tpm3-rs7

Other (unknown)

Gene
names

Biological Process

Ogdh

Carbohydrate Metabolism

Q9CZU6
P97807
Q8R059
D3Z3F7
F8VQM5
P20029
Q9CQN1
B1AXW5
P09103
E9PXX7
A0A087WS98
E9Q3W4
F8WIX8

2-oxoglutarate dehydrogenase,
mitochondrial
Citrate synthase, mitochondrial
Fumarate hydratase, mitochondrial
UDP-glucose 4-epimerase
UDP-glucose 6-dehydrogenase
Sucrase isomaltase (alpha-glucosidase)
78 kDa glucose-regulated protein
Heat shock protein 75 kDa, mitochondrial
Peroxiredoxin-1
Protein disulfide-isomerase
Thioredoxin domain-containing protein 5
Actin-related protein 3
Plectin
Histone H2A

Cs
Fh
Gale
Ugdh
Sis
Hspa5
Trap1
Prdx1
P4hb
Txndc5
Actr3
Plec
Hist1h2al

Q02819

Nucleobindin-1

Nucb1

E9Q7D8

Poly(rC)-binding protein 3

Pcbp3

Q8BWT1
Q03265
Q9WUD0
Q9DCW4
Q99KP3

Acaa2
Atp5a1
Cyp2b10
Etfb
Cryl1
Acadl

Lipid Metabolism

Acsl5
Acox1
Hsd17b4
Cnpy2
Aldh2
Aldh1b1

Lipid Metabolism
Lipid Metabolism
Lipid Metabolism
Lipid Metabolism
Oxidation/Reduction
Oxidation/Reduction

Uqcrc1

Oxidation/Reduction

Dlst

Oxidation/Reduction

Q3TML0

3-ketoacyl-CoA thiolase, mitochondrial
ATP synthase subunit alpha, mitochondrial
Cytochrome P450 2B10
Electron transfer flavoprotein subunit beta
Lambda-crystallin homolog
Long-chain specific acyl-CoA
dehydrogenase, mitochondrial
Long-chain-fatty-acid--CoA ligase 5
Peroxisomal acyl-coenzyme A oxidase 1
Peroxisomal multifunctional enzyme type 2
Protein canopy homolog 2
Aldehyde dehydrogenase, mitochondrial
Aldehyde dehydrogenase X, mitochondrial
Cytochrome b-c1 complex subunit 1,
mitochondrial
Dihydrolipoyllysine-residue
succinyltransferase component of 2oxoglutarate dehydrogenase complex,
mitochondrial
Protein disulfide-isomerase A6

Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Carbohydrate Metabolism
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cell Stress Response
Cytoskeleton Organization
Cytoskeleton Organization
DNA Binding
DNA Binding/Nucleotide
Metabolism
DNA Binding/Nucleotide
Metabolism
Lipid Metabolism
Lipid Metabolism
Lipid Metabolism
Lipid Metabolism
Lipid Metabolism

Pdia6

O55029

Coatomer subunit beta

Copb2

Q9D1M0

Protein SEC13 homolog

Sec13

Oxidation/Reduction
Protein Localization/
Transport
Protein Localization/
Transport

Z4YJV4

P51174
Q8JZR0
Q9R0H0
P51660
Q9QXT0
P47738
Q9CZS1
Q9CZ13

Q9D2G2
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E9Q1S3

Protein transport protein Sec23A

Sec23a

E9Q6R3

Vesicle-trafficking protein SEC22b

Sec22b

Q8K0C5

Zymogen granule membrane protein 16

Zg16

O08691
P05202
Q9Z110
P26443
P29758
Q9Z2U0
P38647
Q9D8N0
P58252
J3QPS8

Arginase-2, mitochondrial
Aspartate aminotransferase, mitochondrial
Delta-1-pyrroline-5-carboxylate synthase
Glutamate dehydrogenase 1, mitochondrial
Ornithine aminotransferase, mitochondrial
Proteasome subunit alpha type-7
Stress-70 protein, mitochondrial
Elongation factor 1-gamma
Elongation factor 2
Eukaryotic translation initiation factor 5A-1
Heterogeneous nuclear ribonucleoproteins
A2/B1
Heterogeneous nuclear ribonucleoprotein U
Alkaline phosphatase
Haloacid dehalogenase-like hydrolase
domain-containing protein 3

Arg2
Got2
Aldh18a1
Glud1
Oat
Psma7
Hspa9
Eef1g
Eef2
Eif5a

Protein Localization/
Transport
Protein Localization/
Transport
Protein Localization/
Transport
Protein/AA Metabolism
Protein/AA Metabolism
Protein/AA Metabolism
Protein/AA Metabolism
Protein/AA Metabolism
Protein/AA Metabolism
Protein/AA Metabolism
Transcription/Translation
Transcription/Translation
Transcription/Translation

Hnrnpa2b1

Transcription/Translation

Hnrnpu
Akp3

Transcription/Translation
Other (dephosphorylation)

Hdhd3

Other (hydrolase)

O88569
G3XA10
F8VQM0
Q9CYW4
P40142

Transketolase

Tkt

Q9D8L3

Translocon-associated protein subunit delta

Ssr4

Other (pentose phosphate
pathway, glyceraldehyde-3phosphate biosynthesis)
Other (receptor)
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Table 3.3 Lipid metabolism related proteins identified in the enterocyte CLD fraction from
chronically high fat fed WT and Dgat1-/- mice
A ✓indicates a protein was identified in the enterocyte CLD fraction and or indicates that
the protein was present at relatively higher or lower levels, respectively, in the enterocyte CLD
fraction from Dgat1-/- compared to WT mice. *Proteins validated as being associated with CLDs
using immunohistochemistry and/or Western blot. †Proteins associated with the cellular
component GO term: mitochondrion (GO: 005739). References [6, 10, 22, 23] used enterocyte
models.

Protein
3-ketoacyl-CoA thiolase A,
peroxisomal†
Acylcarnitine hydrolase
Aminopeptidase B
ATP synthase subunit beta,
mitochondrial†
Bifunctional epoxide hydrolase 2
Cytochrome P450 2D26
Leukotriene A-4 hydrolase
Microsomal triglyceride transfer
protein large subunit*
Perilipin-3*
3-ketoacyl-CoA thiolase,
mitochondrial†
Aspartate aminotransferase,
mitochondrial†
ATP synthase subunit alpha,
mitochondrial†
Cytochrome P450 2B10
Lambda-crystallin homolog
Long-chain-fatty-acid--CoA ligase
5*†
Long-chain specific acyl-CoA
dehydrogenase, mitochondrial†
Peroxisomal acyl-coenzyme A
oxidase 1†
Peroxisomal multifunctional
enzyme type 2†
Protein canopy homolog 2

Gene

Previously Identified in
Other CLD Proteomic
Studies

WT

Acaa1a

[36-40]

✓

Ces2c
Rnpep

[6, 10, 39, 40]
[6, 40]

✓
✓

Atp5b

[6, 10, 22, 36-43]

✓

Ephx2
Cyp2d26
Lta4h

[6, 10, 37, 39, 40]
[6, 10, 39, 40]
[6, 39, 40]

✓
✓
✓

Mttp

[6, 10, 22, 23, 39, 40, 43]

✓

Plin3

[6, 10, 22, 23, 38-49]

✓

Acaa2

[36, 38-40, 42]

✓

Got2

[37-40, 42, 43]

✓

Atp5a1

[6, 10, 36-43]

✓

Cyp2b10
Cryl1

[6, 10]
[6, 40]

✓
✓

Acsl5

[6, 10, 23, 39, 40]

✓

Acadl

[10, 38-40, 42, 49]

✓

Acox1

[10, 37-40]

✓

Hsd17b4

[6, 36, 38-40, 42, 43, 47, 49]

✓

Cnpy2

[36, 38-40, 42]

✓

Dgat1-/-

✓
✓
✓

✓
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Figure 3.1 Chronically high fat fed Dgat1-/- mice exhibit a decreased postprandial plasma TAG
response and a decreased intestinal TAG secretion rate in response to an acute dietary fat
challenge compared to WT mice
(A) Postprandial plasma TAG levels and (B) intestinal TAG secretion rate after being fed a 60%
high fat diet for nine weeks. Significant differences between groups at individual time points, as
well as in areas under the curve (AUC) for (A), were determined using a t test (n=4-6 mice/group,
*p < 0.05).
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Figure 3.2 Body weights (BWs) and body composition of chronically high fat fed WT and
Dgat1-/- mice
Mice were fed a 60% high fat diet for 12 weeks, starting at 5-6 weeks of age. (A) Body weights
were assessed weekly and are reported as a change in BW. * p < 0.05 (t-test), n =13-15
mice/group. (B) Final body weights and percent body fat were determined at the end of the 12
week high fat feeding period. Data represented as mean ± SEM. * p < 0.001 vs WT (t test), n= 46 mice/group.
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Figure 3.3 Chronically high fat fed Dgat1-/- mice exhibit an altered enterocyte CLD size
distribution compared to WT mice
Mice were fed a high fat diet for 12 weeks and jejunal tissue samples were harvested in the fed
state (after a 2 h fast at the beginning of the light cycle) for TEM analysis. (A) Representative
TEM images of WT and Dgat1-/- enterocytes containing CLDs. The average number of CLDs per
cell (B) were determined for both WT and Dgat1-/- mice and assessed using a t test, and
enterocyte CLD diameter distributions (C) were assessed using a Kolmogorov-Smirnov (KS) test.
(16-20 cells/mouse, n = 3 mice/group)
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Figure 3.4 Identification and classification of enterocyte CLD-associated proteins in chronically
high fat fed WT and Dgat1-/- mice
(A) Negative stain EM images of the CLD-enriched fraction from both WT and Dgat1-/- mice. (B)
Overlap of enterocyte CLD-associated proteins identified in high fat fed WT and Dgat1-/- mice.
(C) Classification of enterocyte CLD-associated proteins identified in both WT and Dgat1-/- mice
based on GO terms for biological process and molecular function.
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Figure 3.5 Proteins present at relatively different levels in the enterocyte CLD-enriched fraction
from chronically high fat fed WT and Dgat1-/- mice
Log transformed relative protein levels were compared using a t test. The difference in relative
protein levels between WT and Dgat1-/- mice of all the proteins shown are statistically significant
(p < 0.05).
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Figure 3.6 Similar Ces2 mRNA levels in the intestinal mucosa of chronically high fat fed WT
and Dgat1-/- mice
mRNA levels of Ces2c, Ces2e, and Ces2g were assessed in intestinal mucosa collected from the
proximal third of the small intestine after 12 weeks of high fat feeding in the fed state (after a 2h
fast at the beginning of the light cycle), with WT mice as the reference group. Fold changes in
Dgat1-/- compared to WT mice were not significantly different.
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Figure 3.7 STRING analysis of lipid metabolism related proteins identified in the enterocyte
CLD-enriched fractions of chronically high fat fed WT and Dgat1-/- mice
Proteins are clustered based on structural and functional relationships, with the thickness of the
line between two proteins representing the strength of evidence supporting their relationship.
Proteins that were present at relatively different levels in WT and Dgat1-/- mice, or were only
identified in Dgat1-/- mice, are highlighted.
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Figure 3.8 Chronically high fat fed Dgat1-/- enterocytes have similar CLD-mitochondria contact
but altered mitochondrial morphology compared to WT mice
Mice were fed a high fat diet for 12 weeks and jejunal tissue samples were harvested in the fed
state (after a 2 h fast at the beginning of the light cycle) for TEM analysis. (A) The average
number of mitochondria within individual enterocytes. (B) Representative image of
mitochondria in contact with CLDs (black arrowheads) and (C) percent of mitochondria in
contact with CLDs. (D) Representative images of mitochondria with normal, partially altered
(swelling but most cristae still intact), and altered (matrix clearing, few/disrupted cristae)
morphology. (E) Percentage of mitochondria with normal and altered (includes both partially
altered and altered mitochondria) morphology. Significant differences between the groups were
determined using a t test (15 cells/mouse, 3 mice/group, *p < 0.05)
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Figure 3.9 Results summary
In response to chronic high fat feeding, Dgat1-/- enterocytes contained a similar number of CLDs
compared to WT enterocytes, but more of these CLDs were larger in size. In addition, a greater
number of total proteins were identified in the enterocyte CLD-enriched fraction from Dgat1-/compared to WT mice, including more proteins involved in lipid metabolism, and in particular
mitochondrial/FAO related proteins. There were no differences in the amount of contact between
CLDs and mitochondria between the models, but there were more mitochondria with altered
morphology in Dgat1-/- compared to WT enterocytes. These alterations within Dgat1-/enterocytes were accompanied by a decreased intestinal TAG secretion rate.
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CHAPTER 4.
ORAL GLUCOSE MOBILIZES TRIACYLGLYCEROL
STORES FROM THE HUMAN INTESTINE

4.1

Abstract
The small intestine plays an important role in whole body lipid homeostasis. The digestive

products of dietary triacylglycerol (TAG) are absorbed by enterocytes, re-synthesized into TAG,
and either secreted into the lymph duct within chylomicrons (CMs) or temporarily stored in
cytoplasmic lipid droplets (CLDs) until mobilized by various stimuli. It has previously been
shown that oral and intravenous glucose enhances CM particle secretion; however the specific
mechanisms by which this process occurs have not been clearly defined. To assess this, healthy
volunteers ingested a high fat liquid meal and, 5 hours later, were randomly assigned to ingest
either an oral glucose solution or water. Plasma and lipoprotein TAG and apoB48 concentrations
were monitored in a subset of subjects, while duodenal biopsies were obtained from a separate
cohort of subjects one hour after ingesting either glucose or water. Ultrastructural and proteomic
analyses were performed on the duodenal biopsies. Compared with water, glucose ingestion
resulted in a rise in circulating TAG and apoB48 within 30 minutes, mainly in the CM fraction.
Glucose decreased the total number of enterocyte CLDs within individual enterocytes and altered
the CLD size distribution towards a reduction in the proportion of large CLDs. Furthermore, we
identified a total of 2919 proteins present in human duodenal tissue, 270 of which are related to
lipid metabolism and 134 of which were differentially present in response to glucose compared
to water ingestion. These results demonstrate that oral glucose mobilizes TAG stored within
enterocyte CLDs to provide substrate for CM synthesis and secretion. Future studies elucidating
the underlying signaling pathways may provide mechanistic insights that lead to the development
of novel therapeutics for the treatment of hypertriglyceridemia.

The collection of the blood lipid and biopsy samples, as well as the analysis of blood lipids, were
done by our collaborators at the University of Toronto (C. Xiao, P. Stahel, S. Dash, and G.F. Lewis).
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4.2

Introduction
Hypertriglyceridemia, in both fasting and postprandial states, is a highly prevalent

condition and significant risk factor for cardiovascular disease [1]. Triacylglycerol (TAG), the
main form of dietary fat, is hydrolyzed into fatty acids (FAs), glycerol and monoacylglycerol by
digestive enzymes in the intestinal lumen. These digestive products of dietary TAG are taken up
by absorptive cells of the small intestine (enterocytes), where the majority of re-esterified TAG
is packaged into chylomicrons (CMs) and secreted into the circulation via the lymphatic system
[2]. There is increasing recognition that nutrients, hormones, and both neural and systemic
factors actively regulate intestinal CM assembly and secretion; a level of regulation that goes
beyond the dominant regulation by lipid substrate availability. Thus the intestine actively
participates in the regulation of whole-body lipid metabolism via nutrient, hormonal, metabolic
and neural regulatory pathways [3].
Aside from TAG incorporation into CMs, dietary TAG may be stored in the intestine for
several hours after the absorptive phase. Furthermore, not all assembled CMs are rapidly
secreted by the intestine postprandially. We have recently come to appreciate that the intestine
can retain and store a considerable quantity of fat, however the purpose of this is not well
understood [4]. In addition, the exact site(s) of retained intestinal lipid stores and the quantity
stored in each location has not been well defined. Lipid retained in the intestine has been
observed within enterocyte cytoplasmic lipid droplets (CLDs), in enterocyte organelles such as
the ER, the Golgi and secretory vesicles (SVs) in the form of CMs, and within CMs in the
intercellular space, the lamina propria, lacteals and mesenteric lymph [5, 6]. CLDs are the best
studied of these various lipid pools with respect to lipid storage and mobilization. CLDs consist
of a neutral lipid core surrounded by a phospholipid monolayer. Numerous CLD membraneassociated proteins have been identified and several have been shown to regulate CLD storage
and metabolism [7]. The exact role of CLDs in the process of dietary fat absorption and their
contribution to CM assembly and secretion is unknown, but studies in mice indicate that CLD
stores undergo dynamic changes in response to a high dietary fat challenge [8]. Therefore, it is
thought that CLDs may function as a temporary storage pool of neutral lipids for incorporation in
CMs at later time points [7, 9].
Various dietary and hormonal factors play a role in mobilizing TAG stored within
enterocytes from a previous meal. Several stimuli, including mixed meals [10], glucose ingestion
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[6], the gut hormone glucagon-like peptide-2 (GLP-2) [11] and sham fat feeding [12], may
trigger the mobilization of intestinal lipid stores. Ingestion of a mixed meal following a previous
high fat meal may elicit a peak in plasma TAG levels prior to the absorption of lipid from the
current meal [10]. Glucose ingestion 5 hours after a high fat meal decreases lipid stores in human
enterocytes [13]. In healthy volunteers, under the conditions of constant intraduodenal feeding
and a pancreatic clamp, subcutaneous injection of GLP-2 caused a rapid and transient rise in
plasma TAG and TAG-rich lipoprotein particle levels [11]. In the latter study GLP-2 mobilized
lipid ingested 7 hours earlier, including preformed CMs, which were presumably retained in one
or more of the above mentioned intestinal lipid pools [11]. Furthermore, sham fat feeding was
shown to stimulate CM secretion, suggesting involvement of a neural regulatory pathway in
intestinal lipid mobilization [12]. Collectively, mounting evidence supports the existence of TAG
stores in the human intestine, which are subject to release in response to certain stimuli. However
the specific mechanism(s) through which this TAG mobilization occurs is unclear.
The goal of this study was to investigate the mechanism by which oral glucose mobilizes
TAG stored within enterocytes in humans and identify the specific lipid pools that are mobilized.
In each experiment, participants ingested a high fat liquid meal and, 5 hours later, ingested
glucose or water. In Aim 1, in vivo circulating lipid responses to oral glucose were examined. In
Aims 2 and 3, duodenal biopsies were obtained and ultrastructural and molecular responses were
characterized.

4.3

Materials and Methods

4.3.1 Aim 1
4.3.1.1 Subjects
Six healthy men were recruited through advertisement in a local newspaper. Their
demographic and biochemical characteristics are listed in Table 4.1. Subjects were in good
health, with no known medical conditions, and were not taking any medication. The study
protocol was approved by the Research Ethics Board at the University Health Network,
University of Toronto. All participants gave written, informed consent.
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4.3.1.2 Study protocol
The study design is illustrated in Figure 4.1. Each subject was studied on two occasions,
4 to 6 weeks apart, in random order. On each occasion, subjects were admitted to the Endocrine
Test Centre at the Toronto General Hospital following an overnight fast. An indwelling catheter
was inserted into a superficial arm vein for blood sampling. At 7 am (referred to as t = 0),
subjects ingested a 100 ml high fat liquid meal (Calogen®, Nutricia Advanced Medical Nutrition,
Wiltshire, UK). Each 100 ml of the liquid drink contains 450 kcal energy, 50 g fat (5.3 g
saturated fat, 30.4 g monounsaturated fat, 14.3 g polyunsaturated fat), 0 g protein, 0.1 g
carbohydrate. Five hours later (t = 5 h), subjects ingested a glucose solution (50%, 50 ml) in one
arm of the study and 50 ml of water in the other arm, 4 to 6 weeks apart. Blood samples were
drawn at baseline and at regular intervals until the end of the study (t = 8 h).
4.3.1.3 Laboratory analysis
TAG-rich lipoprotein (TRL), CM and VLDL fractions were isolated using
ultracentrifugation, as previously described [11]. Plasma glucose was measured at the bedside
with a glucose analyzer (Analox Instruments, Stourbridge, UK). TAG in plasma and lipoprotein
fractions was measured with a commercial kit (Roche Diagnostics).
4.3.2 Aim 2
4.3.2.1 Subjects
24 individuals undergoing diagnostic gastroduodenoscopy for a variety of gastrointestinal
symptoms were recruited after obtaining informed consent. All participants had no known
duodenal pathology and were observed to have normal duodenal mucosa by visual inspection
during the endoscopy. Their demographics are in Table 4.2. The study protocol was approved by
the Research Ethics Board at the University Health Network, University of Toronto. All
participants gave written, informed consent.
4.3.2.2 Study protocol
After providing informed consent, patients were randomized to receive either glucose or
water treatment. At 7 am following an overnight fast (referred to as t = 0), subjects ingested a
100 ml high fat liquid meal containing 50 g of fat (Calogen®, Nutricia Advanced Medical
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Nutrition, composition provided above). Five hours later (t = 5 h), subjects ingested either a
glucose solution (50%, 50 ml) or 50 ml of water. One hour after ingesting either glucose or water
(t = 6 h), duodenal biopsy samples were obtained during an endoscopy. Samples were snap
frozen in dry ice and stored at -80°C for proteomic analysis or preserved in 2.5% glutaraldehyde
in 0.1 M sodium cacodylate (pH 7.4) at 4°C for transmission electron microscopy (TEM).
4.3.3 Aim 3
4.3.3.1 Delayed fasting
In order to further examine the time course of fat retention in the intestine and its
subsequent mobilization by oral glucose, duodenal biopsies were taken from an additional 10
individuals. These individuals were randomly assigned to ingest glucose or water 9 hours after
ingestion of the high fat liquid meal, which was administered at 10 pm the night prior to
undergoing gastroduodenoscopy (subject demographics shown in Table 4.3). The study protocol
was otherwise identical to that described above for Aim 2.
4.3.4 Transmission electron microscopy (TEM)
Duodenal biopsy samples were immediately fixed using 2.5% glutaraldehyde in 0.1 M
sodium cacodylate (pH 7.4) and stored at 4°C until processed. The tissues were then fixed with a
secondary fixative, 1% osmium tetroxide in 0.1 M sodium cacodylate (pH 7.4) for 1 hour at
room temperature, washed repeatedly in distilled deionized water, dehydrated with a graded
series of ethanol, and embedded in Embed 812 resin. Thick sections (0.5 μm) were stained with 1%
toluidine blue and examined by light microscopy to confirm tissue orientation. Thin sections (80
nm) were cut on a Leica UC6 ultramicrotome and stained with 2% uranyl acetate and lead citrate.
Images were either acquired on a Tecnai T20 transmission electron microscope (FEI, Hillsboro,
OR) equipped with a LaB6 source and operating at 100 kV, or a CM-100 transmission electron
microscope (FEI/Philips, Hillsboro, OR) operating at 80 kV. Intact enterocytes were examined
for the presence of CLDs (40-63 enterocytes/biopsy, 5 or 12 biopsy samples/group). Quantitative
analyses were performed on enterocytes containing CLDs. The numbers of CLDs per enterocyte
were counted and the diameters of individual CLDs were measured using ImageJ software (NIH,
USA). Measured diameters were used to estimate the area of individual CLDs (area =
π(diameter/2)2), and the total CLD area per enterocyte was estimated by multiplying the average
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CLD area by the average CLD number. Qualitative assessments of lipid within the secretory
pathway (ER, Golgi, and SVs) were made using a ranking system. Individual enterocytes were
classified as containing low, moderate, or high amounts of secretory lipid, and then this
information was used to assign each biopsy an overall ranking of low, moderate, or high.
Previous electron microscopy analyses of intestinal lipid stores were used as a reference for the
identification of intestinal lipid storage pools in the current study [14-18].
4.3.5 Sample preparation for LC-MS/MS analysis
Biopsy samples were washed once with 100 µl of purified water followed by 100 µl
washes using 100 mM ammonium bicarbonate (ABC) until the supernatant was clear to remove
the presence of blood in some samples. Tissue samples were then placed into 2 ml reinforced
tubes containing 2.8 mm ceramic (zirconium oxide) beads (Cayman Chemical). 200 µl of 100
mM ABC was added to each sample, and the tubes were loaded into a Precellys 24 homogenizer
(Bertin Instruments). The tissue was homogenized at 6500 rpm using three 20 second cycles.
Protein concentrations were determined for each of the tissue solutions using a Pierce™ BCA
assay kit (Thermo Scientific). An aliquot containing 100 µg of protein was taken for processing.
Before the digestion, the protein was precipitated and concentrated from solution using acetone.
After drying the precipitated pellets, the protein samples were reduced using 10 mM 1,4dithiothreitol (DTT) followed by alkylation using iodoethanol. Sequence grade Lys-C/Trypsin
(Promega) was used to enzymatically digest the protein samples in the Barocycler NEP2320
(Pressure Biosciences, Inc.) at 50°C under 20,000 psi for 1 hour. Digested samples were cleaned
using C18 spin columns (Nest Group) and dried. Resulting pellets were resuspended in 97%
purified water/3% acetonitrile (ACN)/0.1% formic acid (FA) before LC/MS analysis.
4.3.6 LC-MS/MS
Digested samples were analyzed using the Dionex UltiMate 3000 RSLC Nano System,
which was coupled to a Q Exactive™ HF Hybrid Quadrupole-Orbitrap Mass Spectrometer
(Thermo Scientific, Waltham, MA). Peptides generated during the digestion were loaded onto a
300 µm i.d. x 5mm C18 PepMap™ 100 trap column and washed with 98% purified water/2%
ACN/0.01% FA using a flow rate of 5 µl/minute. The trap column was switched in-line with the
analytical column after 5 minutes, and peptides were separated over a 75 µm x 150 mm reverse
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phase Acclaim™ PepMap™ RSLC C18 analytical column using a 120 minute method at a flow
rate of 300 nl/minute. Mobile phase A contained 0.01% FA in water while mobile phase B
consisted of 0.01% FA in 80% ACN. The linear gradient began at 5% B and reached 30% B in
80 minutes, 45% B in 91 minutes, and 100% B in 93 minutes. The column was held at 100% B
for the next 5 minutes before returning to 5% B, where it was equilibrated for 20 minutes.
Samples were injected into the QE HF through the Nanospray Flex™ Ion Source fitted with a
stainless steel emission tip from Thermo Scientific. Data acquisition was performed by
monitoring the top 20 precursors at 120,000 resolution with an injection time of 100 ms.
4.3.7 Proteomic data analysis
The results from the mass spectrometer were processed using the MaxQuant
computational proteomics platform [19]. The peak list generated was searched against the Homo
sapiens sequences from UNIPROT and a common contaminants database. The following settings
were used for the MaxQuant run: trypsin and Lys-C digestion enzymes with two missed
cleavages allowed, ethanolyl addition to cysteine as a fixed modification, N-terminal acetylation
and oxidation of methionine as variable modifications, with three modifications allowed for each
peptide, default Orbitrap parameters, minimum peptide length of seven amino acids, ‘Label-free
quantification’ (LFQ) was selected, ‘Match between runs’ was selected and the interval was set
to 1 min, and the protein FDR was set to 1%. An in-house script was used to perform the
following on the MaxQuant results: remove all of the contaminant proteins, log transform
[log2(x)] the LFQ intensity values, and input missing values using half of the highest intensity
when all the values for a given protein were missing in one group and present in at least 3
samples of the other group. Only proteins that were identified in at least 3 samples in one
treatment group were considered present in the duodenal biopsy samples. Only the relative LFQ
values of proteins that were identified in at least 3 samples in both treatment groups, or identified
in at least 3 samples in one treatment group and 0 samples in the other treatment group (imputed
values used) were compared statistically. The statistical analyses were performed in the R
environment (www.cran.r-project.org). A t test was performed on the LFQ intensities, with a pvalue < 0.05 considered a statistically significant difference between the groups. The
differentially present proteins were classified into broad groups based on Gene Ontology (GO)
terms for biological process or molecular function using the Database for Annotation,
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Visualization, and Integrated Discovery (DAVID) v 6.7 and the UniProt database. Proteins with
GO terms related to lipid (TAG, phospholipid, cholesterol, and fatty acid) metabolism,
lipoprotein metabolism and transport, and CLD storage and metabolism were identified and
classified using DAVID functional annotation clustering and functional annotation tables as well
as the UniProt database (see Tables 4.4 and 4.5 for a full list of GO terms). Protein-protein
interactions were visualized with STRING version 10.5 using the confidence view (high
confidence, score 0.700).
4.3.8 Statistical analysis
Data are presented as mean ± SEM. Plasma glucose concentrations, plasma TAG concentration
vs time curves and lipoprotein fractions (TRL, CM and VLDL) were compared using a repeated
measures ANOVA with a paired t test post hoc analysis. Mean CLD numbers, diameters, and
areas were compared with a one-tailed t test. CLD size distribution was compared using a
Kolmogorov-Smirnov test. Secretory lipid was assessed using a Fisher’s exact test.

4.4

Results

4.4.1 Oral glucose ingested 5 hours after a high fat liquid meal acutely increases plasma TAG
concentrations
The ability of oral glucose to affect plasma lipid and lipoprotein concentrations was
evaluated in vivo in Aim 1. As expected, plasma glucose levels increased in response to the
consumption of the glucose drink but not water (data not shown). Plasma TAG increased to a
postprandial peak at approximately 3 hours post fat ingestion (Figure 4.2 A and B) before
declining towards baseline. At the time that either water or glucose was ingested (5 hours post fat
ingestion) the plasma TAG concentration versus time curve was still declining towards baseline.
With water ingestion, the decline in plasma TAG continued unabated and approached basal
levels at approximately 7 hours. In contrast, after glucose ingestion, the decline in plasma TAG
levels was attenuated during the following 3 hours.
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4.4.2 Oral glucose ingested 5 hours after a high fat liquid meal increased TAG in circulating
total and CM-sized but not in smaller, VLDL-sized TRL particles
An increase in circulating total TRL TAG was observed following glucose ingestion
(Figure 4.2 C). To identify whether large or small TRLs were most responsible for the rise in
plasma and TRL TAG following glucose ingestion, TRLs were separated by ultracentrifugation
into larger CM-sized particles (Sf > 400, presumably intestinally derived CMs) and smaller
VLDL-sized particles (Sf 20-400, presumably comprised of both hepatically-derived apoB100containing VLDL and smaller, intestinally derived apoB48-containing lipoproteins). An increase
in the larger, CM-sized TRL TAG was observed with glucose ingestion (Fig 4.2 D), while
changes in the smaller, VLDL-sized TRL TAG (Fig 4.2 E) were similar with both glucose and
water ingestion. These results suggest that the increase in plasma TAG concentration in response
to glucose compared to water ingestion was due exclusively to an increase in CM TAG.
Although Aim 1 was not designed to determine the origin of the TAG, the following biopsy
results and data from a previous study (see Discussion), are highly suggestive that the increase in
CM TAG was due to mobilization of enteral TAG stores.
4.4.3 Presence of lipid pools within the intestinal mucosa
Duodenal biopsies obtained 1 hour after glucose or water ingestion were subjected to
ultrastructural analysis of enterocyte lipid stores using TEM. Although the duodenal samples
were obtained 6 hours after fat ingestion, corresponding to the late postprandial period,
considerable quantities of lipid were still visible using TEM (Figure 4.3). Within enterocytes,
lipid was observed in large CLDs, in smaller lipid droplets within the ER and within the Golgi
(Figure 4.3 B, C, and D). In addition, secreted CMs were present in the intercellular spaces
between enterocytes. Overall, the enterocyte ultrastructure and lipid pools observed in human
duodenal enterocytes appeared similar to what has been observed previously in mice [5].
4.4.4 Oral glucose mobilizes enterocyte CLD stores
We performed a quantitative analysis of enterocyte CLDs in order to compare samples
obtained from individuals who ingested water and from those who ingested glucose (Figure 4.4).
Overall, 44 and 34% of enterocytes per biopsy sample contained CLDs in response to glucose
and water ingestion, respectively (Figure 4.4 A, p = 0.14). In the samples containing CLDs, there
were fewer CLDs per cell in response to glucose compared to water (Figure 4.4 B, p = 0.02).
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While the average diameters (Figure 4.4 C, p = 0.18) and areas (Figure 4.4 D, p = 0.17) of
individual CLDs were not significantly different between the treatments, there were differences
in the CLD diameter distributions, with more CLDs falling into the smaller size range and fewer
into larger size ranges following glucose compared to water ingestion (Figure 4.4 E, p = 0.03).
However, the total CLD area per enterocyte was not significantly different between treatments
(Figure 4.4 F, p = 0.11). Taken together, glucose ingestion resulted in fewer CLDs in enterocytes
and a shift towards smaller sized CLDs.
4.4.5 Similar enterocyte secretory lipid content in response to glucose compared to water
ingestion after a high fat liquid meal
We also assessed the amount of lipid within the secretory pathway in enterocytes, which
includes lipid in the ER, Golgi, and Golgi-derived secretory vesicles. Representative examples of
enterocytes containing a range of secretory lipid content are shown in Figure 4.5 A. There were
no significant differences in the proportion of biopsies containing low, moderate, or high
amounts of secretory lipid in response to glucose compared to water ingestion (Figure 5B, p =
0.29).
4.4.6 Similar enterocyte lipid stores in response to glucose compared to water ingestion after
delayed fasting
To investigate whether glucose mobilization of intestinal lipid stores persists following
prolonged fasting, a separate group of subjects ingested glucose or water 9 hours after the high
fat liquid meal. Duodenal biopsies were collected 1 hour later (10 hours after the ingestion of the
high fat liquid meal). Under these conditions, no stimulatory effect of glucose on lipid
mobilization was observed. There were no significant differences in the percent of cells with
CLDs, CLD number or size, CLD diameter distribution, or in the amount of lipid within the
secretory pathway in enterocytes in response to glucose compared to water ingestion (Figure 4.6).
This was likely due to a lower proportion of enterocytes containing CLDs after prolonged (10
hour) fasting compared with the 6 hour fast (Figure 4.7). Thus, mobilization of enterocyte CLDs
by oral glucose appears to depend on the presence of a sufficient pool of intestinal lipid stores.
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4.4.7 Differential presence of proteins in duodenal biopsies from subjects administered glucose
or water after a high fat liquid meal
To identify proteins potentially involved in regulating the mobilization of lipid from
enterocytes by glucose, we conducted an untargeted proteomic analysis of proteins present
within human duodenal biopsies collected from patients 6 hours after a high fat liquid meal and 1
hour after glucose or water ingestion. We identified a total of 2919 proteins in the duodenal
biopsies, with 2900 present in both groups, 10 only identified in response to water, and 9 only
identified in response to glucose ingestion (Figure 4.8 A). Of these proteins, 48 were present at
relatively lower levels in response to glucose compared to water ingestion, and 86 were present
at relatively higher levels in response to glucose compared to water (Table 4.6, proteins unique
to one treatment are highlighted). These differentially present proteins were classified into broad
groups based on GO terms for biological process and molecular function (Figure 4.8 B). Protein
folding/transport (19%), immune response (15%), and transcription/RNA processing/translation
(15%) were the most abundant functions among the 48 proteins present at relatively lower levels
in response to glucose compared to water ingestion. Of the 86 proteins present at relatively
higher levels in response to glucose compared to water, those involved in protein metabolism
(21%), associated with mitochondria/redox (16%), and involved in transcription/RNA
processing/translation (15%) were the most abundant. Interestingly, the differentially present
histone proteins identified were all present at relatively lower levels in response to glucose
compared to water, and the differentially present proteins involved in carbohydrate metabolism,
ion transport, and lipid metabolism were all present at relatively higher levels in response to
glucose compared to water ingestion.
Since our goal was to identify mechanisms through which lipid stored in the intestine is
mobilized in response to glucose ingestion, we looked specifically at lipid metabolism related
proteins present in the duodenal biopsies. Of the 2919 proteins identified, 270 (9%) of them are
involved in lipid/lipoprotein metabolism and transport. The majority of these proteins are
involved in FA modification, metabolism, and transport (32%, Figure 4.9, Cluster 4) and
lipoprotein metabolism (23%, Figure 4.9, Cluster 2), however proteins involved in
cholesterol/steroid metabolism (Figure 4.9, Cluster 3), TAG/phospholipid metabolism (Figure
4.9, Cluster 1), lipid binding, eicosanoid metabolism, CLD storage/metabolism, and CM
trafficking were also identified (Figure 4.9). A STRING analysis was used to visualize structural
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and functional relationships between these lipid metabolism proteins, and several clusters
corresponding to some of the broad functional categories mentioned above were observed
(Figure 4.9 B). A total of 9 of these lipid related proteins: acyl-coenzyme A thioesterase 8,
ethylmalonyl-CoA decarboxylase, acetyl-coenzyme A synthetase; cytoplasmic,
phosphatidylinositol glycan anchor biosynthesis class U protein, 3-beta-hydroxysteroid-delta(8);
delta(7)-isomerase, acyl-CoA-binding protein, 7-dehydrocholesterol reductase, fatty acyl-CoA
reductase 1, and ethanolaminephosphotransferase 1, were present at relatively higher levels in
response to glucose compared to water ingestion (Table 4.7).
A similar comparative proteomic analysis was performed in response to glucose or water
ingestion after a prolonged fast following the consumption of a high fat liquid meal (samples
collected 10 hours after a high fat meal and 1 hour after glucose/water ingestion), at which point
there were no observed differences in enterocyte lipid stores. A total of 1683 proteins were
identified in this analysis, with 1673 proteins common to both groups, 9 only identified in
response to water, and 1 only identified in response to glucose ingestion (Figure 4.10 A). The 96
proteins that were differentially present in this analysis are involved in a variety of cellular
processes, with a greater proportion of proteins involved in transcription and translation (35% of
the proteins that were lower and 40% of the proteins that were present at higher levels in
response to glucose compared to water ingestion) compared to the initial study (Figure 4.9 B and
Table 4.8). The 186 lipid metabolism related proteins identified in this delayed fasting study are
involved in similar processes as the initial study (Figure 4.11), however none of the 6 lipid
metabolism proteins that were differentially present in response to glucose compared to water
ingestion were the same as those identified at 6 hours after ingesting a high fat meal (Table 4.9).

4.5

Discussion
The intestine plays an important regulatory role in whole-body lipid homeostasis beyond

its conventionally viewed passive role of digesting and absorbing nutrients. Among other
findings, the intestine retains dietary lipids for a prolonged time period after fat ingestion, and
these lipid stores are subsequently released by various stimuli. We are only beginning to
understand the mechanisms regulating this intestinal lipid storage and release cycle. In this study,
we examined the mechanism of one stimulus that has previously been shown to mobilize
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intestinal lipid stores, oral glucose. In order to assess this, we performed in vivo assessments of
plasma lipids along with ultrastructural and proteomic analyses of human duodenal biopsies in
response to glucose compared to water ingestion several hours after the ingestion of a high fat
meal. We confirmed that oral glucose ingestion mobilizes lipid from the intestine and showed
that this lipid was stored within enterocyte CLDs. Furthermore, a proteomic analysis of duodenal
biopsies demonstrates marked differential expression of intestinal proteins in response to oral
glucose compared water, some of which may be involved in regulating the mobilization of
intestinal lipid stores.
Several lines of evidence, including the results of the current study, support the notion that
the small intestine retains lipid for several hours after fat ingestion. Studies in humans detected
an early peak in plasma CM TAG following a fat-rich meal, and the origin of this early peak is
believed to be from an enteral storage site of lipids derived from a previous meal [20, 21]. Lipid
stored in the human gut has also been shown to contribute to CM secretion up to 16 hours after
the last meal [12, 22]. In addition, abundant lipid droplets are visible in the cytoplasm of jejunal
enterocytes when examined 6 hours after ingestion of a high fat liquid meal [6]. Although the
exact cellular and extracellular location(s) of this stored lipid are not well defined, lipid droplets
have been visualized in the cytoplasm of jejunal enterocytes in humans [6] and mice [23], and
CMs have been observed within the intracellular secretory pathway in enterocytes, in the lamina
propria or within lacteals of the lymphatic system [24]. Collectively, postprandial retention of
lipid in the gut may occur in various locations within the intestinal structure and in various forms,
as intracellular CLDs and possibly as pre-formed lipoprotein particles, either intracellularly or in
the extracellular space. In the current study, we detected abundant lipid depots, especially CLDs,
within duodenal enterocytes of subjects who ingested a high fat meal 6 hours previously. Six
hours after a high fat liquid meal plasma TAG levels have almost returned to baseline, clearly
demonstrating the lipid storage capacity of the gut. Glucose ingestion reduced the amount of
lipid stored within enterocyte CLDs, providing evidence of glucose-stimulated lipid mobilization.
This corresponded to the attenuated decline of postprandial plasma TAG levels in response to
glucose ingestion 5 hours after a high fat liquid meal, which was mainly due to an increase in
CM TAG. As there was no other food intake during the study period, the high fat liquid meal is
likely the source of this TAG. Together these results suggest that considerable dietary lipid is
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retained in intestinal CLDs well into the late postprandial period, which can be subsequently
secreted within CMs.
Intestinal lipid stores may be mobilized in response to various stimuli. Several of these
stimuli have been demonstrated or implicated in studies in humans, including oral glucose [6],
GLP-2 [11] and sham fat feeding [12, 22]. Robertson et al. demonstrated that glucose ingestion 5
hours after a high fat liquid meal resulted in a postprandial peak in plasma TAG and CM TAG,
which was accompanied by a decrease in lipid depots in jejunal enterocytes and the lamina
propria [6]. In the current study, we not only confirmed that oral glucose is able to mobilize
intestinal lipid stores, but also expanded this observation with high-quality visualization of
subcellular CLDs and lipid within the secretory pathway. Furthermore, through detailed,
quantitative analysis of the effects of glucose ingestion on intestinal lipid mobilization, we
demonstrated that glucose ingestion resulted in fewer and smaller CLDs in enterocytes. This
study thus identified CLDs as dynamic and regulated lipid storage depots that mediate intestinal
lipid handling and CM secretion. The ability to store TAG in CLDs and mobilize this lipid at
later times may enhance the overall efficiency of dietary fat absorption and prevent toxicity both
locally within enterocytes as well as systemically [4, 7, 9]. In the enterocyte, CLDs provide a
buffering depot for lipid that cannot rapidly be incorporated into CMs for secretion. Systemically,
this process may also attenuate an otherwise rapid rise in postprandial lipids that could
overwhelm the lipid storage capacity of adipose tissues, resulting in fatty acid spillover and
lipotoxicity [25]. Furthermore, early postprandial CLD mobilization may serve a priming
function for the enterocyte’s CM assembly and secretion pathway, which needs to rapidly and
efficiently cope with the large influx of lipid during food ingestion. Together with the increase in
plasma and CM TAG concentrations, these results support that oral glucose functioned as a
stimulus to mobilize enterocyte lipid stores for use in CM synthesis and secretion. It is
envisioned, based on the known and well described biology of CM assembly and secretion [26],
that glucose ingestion would have initiated a sequence of events, including hydrolysis of TAG
stored within CLDs, TAG re-synthesis at the ER membrane, CM assembly and secretion from
enterocytes, and transport through the lymphatics and into the circulation. Although the exact
mechanism is unclear, lumenal contact with glucose may not be critical, as it has previously been
demonstrated that prolonged, continuous infusion of glucose into the duodenum, as well as
intravenous infusion of glucose, increased CM particle synthesis in humans [27, 28]. In the
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current study we also found that the effects of glucose ingestion depend on sufficient lipid stores
within the enterocyte, as the stimulatory effect of glucose was absent following prolonged fasting
(10 hours after fat ingestion), which had resulted in a significant reduction in intestinal CLD
stores.
To gain further insight into proteins potentially regulating the observed glucose-stimulated
lipid mobilization from the small intestine, we performed a comparative proteomic analysis of
the duodenal biopsies in response to glucose compared to water ingestion. We identified 134
proteins that were present at relatively different levels 6 hours after consuming a high fat meal, 9
of which have known roles in lipid metabolism. To our knowledge this is the first time an
untargeted comparative proteomic analysis of human duodenal tissues has been conducted in
response to a dietary challenge. Previous studies have used both untargeted and targeted
approaches to identify duodenal proteins in insulin resistant compared to insulin sensitive
individuals, but these duodenal tissue samples were collected in the fasted state [29, 30].
Although validation of the presence of the identified proteins within the small intestine by
additional methods is needed, the present study provides us with candidate proteins that are
present in the duodenum in response to dietary fat and glucose ingestion. In addition, this study
identifies potential glucose regulated proteins within the duodenum, some of which may also be
involved in regulating glucose-stimulated mobilization of lipid from the small intestine.
In attempt to identify potential proteins involved in regulating glucose-stimulated lipid
mobilization from the small intestine, we performed a targeted search of our proteomics data to
identify proteins with known roles in intestinal lipid/lipoprotein metabolism and transport. From
this list we identified differentially present lipid metabolism proteins in the duodenum 6 hours
after lipid and 1 hour after glucose or water ingestion, which were all present at relatively higher
levels in response to glucose compared to water. Several of these proteins are involved in fatty
acid metabolism (acetyl-coenzyme A synthetase; cytoplasmic, acyl-coenzyme A thioesterase 8,
ethylmalonyl-CoA decarboxylase, and fatty acyl-CoA reductase 1), a couple are involved in
cholesterol biosynthesis (3-beta-hydroxysteroid-delta(8); delta(7)-isomerase and 7dehydrocholesterol reductase), two are involved in phospholipid synthesis
(ethanolaminephosphotransferase 1 and phosphatidylinositol glycan anchor biosynthesis class U
protein), and one is a lipid binding protein (acyl-CoA-binding protein). There is not a lot known
about the particular roles of these proteins within the small intestine specifically, however acyl-
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CoA binding protein was previously shown to be present at high levels in mouse intestinal
epithelium and to co-localize with fatty acid binding protein 2 (FABP2/I-FABP) [31]. FABP2
was also identified in the current study but not differentially present between the treatment
groups. Future work will include validation of the presence and localization of these proteins
within the small intestine, but their initial identification and differential presence in the two
treatment groups suggests there may be a general increase in intestinal lipid metabolism in
response to glucose ingestion. Furthermore, the differentially present lipid metabolism related
proteins identified in duodenal biopsies after prolonged fasting (10 hours) were not the same as
those identified in the shorter (6 hour) fasting study, however they were involved in similar
processes. This suggests that glucose may exert different regulatory effects in the intestine
depending on dietary status (i.e. when the last meal was consumed).
Interestingly, we did not see differences in the levels of several proteins with established
roles in CM synthesis and secretion or CLD metabolism 6 hours after fat and 1 hour after
glucose or water ingestion. We identified both perilipin 2 (PLIN2) and PLIN3, which play roles
in regulating CLD storage [32], but these proteins were present at similar levels in both treatment
groups. In addition, we only identified one of the four enzymes involved in cytoplasmic TAG
lipolysis, monoacylglycerol lipase (MGL), in the current study, and it was not differentially
present in response to glucose compared to water ingestion. This is consistent, though, with the
lack of identification of any cytoplasmic lipases other than MGL within duodenal tissue
collected from fasted insulin sensitive or insulin resistant individuals [30]. It is possible that
these proteins are present at levels below the mass spec detection limit, and/or that other
enzymes or pathways play more of a role in TAG mobilization from enterocytes under the
conditions of the current study. In fact, we identified lysosomal acid lipase (LAL), which
hydrolyzes TAG within the lysosome during lipophagy [33], at similar levels in both treatment
groups, along with several other lipases (gastric triacylglycerol lipase (LIPG), pancreatic
triacylglycerol lipase (LIPP), and lipid droplet-associated hydrolase(LDAH)). We also identified
key proteins involved in CM synthesis and trafficking (APOB, MTP, SAR1B), but again did not
see differences in their protein levels in response to glucose compared to water ingestion.
However, since an untargeted proteomic approach does not provide any information about the
function or localization of proteins, it is still possible that glucose ingestion results in alterations
in the activities (e.g. through phosphorylation) or in the subcellular locations of these proteins
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within enterocytes that in turn alters CM synthesis and secretion. Since the major effect of oral
glucose was mobilization of enterocyte CLDs, and CLD-associated proteins can participate in
CLD metabolism, future studies identifying proteins present in specific subcellular locations,
including those associated with the CLD membrane, would be of interest. This was not possible
in the current study due to the limited amount of tissue obtained from the duodenal biopsies.
To examine whether proteins without known roles in lipid metabolism are involved in the
observed glucose-stimulated mobilization from the small intestine, we also looked at non-lipid
related proteins that were differentially present in response to glucose compared to water
ingestion. Several of these differentially present proteins were only identified in response to
either glucose or water at 6 hours after fat and 1 hour after glucose or water ingestion. These
proteins are involved in a variety of biological processes, including transcription/translation,
protein folding and transport, protein metabolism, redox, immune response and associated with
the cytoskeleton, however little is known about their roles in the small intestine. Further
investigation into their intestine-specific functions would be beneficial due to their potential to
be glucose regulated and possible involvement in glucose-stimulated lipid mobilization from the
intestine. One potential protein of interest for follow-up is syntaxin-binding protein 5, which was
identified in response to water but not in response to glucose ingestion. Syntaxin-binding protein
5 is involved in regulating exocytosis in multiple cell types, including platelets and endothelial
cells lining blood vessel walls [34]. This protein is also a negative regulator of insulin exocytosis
in pancreatic beta cells, and glucose has been shown to inhibit syntaxin-binding protein 5 and
induce its degradation in these cells in order to promote insulin secretion [35]. It is possible that
glucose also negatively regulates this protein in enterocytes, and that this regulation has an
impact on intestinal lipid mobilization, however this requires further investigation.

4.6

Conclusion
Here we present evidence from both in vivo lipid responses and intestinal biopsies that

support a role of glucose ingestion in mobilizing lipid stores from the human intestine. Glucose
ingestion mobilizes enterocyte CLDs to provide substrate for CM synthesis and secretion, likely
involving multiple molecular players. Although the precise mechanisms by which intestinal lipid
stores are mobilized remain largely elusive, the current study using glucose as a model stimulus
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provides novel insights. Future work will include further investigation into the molecular
regulation of this response. An increased understanding of the effects of glucose ingestion on the
metabolism of dietary fat can help to identify novel therapeutic targets for treatment of
hypertriglyceridemia, as well as provide novel dietary guidance for lowering blood TAG levels
and decreasing cardiovascular disease risk.
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Table 4.1 Demographics and biochemical characteristics of Aim 1 participants

Subject

Age
(yrs)

Weight
(kg)

Height
(cm)

BMI
(kg/m2)

Waist
(cm)

1
2
3
4
5
6
Mean
SEM

58
46
46
53
29
57
48.2
4.4

72
77
87
76
87
84
80.5
2.6

178
166
182
172
182
179
176.5
2.6

23
27
26
25.7
26.4
26
25.7
0.6

95.5
101
100
87
94
88
94.3
2.4

Fasting
Glucose
(mM)
5.6
4.9
4.5
4.9
4.4
4.5
4.8
0.2

Fasting
TAG
(mM)
0.76
0.73
0.97
1.99
0.68
0.59
1.0
0.2

Fasting
Insulin
(pM)
35
48
37
94
36.5
29
46.6
9.8
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Table 4.2 Demographics of participants participating in Aim 2

n
BMI (kg/m2)
Age (yrs)
Gender

Glucose
12
25.3 ± 0.9
25.5 ± 1.5
4M/8F

Placebo
12
25.3 ± 0.9
25.5 ± 1.5
2M/10F

Data are Mean ± SEM for BMI and Age
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Table 4.3 Demographics of participants participating in Aim 3 (delayed fasting)

n
BMI (kg/m2)
Age (yrs)
Gender

Glucose
5
23.8 ± 1.2
33.0 ± 3.8
1M/4F

Placebo
5
22.2 ± 1.4
33.6 ± 3.2
1M/4F

Data are Mean ± SEM for BMI and Age
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Table 4.4 Gene ontology (GO) terms associated with lipid metabolism related proteins present in
duodenal biopsies 6 h after a high fat liquid meal

Cholesterol/Steroid Metabolism
UP_KEYWORDS
Cholesterol biosynthesis
GOTERM_BP_DIRECT
cholesterol biosynthetic process
UP_KEYWORDS
Cholesterol metabolism
UP_KEYWORDS
Steroid biosynthesis
KEGG_PATHWAY
Steroid hormone biosynthesis
UP_KEYWORDS
Steroid metabolism
UP_KEYWORDS
Sterol biosynthesis
GOTERM_MF_DIRECT
sterol esterase activity
UP_KEYWORDS
Sterol metabolism
CLD Storage/Metabolism
GOTERM_CC_DIRECT
lipid droplet
GPTERM_BP_DIRECT
lipid storage
CM Trafficking
GOTERM_CC_DIRECT
COPII vesicle coat
GOTERM_CC_DIRECT
ER to Golgi transport vesicle membrane
GOTERM_MF_DIRECT
SNARE binding
GOTERM_CC_DIRECT
SNARE complex
GOTERM_BP_DIRECT
vesicle fusion
Eicosanoid Metabolism
UP_KEYWORDS
Leukotriene biosynthesis
GOTERM_BP_DIRECT
leukotriene biosynthetic process
GOTERM_BP_DIRECT
leukotriene metabolic process
GOTERM_BP_DIRECT
prostaglandin biosynthetic process
FA Modification/Metabolism/Transport
GOTERM_BP_DIRECT
fatty acid biosynthetic process
GOTERM_MF_DIRECT
3-hydroxyacyl-CoA dehydrogenase activity
INTERPRO
3-hydroxyacyl-CoA dehydrogenase, conserved site
INTERPRO
3-hydroxyacyl-CoA dehydrogenase, C-terminal
INTERPRO
3-hydroxyacyl-CoA dehydrogenase, NAD binding
GOTERM_MF_DIRECT
acyl-CoA dehydrogenase activity
INTERPRO
Acyl-CoA dehydrogenase, conserved site
INTERPRO
Acyl-CoA dehydrogenase/oxidase
INTERPRO
Acyl-CoA dehydrogenase/oxidase C-terminal
INTERPRO
Acyl-CoA dehydrogenase/oxidase, N-terminal
GOTERM_MF_DIRECT
acyl-CoA hydrolase activity
GOTERM_BP_DIRECT
acyl-CoA metabolic process
INTERPRO
Acyl-CoA oxidase
PIR_SUPERFAMILY
acyl-CoA oxidase
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Table 4.4 continued

INTERPRO
INTERPRO
INTERPRO
INTERPRO
GOTERM_MF_DIRECT
INTERPRO
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
KEGG_PATHWAY
KEGG_PATHWAY
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
KEGG_PATHWAY
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
Lipid Binding Proteins
INTERPRO
INTERPRO
INTERPRO
UP_SEQ_FEATURE
INTERPRO
INTERPRO
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
UP_KEYWORDS
UP_KEYWORDS
UP_KEYWORDS
Lipoprotein Metabolism
INTERPRO

Acyl-CoA oxidase, C-terminal
Acyl-CoA oxidase/dehydrogenase, central domain
AMP-binding, conserved site
AMP-dependent synthetase/ligase
decanoate--CoA ligase activity
Domain of unknown function DUF4009
fatty acid beta-oxidation
fatty acid beta-oxidation using acyl-CoA dehydrogenase
fatty acid beta-oxidation using acyl-CoA oxidase
Fatty acid biosynthesis
Fatty acid degradation
fatty acid elongation
fatty acid metabolic process
Fatty acid metabolism
fatty acid transport
fatty-acyl-CoA binding
fatty-acyl-CoA biosynthetic process (BP)
lipid homeostasis
long-chain fatty acid import
long-chain fatty acid metabolic process
long-chain fatty acid-CoA ligase activity
long-chain fatty-acyl-CoA biosynthetic process
long-chain fatty-acyl-CoA metabolic process
very long-chain fatty acid-CoA ligase activity
Acyl-CoA-binding protein, ACBP
Acyl-CoA-binding protein, ACBP, conserved site
Cytosolic fatty-acid binding
domain:ACB
Lipocalin/cytosolic fatty-acid binding protein domain
Lipocalin/cytosolic fatty-acid binding protein domain
retinal binding
retinoic acid binding
retinoid binding
retinol binding
Retinol-binding
Retinol-binding
Vitamin A
Apolipoprotein A1/A4/E
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GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_CC_DIRECT
UP_KEYWORDS
GOTERM_BP_DIRECT
UP_KEYWORDS
GOTERM_CC_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_CC_DIRECT
UP_KEYWORDS
SMART
GOTERM_MF_DIRECT
UP_KEYWORDS
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
INTERPRO
INTERPRO
GOTERM_CC_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT

cholesterol binding
cholesterol efflux
cholesterol homeostasis
cholesterol metabolic process
cholesterol transporter activity
chylomicron
Chylomicron
chylomicron remnant clearance
HDL
high-density lipoprotein particle
high-density lipoprotein particle assembly
high-density lipoprotein particle clearance
high-density lipoprotein particle receptor binding
high-density lipoprotein particle remodeling
intermediate-density lipoprotein particle
LDL
LDLa
lipase inhibitor activity
Lipid transport
lipid transport
lipid transporter activity
lipoprotein biosynthetic process
lipoprotein metabolic process
Low-density lipoprotein (LDL) receptor class A repeat
Low-density lipoprotein (LDL) receptor class A, conserved site
low-density lipoprotein particle
low-density lipoprotein particle remodeling
negative regulation of cholesterol transport
negative regulation of lipid catabolic process
negative regulation of lipid metabolic process
negative regulation of receptor-mediated endocytosis
negative regulation of very-low-density lipoprotein particle clearance
negative regulation of very-low-density lipoprotein particle remodeling
neuron projection regeneration
phosphatidylcholine binding
phosphatidylcholine-sterol O-acyltransferase activator activity
phospholipid efflux
positive regulation of cholesterol esterification
positive regulation of fatty acid biosynthetic process
positive regulation of lipoprotein lipase activity
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GOTERM_BP_DIRECT
positive regulation of triglyceride catabolic process
GOTERM_BP_DIRECT
regulation of Cdc42 protein signal transduction
GOTERM_BP_DIRECT
regulation of intestinal cholesterol absorption
GOTERM_BP_DIRECT
reverse cholesterol transport
GOTERM_CC_DIRECT
spherical high-density lipoprotein particle
GOTERM_BP_DIRECT
triglyceride homeostasis
GOTERM_CC_DIRECT
very-low-density lipoprotein particle
GOTERM_BP_DIRECT
very-low-density lipoprotein particle remodeling
UP_KEYWORDS
VLDL
TAG & PL Synthesis/Metabolism
GOTERM_MF_DIRECT
1-acylglycerol-3-phosphate O-acyltransferase activity
GOTERM_BP_DIRECT
acylglycerol catabolic process
GOTERM_MF_DIRECT
acylglycerol lipase activity
GOTERM_BP_DIRECT
CDP-diacylglycerol biosynthetic process
GOTERM_BP_DIRECT
ether lipid biosynthetic process
GOTERM_BP_DIRECT
glycerolipid metabolic process
GOTERM_BP_DIRECT
glycerophospholipid biosynthetic process
GOTERM_BP_DIRECT
glycerophospholipid catabolic process
KEGG_PATHWAY
Glycerophospholipid metabolism
GOTERM_BP_DIRECT
GPI anchor biosynthetic process
GOTERM_MF_DIRECT
lysophospholipase activity
GOTERM_BP_DIRECT
phosphatidic acid biosynthetic process
UP_KEYWORDS
Phospholipid biosynthesis
GOTERM_BP_DIRECT
phospholipid biosynthetic process
GOTERM_BP_DIRECT
phospholipid catabolic process
GOTERM_BP_DIRECT
phospholipid metabolic process
UP_KEYWORDS
Phospholipid metabolism
GOTERM_BP_DIRECT
phospholipid transport
INTERPRO
Phospholipid/glycerol acyltransferase
SMART
PlsC
UP_SEQ_FEATURE
short sequence motif:HXXXXD motif
GOTERM_BP_DIRECT
triglyceride biosynthetic process
GOTERM_MF_DIRECT
triglyceride lipase activity
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Table 4.5 Gene ontology (GO) terms associated with lipid metabolism related proteins present in
duodenal biopsies 10 h after a high fat liquid meal

Cholesterol/Steroid Metabolism
UP_KEYWORDS
Cholesterol biosynthesis
GOTERM_BP_DIRECT
cholesterol biosynthetic process
UP_KEYWORDS
Cholesterol metabolism
GOTERM_BP_DIRECT
isoprenoid biosynthetic process
UP_KEYWORDS
Steroid biosynthesis
KEGG_PATHWAY
Steroid hormone biosynthesis
GOTERM_BP_DIRECT
steroid metabolic process
UP_KEYWORDS
Steroid metabolism
UP_KEYWORDS
Sterol biosynthesis
GOTERM_MF_DIRECT
sterol esterase activity
UP_KEYWORDS
Sterol metabolism
CLD Storage/Metabolism
GOTERM_CC_DIRECT
lipid droplet
GOTERM_BP_DIRECT
lipid storage
CM Trafficking
GOTERM_CC_DIRECT
ER to Golgi transport vesicle membrane
Eicosanoid Metabolism
GOTERM_MF_DIRECT
arachidonic acid epoxygenase activity
KEGG_PATHWAY
Arachidonic acid metabolism
GOTERM_BP_DIRECT
cyclooxygenase pathway
GOTERM_BP_DIRECT
epoxygenase P450 pathway
GOTERM_BP_DIRECT
leukotriene metabolic process
UP_KEYWORDS
Prostaglandin biosynthesis
GOTERM_BP_DIRECT
prostaglandin biosynthetic process
UP_KEYWORDS
Prostaglandin metabolism
GOTERM_MF_DIRECT
steroid hydroxylase activity
FA Modification/Metabolism/Transport
GOTERM_MF_DIRECT
acyl-CoA dehydrogenase activity
INTERPRO
Acyl-CoA dehydrogenase, conserved site
INTERPRO
Acyl-CoA dehydrogenase/oxidase
INTERPRO
Acyl-CoA dehydrogenase/oxidase C-terminal
INTERPRO
Acyl-CoA dehydrogenase/oxidase, N-terminal
GOTERM_MF_DIRECT
acyl-CoA hydrolase activity
GOTERM_BP_DIRECT
acyl-CoA metabolic process
INTERPRO
Acyl-CoA oxidase/dehydrogenase, central domain
INTERPRO
Acyltransferase ChoActase/COT/CPT
INTERPRO
AMP-binding, conserved site
INTERPRO
AMP-dependent synthetase/ligase
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Table 4.5 continued

UP_SEQ_FEATURE
GOTERM_MF_DIRECT
INTERPRO
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
UP_KEYWORDS
KEGG_PATHWAY
KEGG_PATHWAY
UP_KEYWORDS
KEGG_PATHWAY
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
UP_SEQ_FEATURE
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
Lipid Binding Proteins
INTERPRO
INTERPRO
INTERPRO
UP_SEQ_FEATURE
GOTERM_MF_DIRECT
INTERPRO
GOTERM_MF_DIRECT
Lipoprotein Metabolism
INTERPRO
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT

binding site:Carnitine
decanoate--CoA ligase activity
Domain of unknown function DUF4009
fatty acid alpha-oxidation
fatty acid beta-oxidation
fatty acid beta-oxidation using acyl-CoA dehydrogenase
Fatty acid biosynthesis
Fatty acid biosynthesis
Fatty acid degradation
Fatty acid metabolism
Fatty acid metabolism
flavin adenine dinucleotide binding
hydroxyacyl-CoA dehydrogenase activity
lipid homeostasis
long-chain fatty acid import
long-chain fatty acid metabolic process
long-chain fatty acid-CoA ligase activity
negative regulation of fatty acid metabolic process
oxidoreductase activity, acting on the CH-CH group of donors
oxidoreductase activity, acting on the CH-CH group of donors, with a
flavin as acceptor
palmitoyl-CoA hydrolase activity
region of interest:Coenzyme A binding
transferase activity, transferring acyl groups
very long-chain fatty acid-CoA ligase activity
Acyl-CoA-binding protein, ACBP
Acyl-CoA-binding protein, ACBP, conserved site
Cytosolic fatty-acid binding
domain:ACB
fatty-acyl-CoA binding
Lipocalin/cytosolic fatty-acid binding protein domain
retinoic acid binding
Apolipoprotein A1/A4/E
cholesterol binding
cholesterol efflux
cholesterol homeostasis
cholesterol metabolic process
cholesterol transporter activity
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GOTERM_CC_DIRECT
UP_KEYWORDS
GOTERM_BP_DIRECT
UP_KEYWORDS
GOTERM_CC_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_CC_DIRECT
GOTERM_MF_DIRECT
UP_KEYWORDS
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_CC_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_MF_DIRECT
GOTERM_MF_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_CC_DIRECT
GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
GOTERM_CC_DIRECT
GOTERM_BP_DIRECT
UP_KEYWORDS

chylomicron
Chylomicron
chylomicron remnant clearance
HDL
high-density lipoprotein particle
high-density lipoprotein particle assembly
high-density lipoprotein particle clearance
high-density lipoprotein particle receptor binding
high-density lipoprotein particle remodeling
intermediate-density lipoprotein particle
lipase inhibitor activity
Lipid transport
lipid transport
lipid transporter activity
lipoprotein biosynthetic process
lipoprotein metabolic process
low-density lipoprotein particle
low-density lipoprotein particle remodeling
negative regulation of cholesterol transport
negative regulation of lipid catabolic process
negative regulation of lipid metabolic process
negative regulation of receptor-mediated endocytosis
negative regulation of very-low-density lipoprotein particle clearance
negative regulation of very-low-density lipoprotein particle remodeling
phosphatidylcholine binding
phosphatidylcholine-sterol O-acyltransferase activator activity
phospholipid efflux
positive regulation of cholesterol esterification
positive regulation of fatty acid biosynthetic process
positive regulation of lipoprotein lipase activity
positive regulation of triglyceride catabolic process
regulation of Cdc42 protein signal transduction
regulation of intestinal cholesterol absorption
reverse cholesterol transport
spherical high-density lipoprotein particle
triglyceride catabolic process
triglyceride homeostasis
very-low-density lipoprotein particle
very-low-density lipoprotein particle remodeling
VLDL
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TAG & PL Synthesis/Metabolism
GOTERM_MF_DIRECT
1-acylglycerol-3-phosphate O-acyltransferase activity
GOTERM_MF_DIRECT
1-acylglycerol-3-phosphate O-acyltransferase activity
GOTERM_BP_DIRECT
acylglycerol catabolic process
GOTERM_BP_DIRECT
CDP-diacylglycerol biosynthetic process
GOTERM_BP_DIRECT
CDP-diacylglycerol biosynthetic process
GOTERM_BP_DIRECT
glycerophospholipid biosynthetic process
glycerophospholipid biosynthetic process
GOTERM_BP_DIRECT
glycerophospholipid catabolic process
KEGG_PATHWAY
Glycerophospholipid metabolism
GOTERM_BP_DIRECT
phosphatidic acid biosynthetic process
UP_KEYWORDS
Phospholipid biosynthesis
GOTERM_BP_DIRECT
phospholipid biosynthetic process
UP_KEYWORDS
Phospholipid metabolism
INTERPRO
Phospholipid/glycerol acyltransferase
GOTERM_BP_DIRECT
triglyceride biosynthetic process
GOTERM_BP_DIRECT
triglyceride lipase activity
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Table 4.6 Proteins present at relatively different levels in duodenal biopsies from subjects
administered glucose or water after a high fat liquid meal

Duodenal biopsy samples were collected 6 h post lipid and 1 h post glucose or water ingestion
from patients undergoing a diagnostic endoscopy (n =10 patients per group). Proteins that were
identified in at least 3 samples in both groups and present at relatively different levels (p < 0.05, t
test), or at least 3 samples in one group and 0 samples in the other group, are shown. Average
fold changes of proteins in response to glucose relative to water ingestion are presented. *only
identified in response to water, †only identified in response to glucose

Uniprot
Accession

Protein Name

Gene Name

Fold
Change

T Test
p-value

P05997

Collagen alpha-2(V) chain*

COL5A2

-7.4957

0.0030

Q5T5C0

Syntaxin-binding protein 5*

STXBP5

-6.8628

4.72E-22

LTBP4

-6.7854

0.0002

ADAM10

-6.7264

0.0010

Q8N2S1
O14672

Latent-transforming growth
factor beta-binding protein 4*
Disintegrin and
metalloproteinase domaincontaining protein 10*

Function
Other (extracellular
matrix protein)
Protein
Folding/Transport
Protein
Folding/Transport
Protein Metabolism
Transcription/RNA
Processing/Translation
Cytoskeleton
Cytoskeleton
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation

P17480

Nucleolar transcription factor 1*

UBTF

-6.2100

0.0063

Q8N8S7
Q7Z6K5

ENAH
ARPIN

-5.7620
-5.7573

0.0007
2.02E-19

SRRM2

-5.5687

0.0002

NUP153

-5.1794

0.0079

SDR39U1

-4.1142

3.26E-28

Mitochondria/Redox

HIST1H1C

-1.0513

0.0213

Histone

IGHG3

-1.0063

0.0007

Immune Response

IFI30

-1.0048

0.0116

Mitochondria/Redox

P35580

Protein enabled homolog*
Arpin*
Serine/arginine repetitive matrix
protein 2*
Nuclear pore complex protein
Nup153*
Epimerase family protein
SDR39U1*
Histone H1.2
Immunoglobulin heavy constant
gamma 3
Gamma-interferon-inducible
lysosomal thiol reductase
Myosin-10

MYH10

-0.9176

0.0449

P08590

Myosin light chain 3

MYL3

-0.8947

0.0464

Q71UI9
Q71DI3
A0A0B4J
1X5

Histone H2A.V
Histone H3.2
Immunoglobulin heavy variable
3-74

H2AFV

-0.8933
-0.8572

0.0072
0.0338

Cytoskeleton
Other (regulation of
muscle contraction)
Histone
Histone

IGHV3-74

-0.8112

0.0076

Immune Response

Q99829

Copine-1

CPNE1

-0.7877

0.0101

Transcription/RNA
Processing/Translation

Q9UQ35
P49790
Q9NRG7
P16403
P01860
P13284
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P01780
P42167
P0CG06
Q96KA5
P01859
P84243
Q8IUX7
Q09666
Q9BY50
P07305
P01857
Q9UEW8
P30405
P56378

Immunoglobulin heavy variable
3-7
Lamina-associated polypeptide
2; isoforms beta/gamma
immunoglobulin lambda
constant 2
Cleft lip and palate
transmembrane protein 1-like
protein
Immunoglobulin heavy constant
gamma 2
Histone H3.3
Adipocyte enhancer-binding
protein 1
Neuroblast differentiationassociated protein AHNAK
Signal peptidase complex
catalytic subunit SEC11C
Histone H1.0
Immunoglobulin heavy constant
gamma 1
STE20/SPS1-related prolinealanine-rich protein kinase
Peptidyl-prolyl cis-trans
isomerase F; mitochondrial
6.8 kDa mitochondrial
proteolipid

IGHV3-7

-0.7127

0.0154

Immune Response

TMPO

-0.6933

0.0453

Cell-Cell Adhesion

IGLC2

-0.6852

0.0260

Immune Response

CLPTM1L

-0.6539

0.0031

Other (apoptosis)

IGHG2

-0.6532

0.0234

Immune Response

H3F3A

-0.6487

0.0236

AEBP1

-0.637

0.0226

Histone
Transcription/RNA
Processing/Translation

AHNAK

-0.635

0.0397

Cell-Cell Adhesion

SEC11C

-0.6182

0.0288

Protein Metabolism

H1F0

-0.5824

0.0446

Histone

IGHG1

-0.5542

0.0206

Immune Response

STK39

-0.5436

0.0033

Kinase

PPIF

-0.5252

0.0168

Protein
Folding/Transport

MP68

-0.4738

0.0418

Mitochondria/Redox

P61758

Prefoldin subunit 3

VBP1

-0.4401

0.0427

Q96L92

Sorting nexin-27

SNX27

-0.427

0.0158

O75323

Protein NipSnap homolog 2
DnaJ homolog subfamily B
member 6
Kinectin
Translocating chain-associated
membrane protein 1
Chitinase domain-containing
protein 1

GBAS

-0.4059

0.0315

DNAJB6

-0.3578

0.0384

KTN1

-0.3174

0.0401

TRAM1

-0.3048

0.0452

CHID1

-0.2768

0.0223

O75190
Q86UP2
Q15629
Q9BWS9

Protein
Folding/Transport
Protein
Folding/Transport
Mitochondria/Redox
Protein
Folding/Transport
Cell-Cell Adhesion
Protein
Folding/Transport
Immune Response
Protein
Folding/Transport
Transcription/RNA
Processing/Translation

O00186

Syntaxin-binding protein 3

STXBP3

-0.2611

0.0332

Q02543

60S ribosomal protein L18a

RPL18A

-0.2238

0.0089

P13861

cAMP-dependent protein kinase
type II-alpha regulatory subunit

PRKAR2A

-0.217

0.0098

Kinase

P84085

ADP-ribosylation factor 5

ARF5

-0.1788

0.0354

Protein
Folding/Transport

P28482

Mitogen-activated protein kinase
1

MAPK1

-0.1528

0.0078

Kinase
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P59998
O15145
Q5VTE0
Q8IZ83
Q96A33
Q9NPA0
Q15417
P21281
P48556
O14734
Q9NS69

Actin-related protein 2/3
complex subunit 4
Actin-related protein 2/3
complex subunit 3
Putative elongation factor 1alpha-like 3
Aldehyde dehydrogenase family
16 member A1
Coiled-coil domain-containing
protein 47
ER membrane protein complex
subunit 7
Calponin-3
V-type proton ATPase subunit
B; brain isoform
26S proteasome non-ATPase
regulatory subunit 8
Acyl-coenzyme A thioesterase 8
Mitochondrial import receptor
subunit TOM22 homolog

ARPC4

-0.1477

0.0141

Cytoskeleton

ARPC3

-0.145

0.0464

Cytoskeleton

EEF1A1P5

-0.134

0.0151

Transcription/RNA
Processing/Translation

ALDH16A1

0.1539

0.0433

Mitochondria/Redox

CCDC47

0.1676

0.0403

EMC7

0.1744

0.0474

CNN3

0.1993

0.0488

Other (calcium ion
homeostasis, ERAD)
Other (carbohydrate
binding)
Cytoskeleton

ATP6V1B2

0.2023

0.0460

Ion Transport

PSMD8

0.209

0.0347

Protein Metabolism

ACOT8

0.2101

0.0177

Lipid Metabolism

TOMM22

0.2105

0.0281

Mitochondria/Redox
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Protein
Folding/Transport

P11940

Polyadenylate-binding protein 1

PABPC1

0.2111

0.0441

P78344

Eukaryotic translation initiation
factor 4 gamma 2

EIF4G2

0.2114

0.0490

Q14974

Importin subunit beta-1

KPNB1

0.2177

0.0417

Q13200

26S proteasome non-ATPase
regulatory subunit 2

PSMD2

0.2182

0.0108

O95782

AP-2 complex subunit alpha-1

AP2A1

0.219

0.0059

Q93034
Q9UNZ2

Cullin-5
NSFL1 cofactor p47

CUL5
NSFL1C

0.2198
0.2214

0.0058
0.0150

Q9BTM9

Ubiquitin-related modifier 1

URM1

0.2221

0.0047

VPS26A

0.2305

0.0230

PSMA3
SUGT1

0.2323
0.2356

0.0358
0.0128

LARS

0.2405

0.0207

ATP6V1A

0.2418

0.0123

Ion Transport

USP9X

0.2423

0.0467

Protein Metabolism

HSPA8

0.253

0.0051

O75436
P25788
Q9Y2Z0
Q9P2J5
P38606
Q93008
P11142

Vacuolar protein sortingassociated protein 26A
Proteasome subunit alpha type-3
Protein SGT1 homolog
Leucine--tRNA ligase;
cytoplasmic
V-type proton ATPase catalytic
subunit A
Probable ubiquitin carboxylterminal hydrolase FAF-X
Heat shock cognate 71 kDa
protein

P55060

Exportin-2

CSE1L

0.2541

0.0385

O75146

Huntingtin-interacting protein 1related protein

HIP1R

0.259

0.0285

Protein Metabolism
Protein
Folding/Transport
Protein Metabolism
Protein Metabolism
Transcription/RNA
Processing/Translation
Protein
Folding/Transport
Protein Metabolism
Protein Metabolism
Transcription/RNA
Processing/Translation

Protein
Folding/Transport
Protein
Folding/Transport
Cytoskeleton
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O96008
P15531
P46734
P28070
O75381
Q9NUQ8
Q9Y697
Q02790
Q15020
Q01813

Q5H9R7
O95433
O00231
P31689
O75915
Q9ULA0
Q99757
Q9NTX5
Q96GK7
Q9Y3D9
P23526
P18827
P08621
P28838
Q9NR19
Q8N5G0

Mitochondrial import receptor
subunit TOM40 homolog
Nucleoside diphosphate kinase
A
Dual specificity mitogenactivated protein kinase kinase 3
Proteasome subunit beta type-4
Peroxisomal membrane protein
PEX14
ATP-binding cassette sub-family
F member 3
Cysteine desulfurase;
mitochondrial
Peptidyl-prolyl cis-trans
isomerase FKBP4
Squamous cell carcinoma
antigen recognized by T-cells 3
ATP-dependent 6phosphofructokinase; platelet
type
Serine/threonine-protein
phosphatase 6 regulatory subunit
3
Activator of 90 kDa heat shock
protein ATPase homolog 1
26S proteasome non-ATPase
regulatory subunit 11
DnaJ homolog subfamily A
member 1
PRA1 family protein 3
Aspartyl aminopeptidase
Thioredoxin; mitochondrial
Ethylmalonyl-CoA
decarboxylase
Fumarylacetoacetate hydrolase
domain-containing protein 2A
28S ribosomal protein S23;
mitochondrial
Adenosylhomocysteinase
Syndecan-1
U1 small nuclear
ribonucleoprotein 70 kDa
Cytosol aminopeptidase
Acetyl-coenzyme A synthetase;
cytoplasmic
Small integral membrane protein
20

TOMM40

0.2593

0.0076

Mitochondria/Redox

NME1

0.271

0.0213

Kinase

MAP2K3

0.2752

0.0373

Kinase

PSMB4

0.2764

0.0158

PEX14

0.2803

0.0238

Protein Metabolism
Protein
Folding/Transport

ABCF3

0.2846

0.0347

Cell-Cell Adhesion

NFS1

0.2919

0.0167

Protein Metabolism

FKBP4

0.2953

0.0477

SART3

0.3007

0.0457

PFKP

0.3087

0.0367

Carbohydrate
Metabolism

PPP6R3

0.3154

0.0231

Protein Metabolism

AHSA1

0.3177

0.0091

Protein
Folding/Transport

PSMD11

0.3221

0.0158

Protein Metabolism

DNAJA1

0.3234

0.0479

ARL6IP5
DNPEP
TXN2

0.3236
0.3283
0.3371

0.0439
0.0271
0.0343

Protein
Folding/Transport
Cytoskeleton
Protein Metabolism
Mitochondria/Redox

ECHDC1

0.341

0.0450

Lipid Metabolism

FAHD2A

0.35

0.0195

MRPS23

0.3593

0.0114

AHCY

0.3976

0.0216

SDC1

0.4174

0.0314

SNRNP70

0.4216

0.0144

LAP3

0.4431

0.0436

Transcription/RNA
Processing/Translation
Protein Metabolism

ACSS2

0.4512

0.0470

Lipid Metabolism

SMIM20

0.4532

0.0296

Mitochondria/Redox

Protein
Folding/Transport
Transcription/RNA
Processing/Translation

Other (potential
hydrolase)
Transcription/RNA
Processing/Translation
Other (regulation of
methylation)
Other (cell migration)
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P49247

Ribose-5-phosphate isomerase

Carbohydrate
Metabolism
Transcription/RNA
Processing/Translation

RPIA

0.4698

0.0326

LSM2

0.4741

0.0355

PIGU

0.4799

0.0487

Lipid Metabolism

TRIM3

0.485

0.0174

Immune Response

EBP

0.4859

0.0413

Lipid Metabolism

TXNRD1

0.4905

0.0148

Mitochondria/Redox

DBI

0.4917

0.0382

P07108

U6 snRNA-associated Sm-like
protein LSm2
Phosphatidylinositol glycan
anchor biosynthesis class U
protein
Tripartite motif-containing
protein 3
3-beta-hydroxysteroidDelta(8);Delta(7)-isomerase
Thioredoxin reductase 1;
cytoplasmic
Acyl-CoA-binding protein

P48637

Glutathione synthetase

GSS

0.4944

0.0440

O76003

Glutaredoxin-3
Dihydropyrimidine
dehydrogenase [NADP(+)]
39S ribosomal protein L22;
mitochondrial
Pyridoxine-5'-phosphate oxidase
Enolase-phosphatase E1
Fumarylacetoacetase
Glutamate--cysteine ligase
catalytic subunit
39S ribosomal protein L43;
mitochondrial
7-dehydrocholesterol reductase
Prolyl endopeptidase
28S ribosomal protein S35;
mitochondrial
Fatty acyl-CoA reductase 1
Ancient ubiquitous protein 1
Alpha-synuclein
Serine/threonine-protein
phosphatase CPPED1
Methyltransferase-like protein
7B
Ferritin light chain
Ferritin heavy chain
Selenoprotein O†
UPF0160 protein MYG1;
mitochondrial†

GLRX3

0.4953

0.0403

Lipid Metabolism
Other (glutathione
synthesis)
Mitochondria/Redox

DPYD

0.5076

0.0165

Mitochondria/Redox

MRPL22

0.526

0.0101

PNPO
ENOPH1
FAH

0.5395
0.5544
0.5694

0.0337
0.0307
0.0236

Transcription/RNA
Processing/Translation
Mitochondria/Redox
Protein Metabolism
Protein Metabolism

GCLC

0.5745

0.0241

Mitochondria/Redox

MRPL43

0.5932

0.0266

DHCR7
PREP

0.6045
0.6099

0.0283
0.0244

MRPS35

0.6118

0.0363

FAR1
AUP1
SNCA

0.6231
0.6292
0.6332

0.0223
0.0093
0.0063

Transcription/RNA
Processing/Translation
Lipid Metabolism
Protein Metabolism
Transcription/RNA
Processing/Translation
Lipid Metabolism
Protein Metabolism
Mitochondria/Redox

CPPED1

0.6702

0.0313

Protein Metabolism

METTL7B

0.7067

0.0210

FTL
FTH1
SELENOO

0.8169
0.8959
5.0987

0.0124
0.0144
0.0002

Other (probable
methyltransferase)
Ion Transport
Mitochondria/Redox
Mitochondria/Redox

C12orf10

5.9843

5.8E-16

Mitochondria/Redox

Q9Y333
Q9H490
O75382
Q15125
Q16881

Q12882
Q9NWU5
Q9NVS9
Q9UHY7
P16930
P48506
Q8N983
Q9UBM7
P48147
P82673
Q8WVX9
Q9Y679
P37840
Q9BRF8
Q6UX53
P02792
P02794
Q9BVL4
Q9HB07
P22090

40S ribosomal protein S4†

RPS4Y1

6.7537

0.0018

Q9P003

Protein cornichon homolog 4†

CNIH4

7.1618

1.74E-15

Transcription/RNA
Processing/Translation
Protein
Folding/Transport
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O60938

Keratocan†

KERA

7.4582

0.0050

Other (keratan sulfate
metabolism/cornea
development)

Q9C0D9

Ethanolaminephosphotransferase
1†

SELENOI

7.4638

0.0005

Lipid Metabolism

Q96HV5

Transmembrane protein 41A†

TMEM41A

7.5997

0.0023

SNRPF

7.7847

3.21E-17

HMCN2

11.5204

3.81E-16

P62306
Q8NDA2

Small nuclear ribonucleoprotein
F†
Hemicentin-2†

Other (transmembrane
protein)
Transcription/RNA
Processing/Translation
Immune Response
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Table 4.7 Lipid metabolism proteins present at relatively different levels in duodenal biopsies
from subjects administered glucose or water after a high fat liquid meal

Duodenal biopsy samples were collected 6 h post lipid and 1 h post glucose or water ingestion
from patients undergoing a diagnostic endoscopy (n =10 patients per group). Lipid metabolism
related proteins were identified based on gene ontology (GO) terms, and relative levels of
proteins identified in at least 3 duodenal biopsy samples per group, or identified in at least 3
samples in one group and 0 samples in the other group, were compared. Proteins present at
significantly different levels within the two treatment groups (p < 0.05, t test) are shown.
Average fold changes of proteins in response to glucose relative to water ingestion are presented.
†only identified in response to glucose

Uniprot
Accession

Protein Name

Gene
Name

Fold
Change

T Test
p-value

O14734

Acyl-coenzyme A thioesterase 8

ACOT8

0.2101

0.0177

Q9NTX5

Ethylmalonyl-CoA decarboxylase

ECHDC1

0.341

0.0450

ACSS2

0.4512

0.0470

PIGU

0.4799

0.0487

EBP

0.4859

0.0413

DBI

0.4917

0.0382

P07108

Acetyl-coenzyme A synthetase;
cytoplasmic
Phosphatidylinositol glycan anchor
biosynthesis class U protein
3-beta-hydroxysteroidDelta(8);Delta(7)-isomerase
Acyl-CoA-binding protein

Q9UBM7

7-dehydrocholesterol reductase

DHCR7

0.6045

0.0283

Q8WVX9

Fatty acyl-CoA reductase 1

FAR1

0.6231

0.0223

Q9C0D9

Ethanolaminephosphotransferase 1†

SELENOI

7.4638

0.0005

Q9NR19
Q9H490
Q15125

Lipid Metabolism
Related Function
FA Modification/
Metabolism/Transport
FA Modification/
Metabolism/Transport
FA Modification/
Metabolism/Transport
TAG & PL
Synthesis/Metabolism
Cholesterol/Steroid
Metabolism
Lipid Binding Protein
Cholesterol/Steroid
Metabolism
FA Modification/
Metabolism/Transport
TAG & PL
Synthesis/Metabolism
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Table 4.8 Proteins present at relatively different levels in duodenal biopsies from subjects
administered glucose or water after an overnight fast following the ingestion of a high fat liquid
meal

Duodenal biopsy samples were collected 10 h post lipid and 1 h post glucose or water ingestion
from patients undergoing a diagnostic endoscopy (n =5 patients per group). Proteins that were
identified in at least 3 samples in both groups and present at relatively different levels (p < 0.05,
t test,), or at least 3 samples in one group and 0 samples in the other group, are shown. Average
fold changes of proteins in response to glucose relative to water ingestion are presented. *only
identified in response to water, †only identified in response to glucose

Uniprot
Accession

Protein Name

Gene Name

Fold
Change

T Test
p-value

Function

P02760

Protein AMBP*

AMBP

10.9586

2.33E-05

Protein Metabolism

P35613

Basigin*

BSG

-7.4781

1.28E-05

P42025
Q96GA7

Beta-centractin*
Serine dehydratase-like*
Serine--tRNA ligase;
mitochondrial*
Neutral and basic amino acid
transport protein rBAT*
Anoctamin-10*
ATP-binding cassette sub-family
D member 1*
Thioredoxin-related
transmembrane protein 2*

ACTR1B
SDSL

-6.6073
-6.4238

0.0003
4.13E-05

SARS2

-6.4093

0.0001

SLC3A1

-5.9686

0.0001

ANO10

-5.8317

6.88E-13

Other (extracellular
matrix organization)
Cytoskeleton
Protein Metabolism
Transcription/RNA
Processing/Translation
Protein
Folding/Transport
Ion Transport

ABCD1

-5.296

0.0011

Lipid Metabolism

TMX2

-4.7109

0.0055

Mitochondria/Redox

P62899

60S ribosomal protein L31

RPL31

-1.4463

0.0016

P26583

High mobility group protein B2

HMGB2

-1.3698

0.0205

P62841

40S ribosomal protein S15

RPS15

-1.339

0.0217

O43895

Xaa-Pro aminopeptidase 2
Peptidyl-prolyl cis-trans
isomerase FKBP3

XPNPEP2

-1.2009

0.0161

FKBP3

-1.1226

0.0486

P62424

60S ribosomal protein L7a

RPL7A

-1.0994

0.0165

P99999

Cytochrome c
Cytochrome b-c1 complex
subunit 7
NADH dehydrogenase
[ubiquinone] iron-sulfur protein
4; mitochondrial

CYCS

-1.0634

0.0237

Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Protein Metabolism
Protein
Folding/Transport
Transcription/RNA
Processing/Translation
Mitochondria/Redox

UQCRB

-0.9939

0.0352

Mitochondria/Redox

NDUFS4

-0.9391

0.0220

Mitochondria/Redox

Q9NP81
Q07837
Q9NW15
P33897
Q9Y320

Q00688

P14927
O43181
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Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation

P46783

40S ribosomal protein S10

RPS10

-0.8004

0.0412

Q9UNX3

60S ribosomal protein L26-like
1

RPL26L1

-0.795

0.0441

P62241

40S ribosomal protein S8

RPS8

-0.7606

0.0362

Q00013

55 kDa erythrocyte membrane
protein

MPP1

-0.6858

0.0323

Q9Y3U8

60S ribosomal protein L36

RPL36

-0.6824

0.0149

P04792

Heat shock protein beta-1

HSPB1

-0.6317

0.0415

COX5A

-0.6209

0.0430

Mitochondria/Redox

HDHD5

-0.5832

0.0196

Lipid Metabolism

P20674
Q9BXW7

Cytochrome c oxidase subunit
5A; mitochondrial
Haloacid dehalogenase-like
hydrolase domain-containing 5

Immune Response
Transcription/RNA
Processing/Translation
Protein
Folding/Transport

Transcription/RNA
Processing/Translation
Other (cytokine activity)
Other (putative Omethyltransferase)
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Cytoskeleton

P62081

40S ribosomal protein S7

RPS7

-0.5799

0.0368

Q92520

Protein FAM3C
Catechol O-methyltransferase
domain-containing protein 1
Non-POU domain-containing
octamer-binding protein

FAM3C

-0.5691

0.0467

COMTD1

-0.5488

0.0242

NONO

-0.5382

0.0131

40S ribosomal protein S17

RPS17

-0.5285

0.0429

HP1BP3

-0.5232

0.0430

CTNNA2

-0.5041

0.0231

PFKFB2

-0.4706

0.0010

Carbohydrate
Metabolism

NIPSNAP1

-0.4247

0.0273

Mitochondria/Redox

HNRNPUL1

-0.4204

0.0322

Transcription/RNA
Processing/Translation

Q86VU5
Q15233
P08708
Q5SSJ5
P26232
O60825
Q9BPW8
Q9BUJ2

Heterochromatin protein 1binding protein 3
Catenin alpha-2
6-phosphofructo-2kinase/fructose-2;6bisphosphatase 2
Protein NipSnap homolog 1
Heterogeneous nuclear
ribonucleoprotein U-like protein
1

Protein
Folding/Transport
Other (RNA binding)
Transcription/RNA
Processing/Translation
Other (brush border
assembly, regulation of
microvillus length)
Transcription/RNA
Processing/Translation

P51148

Ras-related protein Rab-5C

RAB5C

-0.4166

0.0228

A0AV96

RNA-binding protein 47

RBM47

-0.4047

0.0211

P26373

60S ribosomal protein L13

RPL13

-0.3879

0.0418

Q9Y6N9

Harmonin

USH1C

-0.3863

0.0445

Q5IFJ7

60S ribosomal protein L9

RPL9

-0.3797

0.0444

P36543

V-type proton ATPase subunit E
1

ATP6V1E1

-0.3609

0.0298

Mitochondria/Redox

P15880

40S ribosomal protein S2

RPS2

-0.313

0.0103

Transcription/RNA
Processing/Translation
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Phosphatidylinositol transfer
protein alpha isoform
AFG3-like protein 2
Vacuolar protein sortingassociated protein 29

PITPNA

-0.2974

0.0315

Lipid Metabolism

AFG3L2

-0.2882

0.0427

VPS29

-0.283

0.0334

Q13232

Nucleoside diphosphate kinase 3

NME3

-0.2655

0.0405

P61106

Ras-related protein Rab-14

RAB14

-0.2269

0.0176

Q8NEV1

Casein kinase II subunit alpha 3
Actin-related protein 2/3
complex subunit 5-like protein
COP9 signalosome complex
subunit 6
Dynamin-like 120 kDa protein;
mitochondrial
116 kDa U5 small nuclear
ribonucleoprotein component
Probable ATP-dependent RNA
helicase DDX17

CSNK2A3

0.1846

0.0033

ARPC5L

0.2192

0.0094

Protein Metabolism
Protein
Folding/Transport
Other (nucleotide
triphosphate synthesis)
Protein
Folding/Transport
Protein Metabolism
Transcription/RNA
Processing/Translation

COPS6

0.2227

0.0237

Protein Metabolism

OPA1

0.2682

0.0189

Mitochondria/Redox

EFTUD2

0.2702

0.0022

DDX17

0.2774

0.0277

Q9Y265

RuvB-like 1

RUVBL1

0.2863

0.0143

Q08211

ATP-dependent RNA helicase A

DHX9

0.2969

0.0021

MARS

0.2985

0.0005

EIF3F

0.3017

0.0358

CCT8

0.3103

0.0462

CTBP1

0.3117

0.0193

SRP72

0.317

0.0088

LRBA

0.3239

0.0462

Immune Response

DYNC1I2

0.3304

0.0080

Cytoskeleton

PRPF8

0.3428

0.0263

Q00169
Q9Y4W6
Q9UBQ0

Q9BPX5
Q7L5N1
O60313
Q15029
Q92841

P56192
O00303
P50990
Q13363
O76094
P50851
Q13409
Q6P2Q9

Methionine--tRNA ligase;
cytoplasmic
Eukaryotic translation initiation
factor 3 subunit F
T-complex protein 1 subunit
theta
C-terminal-binding protein 1
Signal recognition particle
subunit SRP72
Lipopolysaccharide-responsive
and beige-like anchor protein
Cytoplasmic dynein 1
intermediate chain 2
Pre-mRNA-processing-splicing
factor 8

P46940

Ras GTPase-activating-like
protein IQGAP1

IQGAP1

0.3464

0.0427

O95782

AP-2 complex subunit alpha-1

AP2A1

0.3545

0.0240

TCP1

0.3631

0.0078

EIF3A

0.3778

0.0231

PGM3

0.3795

0.0164

P17987
Q14152
O95394

T-complex protein 1 subunit
alpha
Eukaryotic translation initiation
factor 3 subunit A
Phosphoacetylglucosamine
mutase

Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Protein
Folding/Transport
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation

Transcription/RNA
Processing/Translation
Other (cellular response
to calcium & growth
factor stimuli)
Protein
Folding/Transport
Protein
Folding/Transport
Transcription/RNA
Processing/Translation
Carbohydrate
Metabolism
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O43143
Q9P2J5
P13010
O75643
Q53EL6
Q8N163
Q15008
P00325
P07478
Q9Y262
Q93009
Q86VP6

Pre-mRNA-splicing factor ATPdependent RNA helicase
DHX15
Leucine--tRNA ligase;
cytoplasmic
X-ray repair crosscomplementing protein 5
U5 small nuclear
ribonucleoprotein 200 kDa
helicase
Programmed cell death protein 4
Cell cycle and apoptosis
regulator protein 2
26S proteasome non-ATPase
regulatory subunit 6
Alcohol dehydrogenase 1B
Trypsin-2
Eukaryotic translation initiation
factor 3 subunit L
Ubiquitin carboxyl-terminal
hydrolase 7
Cullin-associated NEDD8dissociated protein 1

Transcription/RNA
Processing/Translation

DHX15

0.3864

0.0448

LARS

0.3966

0.0183

XRCC5

0.4032

0.0284

SNRNP200

0.404

0.0136

PDCD4

0.4079

0.0175

CCAR2

0.4108

0.0094

PSMD6

0.4158

0.0475

Protein Metabolism

ADH1B
PRSS2

0.427
0.4359

0.0394
0.0328

EIF3L

0.4529

0.0493

Mitochondria/Redox
Protein Metabolism
Transcription/RNA
Processing/Translation

USP7

0.455

0.0294

Protein Metabolism

CAND1

0.4561

0.0490

Protein Metabolism

Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation
Transcription/RNA
Processing/Translation

O00410

Importin-5

IPO5

0.4754

0.0232

Q15393

Splicing factor 3B subunit 3

SF3B3

0.4946

0.0349

P07437

Tubulin beta chain
Solute carrier family 12 member
2

TUBB

0.5145

0.0031

Protein
Folding/Transport
Transcription/RNA
Processing/Translation
Cytoskeleton

SLC12A2

0.5237

0.0405

Ion Transport

KPNB1

0.5474

0.0326

Protein
Folding/Transport

0.5546

0.0356

Immune Response

TUBA1B

0.5982

0.0022

Cytoskeleton

NPEPPS

0.5983

0.0495

Protein Metabolism

ADH5

0.5992

0.0360

P55011
Q14974

Importin subunit beta-1

P11766

Immunoglobulin kappa light
chain
Tubulin alpha-1B chain
Puromycin-sensitive
aminopeptidase
Alcohol dehydrogenase class-3

P05451

Lithostathine-1-alpha

REG1A

0.6105

0.0107

Q9BUF5

Tubulin beta-6 chain
Immunoglobulin kappa variable
3-20
von Willebrand factor A
domain-containing protein 5A
Cathepsin G
Phospholipase D3†

TUBB6

0.6265

0.0332

Mitochondria/Redox
Other (positive regulator
of cell proliferation,
carbohydrate binding)
Cytoskeleton

IGKV3-20

1.0274

0.0314

Immune Response

VWA5A

1.1874

0.0346

CTSG
PLD3

1.8843
5.5249

0.0438
1.31E-08

P0DOX7
P68363
P55786

P01619
O00534
P08311
Q8IV08

Other (may act as tumor
suppressor)
Protein Metabolism
Lipid Metabolism
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Table 4.9 Lipid metabolism proteins present at relatively different levels in duodenal biopsies in
response to glucose or water ingestion after an overnight fast following the ingestion of a high fat
liquid meal
Duodenal biopsy samples were collected 10 h post lipid and 1 h post glucose or water ingestion
from patients undergoing a diagnostic endoscopy (n = 5 patients per group). Lipid metabolism
related proteins were identified based on gene ontology (GO) terms, and relative levels of
proteins identified in at least 3 duodenal biopsy samples per group, or identified in at least 3
samples in one group and 0 samples in the other group, were compared. Proteins present at
significantly different levels within the two treatment groups (p < 0.05, t test) are shown. *only
identified in response to water, †only identified in response to glucose

Uniprot
Accession
P33897
Q9BXW7
Q00169

Protein name
ATP-binding cassette sub-family D
member 1*
Haloacid dehalogenase-like
hydrolase domain-containing 5
Phosphatidylinositol transfer protein
alpha isoform

Gene
Name

Fold
Change

T Test
p-value

ABCD1

-5.296

0.00108

HDHD5

-0.5832

0.0196

PITPNA

-0.2974

0.0315

P00325

Alcohol dehydrogenase 1B

ADH1B

0.427

0.0394

P11766

Alcohol dehydrogenase class-3

ADH5

0.5992

0.0360

Q8IV08

Phospholipase D3†

PLD3

5.5249

1.31E-08

Lipid Metabolism
Related Function
FA Modification/
Metabolism/Transport
TAG & PL
Synthesis/Metabolism
Lipoprotein
Metabolism
FA Modification/
Metabolism/Transport
FA Modification/
Metabolism/Transport
TAG & PL Synthesis/
Metabolism
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Figure 4.1 Experimental design for Aims 1 and 2
Different participants were enrolled in Aims 1 and 2. In each Aim, after an overnight fast,
subjects ingested a high fat liquid meal 5 hours prior to ingesting either glucose or water.
Subjects in Aim 1 each participated in 2 studies, 4-6 weeks apart, in which they ingested either
glucose or water in random order. Circulating lipids and lipoproteins were measured throughout
the study. Subjects participating in Aim 2 were randomized to only one of 2 treatments, glucose
or water. One hour after ingesting either glucose or water, subjects participating in Aim 2
underwent an upper endoscopy during which duodenal biopsies were obtained for analysis as
described in the methods section.
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Figure 4.2 Oral glucose increases plasma CM TAG concentrations
TAG concentrations in plasma (A) during the study period and (B) during the last 3 h, expressed
as a percentage of baseline. TAG levels in (C) TRL, (D) CM and (E) VLDL expressed as
percentage of levels at t = 5 h. Arrow indicates time of glucose/water ingestion. N = 6 patients
per group.
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Figure 4.3 Images of lipid pools within the intestinal mucosa
(A) A TEM image of an enterocyte from a duodenal biopsy obtained 6 h after a high fat liquid
meal and 1 h after glucose ingestion. Lipid is present within CLDs (*) as well as in secreted CMs
in the intercellular space (white +). (B) An enterocyte containing several large CLDs (*). (C) An
enterocyte containing lipid within smaller lipid droplets in the ER, which are surrounded by a
bilayer membrane and are usually observed at apical side of the cell. (D) Lipid present within the
Golgi of an enterocyte, which was normally observed above the nucleus. Scale = 1 μm for (A),
(B), and (D) and 0.5 μm for (C).
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Figure 4.4 Oral glucose mobilizes enterocyte CLD stores
Analysis of enterocyte CLDs 6 h after a high fat liquid meal and 1 h after glucose or water
ingestion (n = 12 patients per group). (A) Percent of enterocytes containing CLDs (p = 0.14). (B)
Average CLD number per cell (p = 0.022). Average (C) diameter (p = 0.18) and (D) area (p =
0.17) of individual CLDs. (E) CLD diameter distribution (p = 0.03). (F) Average total CLD area
per cell (p = 0.11). Average CLD number, diameter, area, and total CLD area were compared
with a one-tailed t test, * p < 0.05. KS = Kolmogorov-Smirnov
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Figure 4.5 Analysis of enterocyte secretory lipid content in response to glucose compared to
water ingestion
Analysis of the amount of lipid within the secretory pathway in enterocytes 6 h after a high fat
liquid meal and 1 h after glucose or water ingestion (n = 12 patients per group). (A)
Representative examples of enterocytes containing low (after glucose), moderate (after water)
and high (after water) amounts of lipid within the secretory pathway, which includes lipid in the
ER, Golgi, and Golgi-derived secretory vesicles. (B) Number of biopsies with low, moderate or
high amounts of secretory lipid.
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Figure 4.6 Analysis of enterocyte lipid stores in response to glucose compared to water ingestion
after a delayed fast
Duodenal biopsies were obtained 10 h after ingestion of a high fat liquid meal and 1 h after
ingestion of glucose or water. (A) Percent of enterocytes containing CLDs (p = 0.45). (B)
Average CLD number per cell (p = 0.28), average (C) diameter (p = 0.10) and (D) area (p = 0.12)
of individual CLDs, and (E) average total CLD area per cell (p = 0.18). (F) CLD diameter
distribution. (G) Amount of lipid within the secretory pathway (includes lipid in ER, golgi, and
SVs). Average CLD number, diameter, area, and total CLD area per cell were compared with a
one-tailed t test. KS = Kolmogorov-Smirnov
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Figure 4.7 Comparison of enterocyte lipid stores after different fasting times
Analysis of (A) the percent of cells containing CLDs (p = 0.025) and (B) the amount of lipid
within the secretory pathway (p = 0.15) at 6 h compared to 10 h after the high fat liquid meal,
and 1 h after water consumption. * p < 0.05, one-tailed t test
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Figure 4.8 Proteins present in duodenal biopsies from subjects that ingested glucose or water
after a high fat liquid meal
Duodenal biopsies were collected 6 h after lipid and 1 h after glucose or water ingestion from
patients undergoing a diagnostic endoscopy (n = 10 patients per group). (A) Venn diagram of
proteins identified in response to glucose or water ingestion. Proteins present in at least 3
samples in one group and 0 samples in the other group were considered only present in one
group. Proteins identified in at least 3 samples in one group at least one sample in the other
group were considered present in both groups. (B) Percent of proteins within broad functional
groups that were present at either relatively lower (48 total proteins) or relatively higher (86 total
proteins) levels in response to glucose compared to water ingestion, as classified based on their
biological/molecular functions. Only proteins that were identified in at least 3 samples in both
groups and present at relatively different levels (p < 0.05, t test), or at least 3 samples in one
group and 0 samples in the other group, were included in this classification.
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Figure 4.9 Lipid metabolism related proteins present in duodenal biopsies 6 h after a high fat
liquid meal
Duodenal biopsies were collected 6 h after lipid and 1 h after glucose or water ingestion from
patients undergoing a diagnostic endoscopy (n =10 patients per group). A DAVID search of the
2919 identified proteins resulted in the identification of 270 proteins with gene ontology (GO)
terms related to lipid metabolism. (A) Percent of the 270 lipid metabolism related proteins
involved in more specific lipid related functions. (B) String analysis of the 270 lipid metabolism
related proteins. The thickness of the line represents the strength of evidence of a
structural/functional relationship between two proteins. Cluster 1 is enriched in proteins involved
in TAG & phospholipid (PL) synthesis and metabolism, Cluster 2 is enriched in proteins
involved in lipoprotein metabolism, Cluster 3 is enriched in proteins involved in
cholesterol/steroid metabolism, and Cluster 4 is enriched in proteins involved in fatty acid (FA)
modification/metabolism/transport. Proteins that were present at relatively different levels in
response to glucose compared to water ingestion (p < 0.05, t test) are circled in red.
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Figure 4.10 Proteins present in intestinal biopsies from subjects administered glucose or water
after a prolonged fast following the consumption of a high fat liquid meal
Duodenal biopsies were collected 10 h after lipid and 1 h post glucose or water ingestion from
patients undergoing a diagnostic endoscopy (n = 5 patients per group). (A) Venn diagram of
proteins identified in response to glucose or water ingestion. Proteins present in at least 3
samples in one group and 0 samples in the other group were considered only present in one
group. Proteins identified in at least 3 samples in one group and at least one sample in the other
group were considered present in both groups. (B) Percent of proteins within broad functional
groups that were present at either relatively lower (48 total proteins) or relatively higher (48 total
proteins) levels in response to glucose compared to water ingestion, as classified based on their
biological/molecular functions. Only proteins that were identified in at least 3 samples in both
groups and present at relatively different levels (p < 0.05, t test), or at least 3 samples in one
group and 0 samples in the other group, were included in this classification.
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Figure 4.11 Lipid metabolism related proteins present in duodenal biopsies 10 h after a high fat
liquid meal
Duodenal biopsies were collected 10 h post lipid and 1 h post glucose or water ingestion from
patients undergoing a diagnostic endoscopy (n = 5 patients per group). A DAVID search of the
1683 identified proteins resulted in the identification of 186 proteins with gene ontology (GO)
terms related to lipid metabolism. (A) Percent of the 186 lipid metabolism related proteins
involved in more specific lipid related functions. (B) String analysis of the 186 lipid metabolism
related proteins. The thickness of the line represents the strength of evidence of a
structural/functional relationship between two proteins. Cluster 1 is enriched in proteins involved
in fatty acid (FA) modification/metabolism/transport, Cluster 2 is enriched in proteins involved
in lipoprotein metabolism, Cluster 3 is enriched in proteins involved in TAG & phospholipid (PL)
synthesis and metabolism, and Cluster 4 is enriched in proteins involved in cholesterol/steroid
metabolism. Proteins that were present at relatively different levels (p < 0.05, t test) in response
to glucose compared to water ingestion are circled in red.
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CHAPTER 5.
EFFECT OF ORAL NUTRIENT
EXPOSURE/CONSUMPTION ON INTESTINAL LIPID STORES IN
MICE
5.1

Abstract
Elevated fasting and non-fasting plasma triacylglycerol (TAG) levels are independent risk

factors for cardiovascular disease. The small intestine mediates the process of dietary fat
absorption and is thus a major contributor to postprandial plasma TAG levels. In response to
high dietary fat consumption, the ability to store lipid in the form of TAG within the small
intestine is thought to help regulate the amount and rate at which TAG is secreted into circulation
within chylomicrons (CMs). These intestinal lipid stores are dynamic, and can be present for
several hours after the consumption of a high fat meal. Recently, dietary factors, including oral
exposure to dietary fat and glucose consumption, have been shown to mobilize lipid stored
within the small intestine from a previous meal. However the mechanism through which this
nutrient stimulated lipid mobilization occurs is not known and is challenging to study in humans.
Therefore, the goal of the current study was to determine if mice are a suitable model for
investigating the mechanism(s) through which nutrients stimulate the mobilization of lipid from
the small intestine. To do this we assessed plasma TAG levels, intestinal neutral lipid content,
and mRNA levels of genes involved in lipid mobilization and metabolism in mice in response to
several different nutrient stimuli. The results from these experiments suggest that mice can be
used as models to assess the effects of oral nutrient exposure/consumption on intestinal lipid
stores using imaging techniques and by assessing intestinal mRNA levels.

5.2

Introduction
The small intestine plays an important role in mediating dietary fat absorption and

regulating postprandial plasma triacylglycerol (TAG) levels, which are a risk factor for
cardiovascular disease when elevated [1]. The digestive products of dietary fat are taken up by
enterocytes, the absorptive cells of the small intestine, and re-esterified into TAG at the ER
membrane. A major fate of this re-esterified TAG is incorporation into chylomicrons (CMs)
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destined for secretion into the lymph and ultimately circulation. However when high amounts of
dietary fat are consumed, TAG can also be incorporated into and temporarily stored within
enterocyte cytoplasmic lipid droplets (CLDs). These lipid stores are dynamic, increasing and
decreasing over time in response to dietary fat absorption [2], and their mobilization is thought to
provide substrate for CM secretion and potentially other cellular functions at later times.
Dietary factors, including oral exposure to dietary fat and glucose consumption, have been
shown to mobilize intestinal lipid stores in both humans and rodents. Sham feeding of fat has
been shown to elicit a cephalic phase peak in both plasma and CM TAG levels, as well as to
increase the postprandial triglyceridemic response in multiple studies in humans [3-5]. In
addition, oral fat exposure was shown to induce a prolonged elevation in plasma TAG levels in
rats [6]. Along with this, evidence of a cephalic phase response to oral exposure to long chain
fatty acids, as well as a preference for long chain fatty acids (including linoleic acid) has been
observed in rodents [7-9]. Furthermore, the consumption of an oral glucose solution several
hours after consuming a high fat meal was shown to induce a peak in plasma CM-TAG and
plasma ApoB-48 levels, as well as to decrease enterocyte lipid stores compared to a water
control in humans [10]. Taken together, these studies suggest that oral nutrient
exposure/consumption can stimulate the mobilization of lipid stored within the small intestine
from a previous meal and also augment the postprandial triglyceridemic response to a current
meal. However the mechanism through which nutrient stimulated mobilization of lipid from the
small intestine occurs is unknown.
The goal of the current study was to determine if mice are a suitable model for
investigating the mechanism(s) through which nutrients stimulate the mobilization of lipid from
the small intestine. To assess this, we performed a series of experiments to determine if plasma
TAG levels and intestinal TAG secretion were affected by oral fatty acid (linoleic acid) and
glucose exposure, as well as glucose consumption. In addition, we assessed the effect of oral
glucose exposure/consumption on intestinal lipid stores using oil red O staining, and also
assessed intestinal mRNA levels of lipid metabolism genes in response to these dietary
challenges. Being able to use mice as a model to investigate the regulation of intestinal lipid
stores in response to dietary, or potentially even hormonal, stimuli would allow for the
identification of novel potential therapeutic targets for the treatment of hypertriglyceridemia. In
addition, knowledge gained about how oral nutrient exposure and the consumption of nutrients
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affects intestinal lipid metabolism can help to provide novel dietary guidance to promote healthy
blood lipid levels and decrease cardiovascular disease risk.

5.3

Materials and Methods

5.3.1 Diet and animals
All procedures were approved by the Purdue Animal Care and Use Committee. Male
wild-type (WT) mice from 12-20 weeks of age were used for this study. Mice were housed in a
specific pathogen-free barrier facility with a 12 hour light/dark cycle (6AM/6PM) and fed a lowfat rodent chow diet (PicoLab 5053, Lab Diets, Richmond, IN) containing 13.2% kcal from fat,
24.7% from protein, and 62.1% kcal from carbohydrate post-weaning.
5.3.2 Preparation of linoleic acid solution
Either a 1% or 2% linoleic acid solution was used for the oral fatty acid exposure in the
plasma lipid studies. Linoleic acid was obtained from Spectrum Chemical. The linoleic acid
solutions were prepared using dH2O and xanthan gum (0.3%) as an emulsifying agent. The
solution was homogenized at 7000 rpm for a total of 5 minutes at 1-2 minute intervals using an
IKA ULTRA-TURRAX T18 homogenizer, and then sealed under nitrogen and stored at 4°C
until use. All solutions were made fresh and used within 24 h.
5.3.3 Oral nutrient stimuli
For the assessments of the effect of oral fatty acid exposure on plasma TAG levels, the
stimuli used were either a 1% or 2% linoleic acid solution w/ 0.3% xanthan gum, 0.3% xanthan
gum (texture control), or water (flavor control). For the assessments of the effects of oral glucose
exposure/consumption on plasma TAG levels or intestinal lipid stores, either a 38% glucose
solution or water (control) was used as the stimuli. To assess the effects of oral exposure, 50 μl
of the solution was rubbed on the tongue using a gavage needle, and 200 μl oral glucose or water
boluses were administered by oral gavage.
5.3.4 Plasma TAG levels and intestinal TAG secretion
Mice were fasted for 4 h at the beginning of the light cycle and then administered a 200
µl oral olive oil gavage. Either oral exposure to 50 μl of nutrient stimuli or 200 μl oral boluses
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were administered at various time points following the olive oil gavage to assess the effects of
nutrient exposure or consumption on plasma TAG levels. For assessments of intestinal TAG
secretion, 500 mg/kg of tyloxapol (T0307, Sigma-Aldrich, St. Louis, MO), an inhibitor of
lipoprotein lipase, was administered via an IP injection prior to the administration of the nutrient
stimuli. Blood was collected from the submandibular vein at various time points throughout the
dietary challenges, and plasma TAG concentrations were determined using the Wako L-Type TG
M Assay (Wako Diagnostics, USA). For the assessment of oral fatty acid exposure on plasma
TAG levels, mice were randomized to receive each of the three stimuli on 3 separate occasions
that were 4 weeks apart. For all other blood lipid assessments mice were only exposed to a single
stimulus.
5.3.5 Oil red O (ORO) staining
Mice were fasted for 4 h at the beginning of the light cycle and then administered a 200
µl oral olive oil gavage. Either oral exposure to 50 μl oral glucose/water or a 200 μl oral
glucose/water bolus was administered 5 h after the oil bolus, and jejunal tissue samples were
collected 10 min after the exposure or 1 h after the bolus. The small intestine was divided into 5
equal length regions and tissue sections were obtained from region 2, which represents the
proximal jejunum. Tissue samples were processed for ORO staining [11, 12]. Briefly, tissues
were fixed in 4% formaldehyde in PBS (made using paraformaldehyde, Macron Fine Chemicals)
for 2 h at room temperature and then incubated in 10% sucrose in PBS at 4°C overnight. The
dehydrated tissues were then embedded in Tissue Tek O.C.T. Compound (Sakura) and flash
frozen in 2-methylbutane on dry ice. Tissues were stored at -20°C until processed for ORO
staining. Jejunal tissue samples were sliced into 10 µm thick sections, stained with ORO and
Harris hematoxylin (Fisher Scientific) as a counterstain and imaged using a light microscope.
5.3.6 qPCR
Total RNA was extracted from jejunal mucosa (region 2 of 5 of the small intestine) using
RNA STAT60 (Tel-Test, Friendswood, TX) and then DNase treated with a Turbo DNA-free Kit
(Ambion, Austin, TX). cDNA was synthesized from 1 µg DNase-treated RNA using the
AffinityScript QPCR cDNA Synthesis Kit (Stratagene, La Jolla, CA). SYBR green qPCR was
performed using the Mx3000P QPCR System (Stratagene) and Brilliant III SYBR Green Master
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Mix (Stratagene). Primers used for determination of relative mRNA levels (Table 5.1) were
produced by Integrated DNA technologies (Coralville, IA) and validated for efficiency and
correct product size using cDNA from mouse intestinal mucosa. The relative mRNA levels of
each gene were normalized to 18S rRNA and calculated using the comparative Ct method, with
mice receiving oral exposure to water as the reference group.
5.3.7 Statistical analysis
For plasma TAG levels the area under the curve and means at individual time points were
compared using a one-way ANOVA (oral fatty acid exposure studies) or a two-tailed t test
(glucose studies). A Fisher’s exact test was used to compare the ORO rankings, and a two-tailed
t test was used to compare relative mRNA levels. Statistical analyses were performed using SAS
version 9.4.

5.4

Results

5.4.1 Oral linoleic acid exposure had no effect on the postprandial plasma triglyceridemic
response or intestinal TAG secretion
To determine if oral fatty acid exposure has an effect on the postprandial triglyceridemic
response, plasma TAG levels were assessed in WT mice in response to a 200 µl oral olive oil
gavage and oral exposure to 50 µl of linoleic acid, xanthan gum, or water (n = 11-14 mice/group,
experimental timeline shown in Figure 5.1 A). The oral exposure was administered 1 h after the
oil gavage, and linoleic acid had no significant effect on the area under the curve (AUC) for the
postprandial triglyceridemic response or on plasma TAG levels at 2 and 4 h after the oil gavage
compared to the controls (Figure 5.1 B). Intestinal TAG secretion was also assessed in a separate
set of WT mice (n = 3-4 mice, experimental timeline shown in Figure 5.2 A). Tyloxapol, an
inhibitor of lipoprotein lipase, was administered 0.5 h prior to the 200 µl oral olive oil gavage,
and oral exposure to 50 µl of the stimuli immediately followed the oil bolus and initial blood
collection. The oral linoleic acid exposure again had no significant effect on intestinal TAG
secretion (AUC or intestinal TAG secretion rates at 2 and 4 h post oil gavage and oral stimulus)
compared to the xanthan gum or water controls (Figure 5.2 B).
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5.4.2 Oral glucose exposure had no effect on plasma TAG levels
To determine if oral exposure to glucose impacts plasma TAG levels, WT mice were
orally exposed to 50 µl of glucose or water 4 h after a 200 µl oral olive oil gavage (n = 5
mice/group, experimental timeline shown in Figure 5.3 A). The oral glucose exposure had no
significant effect on the AUC for plasma TAG levels (4-5 h post oil bolus and 0-1 h post oral
exposure) or on plasma TAG levels at 0.5 or 1 h post oral exposure (4-5 h post oil bolus)
compared to water.
5.4.3 Oral glucose consumption had no effect on intestinal TAG secretion
The effect of oral glucose consumption on intestinal TAG secretion was assessed by
administering a 200 µl oral glucose or a water control bolus 5 h after a 200 µl oral olive oil
gavage (n = 3 mice/group, experimental timeline shown in Figure 5.4 A). Tyloxapol was
administered prior to the glucose or water bolus to inhibit TAG clearance from the blood.
Glucose consumption had no significant effect on intestinal TAG secretion during the hour post
consumption (AUC or intestinal TAG secretion rates at 0.5 or 1 h post bolus administration)
compared to water.
5.4.4 Oral glucose consumption, but not oral glucose exposure, decreased intestinal neutral
lipid content
Since we did not observe alterations in plasma TAG levels in response to oral glucose
exposure or consumption, we decided to assess the effect of oral glucose exposure and
consumption directly on intestinal lipid stores using ORO staining. To determine if oral glucose
exposure has an impact on intestinal neutral lipid stores, mice were orally exposed to 50 µl of
glucose or water 5 h after a 200 µl oral olive oil gavage, and jejunal tissue samples were obtained
10 min after the oral exposure and processed for ORO staining (n = 7-8 mice/group,
experimental timeline shown in Figure 5.5 B). The jejunal tissue samples were ranked based on
their neutral lipid content (as indicated by the amount of ORO staining). Samples were ranked
from 1 to 4, with 1 representing samples containing little no to neutral lipid and 4 representing
samples with significant neutral lipid content (Figure 5.5 A). There was no significant difference
in the distribution of rankings in response to oral glucose compared to a water exposure (Figure
5.5 C, Fisher’s exact test). The effect of glucose consumption on intestinal lipid stores was also
assessed. For this experiment mice were administered a 200 µl oral glucose or water bolus 5 h
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after a 200 µl oral olive oil gavage, and the jejunal tissue samples were collected 1 h after
glucose or water consumption (n = 9 mice/group, experimental timeline shown in Figure 5.5 D).
In this case glucose consumption had a significant effect on the rankings of neutral lipid content
within the tissue samples compared to water consumption, with more of the samples containing
less neutral lipid (Figure 5.5 E, Fisher’s exact test).
5.4.5 Oral glucose exposure increased mRNA levels of genes involved in intestinal lipid
mobilization and metabolism
After observing a decrease in jejunal neutral lipid content in response to oral glucose
consumption but not oral glucose exposure, we wanted to determine if there were differences in
intestinal mRNA levels of genes involved in lipid mobilization and metabolism in response to
these dietary challenges. To assess this we determined relative mRNA levels of genes involved
in cytoplasmic TAG lipolysis (Atgl), CM synthesis (Mttp), and fatty acid oxidation (Cpt1a) in
jejunal mucosa. Oral exposure to 50 µl of glucose or water occurred 5 h after a 200 µl oral olive
oil gavage, and jejunal mucosa was collected 10 min after the exposure (n = 7-8 mice/group,
experimental timeline shown in Figure 5.6 A). At this time point we saw a significant increase in
Mttp and Cpt1a mRNA levels in response to glucose compared to water exposure, and a trend
toward an increase in Pnpla2 mRNA levels in response to glucose compared to water (Figure 5.6
B). We also assessed mRNA levels of these genes in response to an oral glucose or water bolus
(samples collected 6 h after a 200 µl oral oil gavage and 1 h after a 200 µl oral glucose/water
bolus, n = 3 mice/group), however results were too variable to draw conclusions from.

5.5

Discussion
We performed a series of experiments to determine whether mice are a suitable model for

investigating the mechanism(s) through which nutrients stimulate the mobilization of lipid from
the small intestine. Contrary to previous observations in humans, oral exposure to fatty acids and
glucose, as well as glucose consumption, did not have any significant effects on plasma TAG
levels or intestinal TAG secretion in mice. However, the ability of oral glucose consumption to
mobilize lipid stored in the intestine from a previous meal was consistent with previous
observations in humans. In addition, there was an increase in mRNA levels of genes involved in
CM synthesis and fatty acid oxidation in response to oral glucose exposure, suggesting that a
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cephalic phase response may be involved in glucose stimulated lipid mobilization from the
intestine. Overall these results suggest that mice may not be an ideal model for assessing the
effects of nutrient exposure/consumption on plasma TAG levels, but could serve as a model to
assess nutrient effects on intestinal lipid storage and mobilization using imaging approaches and
by assessing intestinal mRNA levels.
There are several factors that could contribute to the lack of an effect of oral nutrient
exposure/consumption on plasma TAG levels in mice in the present study. One important factor
to point out is that plasma TAG levels reflect a balance between secretion (from both the
intestine and the liver) and clearance from the circulation, and thus are not specific to or directly
reflective of CM-TAG secretion. The small intestine is the major contributor to postprandial
plasma TAG levels, but only the effects of oral fatty acid exposure were assessed during the
postprandial phase. We also assessed plasma TAG levels after blocking TAG clearance to obtain
an assessment of secretion; however we still did not observe any effects of the nutrient stimuli.
In addition, the amount of TAG specifically in the CM fraction is often assessed in human
studies [3, 10], however in mice we are limited to the amount of blood that can be collected at
each time point and therefore were not able to isolate lipoproteins and assess TAG content using
this method. Another factor that could prevent the detection of a change in plasma TAG levels is
the timing at which it was assessed. The blood collection limitations also limit the number of
blood collections that can be taken, so it is possible that we missed a transient elevation in
plasma TAG levels in response to the oral nutrient stimuli. Furthermore, there was a large
amount of variability in plasma TAG levels within treatment groups, which makes it difficult to
detect small magnitude changes, as would be expected in response to these nutrient stimuli. For
the particular experiments conducted in this study, sample sizes ranging from 17 to several
hundred per group would be necessary to detect differences between groups with a significance
level of 0.05 for a power of 0.8. Most of these are not realistic sample sizes, and the differences
between plasma TAG levels in some cases were trending in the opposite direction as expected in
response to the nutrient compared to the control oral exposure(s).
It is also important to note that there are different challenges in assessing the effects of oral
nutrient exposure versus consumption in humans compared to animal models. In human studies
the effect of oral nutrient exposure can be assessed by asking participants to chew and spit out a
given dietary substance [3-5]. This sham feeding allows the individual to chew (for solid foods)

179
or swish (for liquids) the substance around their mouth and therefore more realistically stimulate
the senses involved in the consumption of food short of actually ingesting it. However in rodents
a nutrient solution is administered onto the tongue, either via an oral catheter (ex: [6]) or by
applying the solution directly to the surface of the tongue [7, 8]. In previous studies
esophagotamized rats or mice have sometimes been used to prevent the interference of postingestive effects downstream of swallowing (ex: [7, 8]). In the present study we did not use any
of these more invasive techniques involving surgery. Instead we administered a small volume of
the nutrient solution to the tongue to minimize any post-ingestive effects of the oral exposure.
This differs from the sham feeding of fat in human studies assessing the effect of oral fat
exposure on plasma/CM TAG levels, which involved repeated oral stimulation over a period of
time to mimic chewing a meal [3-5]. In addition, only the third oral exposure to a corn oil
emulsion or a saccharin solution in rats resulted in a prolonged elevation of plasma TAG levels,
with the effects of the initial exposure to these stimuli being similar compared to control stimuli
[6]. Another difficulty when assessing the effect of oral nutrient exposure on the postprandial
response is preventing the fat load from being detected in the oral cavity. In humans this can be
accomplished by administering the fat load in capsule form (ex: [3, 4]), while in rodents an
intragastric/intraduodenal catheter can be used to deliver the fat load directly to the stomach or
small intestine (ex: [6]). Therefore the administration of the fat loads via oral gavage in the
present study could have impacted the results of the experiments assessing the effect of oral fatty
acid exposure on postprandial plasma TAG levels.
The effects of oral glucose consumption and exposure on intestinal lipid stores and mRNA
levels, on the other hand, suggests that glucose does have an impact on the mobilization of lipid
from the small intestine in mice. The observed decrease in intestinal neutral lipid content in
response to glucose consumption, as assessed by ORO staining, was similar to that observed in
human jejunal biopsies using both ORO staining and transmission electron microscopy [10]. In
addition, the increases in mRNA levels of genes involved in lipid mobilization and fatty acid
oxidation in response to oral glucose compared to a water exposure suggest that oral glucose
exposure may stimulate the mobilization and utilization of lipid stored in the small intestine. This
effect of oral nutrient exposure also provides further evidence for neural regulation of intestinal
TAG secretion.
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In conclusion, the results from these studies suggest that mice can be used as models to
assess the effects of oral nutrient exposure/consumption on intestinal lipid stores using imaging
techniques and by assessing intestinal mRNA levels. However the assessment of plasma TAG
levels in response to nutrient stimuli in mice, as assessed in the current study, is not likely a
reliable measure for assessing this response. Additional work would be needed to determine if
modifications to the methods of assessing TAG secretion from the small intestine, such as
isolating and assessing TAG content within CMs and altering the timing at which blood is
collected, would make a mouse model more reliable for blood lipid assessments in response to
nutrient stimuli. However, the alterations in intestinal mRNA levels and decrease in intestinal
lipid stores in response to oral glucose exposure and consumption, respectively, suggest that
further investigation into the underlying mechanism(s) for these responses are needed. An
understanding of this regulation of intestinal lipid stores by oral nutrient exposure/consumption
will help identify novel therapeutic targets and provide novel dietary guidance for treating
hypertriglyceridemia.
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Table 5.1 Primers used for qPCR
Gene
18S rRNA
Pnpla2
Mttp
Cpt1a

Primer Sequences
F 5’-TTAGAGTGTTCAAAGCAGGCCCGA-3’
R 5’-TCTTGGCAAATGCTTTCGCTCTGG-3’
F: 5’-TGGAACCAAAGGACCTGATGACCA-3’
R: 5’-AGATGCTACCCGTCTGCTCTTTCA-3’
F: 5’-AGTGCAGTTCTCACAGTACCCGTT -3’
R: 5’-AGCATATCGTTCTGGTGGAAGGGA-3’
F: 5’-TGTGGTGTCCAAGTATCTGGCAGT-3’
R: 5’-AACACCATAGCCGTCATCAGCAAC-3’
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Figure 5.1 Oral linoleic acid exposure had no effect on postprandial plasma TAG levels
(A) Timeline for assessing the effect of oral linoleic acid exposure on plasma TAG levels. The
oral stimulus administered was either 2% linoleic acid with 0.3% xanthan gum, 0.3% xanthan
gum, or water. (B) Mice were fasted for 4 h prior to assessing plasma TAG levels in response to
a 200 µl oral olive oil gavage and oral exposure to 50 µl of linoleic acid, xanthan gum or water
(n = 11-14 mice/group, both the area under the curve (0-4 h) and differences between groups at
individual time points were assessed using a one-way ANOVA (not significant)).
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Figure 5.2 Oral linoleic acid had no effect on intestinal TAG secretion
(A) Timeline for assessing the effect of oral linoleic acid exposure on intestinal TAG secretion.
The oral stimulus administered was either 1% linoleic acid with 0.3% xanthan gum, 0.3%
xanthan gum, or water. (B) Mice were fasted for 4 h and administered tyloxapol 0.5 h prior to
assessing plasma TAG levels in response to a 200 µl oral olive oil gavage and oral exposure to
50 µl of linoleic acid, xanthan gum or water (n = 3-4 mice/group, both the area under the curve
(0-4 h) and differences between groups at individual time points were assessed using a one-way
ANOVA (not significant)).
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Figure 5.3 Oral glucose exposure had no effect on plasma TAG levels
(A) Timeline for assessing the effect of oral glucose exposure on plasma TAG levels. Either a 38%
glucose solution or water was administered as the oral stimulus. (B) Mice were fasted for 4 h
prior to administration of a 200 µl oral olive oil gavage, and oral exposure to 50 µl of glucose or
water occurred 4 h after the olive oil gavage. Plasma TAG levels were assessed prior to the oil
bolus as well as prior and in response to the oral exposure (n = 5 mice/group, both the area under
the curve (4-5 h) and differences between groups at individual time points were assessed using a
two-tailed t test (not significant)).
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Figure 5.4 Oral glucose consumption had no effect on intestinal TAG secretion
(A) Timeline for assessing the effect of glucose consumption on intestinal TAG secretion. Either
a 38% glucose solution or water was administered. (B) Mice were fasted for 4 h prior to
administration of a 200 µl oral olive oil gavage, and tyloxapol was administered 4 h after the oil
gavage followed by a 200 µl oral glucose or water bolus. Plasma TAG levels were assessed prior
to the oil bolus as well as prior to and in response to the oral glucose or water bolus (n = 3
mice/group, both the area under the curve (0-1 h post glucose/water) and differences between
groups at individual time points were assessed using a two-tailed t test (not significant)).
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Figure 5.5 Oral glucose consumption, but not exposure, decreased intestinal neutral lipid content
Jejunal tissue samples were collected after oral glucose/water exposure or a bolus administered
5 h after a 200 µl oral olive oil gavage. Tissue neutral lipid content was assessed using Oil Red O
(ORO) staining. (A) Representative images of jejunal neutral lipid staining, with rankings
ranging from little to no lipid (1) to significant neutral lipid content (4). (B) Timeline for
assessing the effect of oral glucose exposure on intestinal neutral lipid content. Either a 38%
glucose solution or water was administered as the oral stimulus. (C) Rankings of jejunal neutral
lipid content in response to oral exposure to 50 µl of oral glucose or water (n = 7-8 mice/group,
Fisher’s exact test). (D) Timeline for assessing the effect of glucose consumption on intestinal
neutral lipid content. (E) Rankings of jejunal neutral lipid content in response to a 200 µl oral
glucose or water bolus (n = 9 mice/group, Fisher’s exact test
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Figure 5.6 Oral glucose exposure increased mRNA levels of genes involved in lipid mobilization
and metabolism
(A) Timeline for assessing the effect of oral glucose exposure on intestinal mRNA levels. (B)
mRNA levels of genes involved in lipolysis (Pnpla2), chylomicron synthesis (Mttp), and fatty
acid oxidation (Cpt1a) in jejunal mucosa collected 10 min after oral exposure to 50 µl of glucose
or water and 5 h 10 min after a 200 µl oral olive oil gavage (n = 7-8 mice/group, * p < 0.05 (twotailed t test))
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CHAPTER 6.

6.1

SUMMARY AND FUTURE DIRECTIONS

Summary
Dietary fat is an energy dense nutrient that also provides essential fatty acids and aids in

the absorption of fat soluble vitamins. The process of dietary fat absorption regulates the amount
and rate at which dietary fat enters circulation, and can therefore contribute to diseases such as
obesity, diabetes and cardiovascular disease when it becomes dysregulated. Triacylglycerol
(TAG), the major form of dietary fat, is efficiently absorbed (>95%) even when high amounts of
fat are consumed. The digestive products of dietary fat are taken up by enterocytes, the
absorptive cells of the small intestine, and rapidly re-synthesized into TAG. This re-synthesized
TAG can either be packed onto chylomicrons (CMs) and secreted into circulation for delivery to
peripheral tissues, or temporarily stored within cytoplasmic lipid droplets (CLDs). This
dissertation work investigates the regulation of enterocyte lipid stores and their contribution to
dietary fat absorption.
To identify potential proteins involved in regulating enterocyte CLD stores, we compared
proteins in the enterocyte CLD fraction from genetic models with alterations in intestinal TAG
synthesis. In response to an acute dietary fat challenge we identified differences in enterocyte
CLD-associated proteins in models with altered intestinal Dgat1 and Dgat2 levels, which is
consistent with the alterations in enterocyte CLD morphology in these models. The differentially
present proteins associated with lipid metabolism in particular have the potential to regulate
TAG storage within CLDs and its subsequent mobilization toward other cellular fates, including
secretion within CMs, which is also altered in these models.
To identify potential beneficial alterations in enterocyte CLD stores that positively impact
health, we compared enterocyte CLD morphology and proteins present in the enterocyte CLD
fraction from mice that are susceptible (WT) or resistant (Dgat1-/-) to diet-induced obesity (DIO).
We found that Dgat1-/- enterocytes contain a greater number of larger sized CLDs that have a
greater number of proteins associated with them compared to WT mice in response to chronic
high fat feeding. This included more proteins associated with the mitochondria and fatty acid
oxidation within enterocyte CLDs. However, the greater proportion of altered mitochondria in
Dgat1-/- compared to WT enterocytes in response to chronic high fat feeding suggests that these
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proteins may not be playing a functional role at the CLD surface. These findings have increased
knowledge about alterations in enterocyte CLD morphology and associated proteins in a DIOresistant model that may be contributing to their beneficial phenotype.
To determine if oral nutrient exposure and consumption are able to mobilize intestinal lipid
stores, we utilized multiple methods of assessment in human subjects as well as mouse models.
Glucose consumption was shown to mobilize lipid stored in the intestine from a previous meal in
both humans and mice. In the clinical study we also identified proteins present in duodenal
biopsies in response to the dietary challenge, 134 of which were present at relatively different
levels in response to glucose consumption compared to the water control. In mice we also
assessed but found no effects of oral glucose exposure on intestinal lipid stores, or of oral fatty
acid or glucose exposure or glucose consumption on plasma TAG levels. Since the plasma TAG
results are not consistent with previous findings in humans, we have concluded that mice can be
used as a model to assess the effects of oral nutrient exposure/consumption on intestinal lipid
stores using imaging methods, but not for assessing their effects on plasma TAG levels. This
work confirms and expands upon findings in previous clinical studies by identifying the specific
enterocyte lipid pools mobilized by glucose consumption. In addition, we have identified
proteins that are present in the duodenum in response to dietary fat and glucose consumption,
some of which are glucose regulated and have the potential to contribute to the observed glucose
stimulated lipid mobilization from the intestine.
Overall, this work identifies novel potential regulators of intestinal lipid storage and
mobilization. Further investigation into their contributions to dietary fat absorption will help to
provide novel dietary and therapeutic strategies for the management of obesity,
hypertriglyceridemia, and related metabolic diseases.

6.2

Future Directions
This dissertation work has identified several potential regulators of intestinal lipid storage

and mobilization. However, future studies are needed to validate these findings and further
investigate potential mechanisms through which the identified proteins and nutrient stimuli may
regulate dietary fat absorption.
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6.2.1 Localization and function of enterocyte CLD-associated proteins
Several proteins were found to be present at relatively different levels in the enterocyte
CLD-enriched fraction from mouse models with alterations in intestinal TAG storage and
mobilization. Those of particular interest are proteins that have the potential to play a functional
role at the CLD surface, or those whose localization to the CLD surface impacts intestinal lipid
storage and mobilization. We did not consistently identify the classical cytoplasmic lipases
(ATGL and it co-factor CGI-58, HSL, and MGL) in the enterocyte CLD fraction in mice or in
human duodenal biopsy samples, and it has also been shown that the activity of these lipases
does not quantitatively account for the hydrolysis of TAG from CLDs that occurs in the small
intestine [1-4]. Therefore it would be of interest to identify other potential lipases that contribute
to the hydrolysis and mobilization of TAG stored within enterocyte CLDs. One particular protein
family of interest are the carboxylesterase 2 enzymes, which were identified in both human
duodenal tissue (CES2) and mouse enterocyte CLD fractions (Ces2c, 2e and 2g). In addition,
these enzymes were present at relatively higher levels in the enterocyte CLD fraction from DIOresistant Dgat1-/- compared to WT, DIO mice. The recent finding that Ces2 exhibits TAG
hydrolase activity and plays a role in regulating liver lipid metabolism [5] provides further
support that these enzymes may play a role in intestinal TAG hydrolysis.
To determine if Ces2 enzymes play a role in TAG hydrolysis in the small intestine, we
could first conduct in vitro studies to determine if the Ces2 family members identified in the
current studies exhibit TAG hydrolase activity. If it is confirmed that one or more of these
enzymes does exhibit TAG hydrolase activity, their effects on intestinal lipid metabolism could
then be assessed in enteroids derived from mouse intestinal stem cells, which have recently been
shown to be a suitable model for assessing the role of intestinal proteins in the process of dietary
fat absorption [6]. If effects on enterocyte CLD morphology or CM-TAG secretion are observed
in response to overexpressing or knocking down these enzymes, the next step would be to
confirm these findings using a genetic mouse model; ideally either mice with intestine-specific
overexpression or an intestine-specific deficiency in the Ces2 family member of interest.
An additional question that would be important to address, in particular since Ces2
enzymes are known to localize to the ER [7], is whether or not these enzymes exhibits TAG
hydrolase activity at the CLD surface. First, it would be necessary to validate the localization of
Ces2 enzymes to the CLD surface, which can be done in mice using immunofluorescence
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microscopy once suitable antibodies are available. As an alternative, the localization of tagged
forms of Ces2 enzymes could be assessed in a cell model. However it is important to keep in
mind that overexpression of a protein can potentially result in abnormal protein localization.
In terms of assessing enzyme activity at the CLD surface, this has been done previously for
eicosanoid synthesis but involves a specialized method [8, 9]. Thus, additional work would likely
be needed to develop a method for detecting TAG hydrolysis activity directly at the CLD surface
in order to address this.
6.2.2 CLD-mitochondria interactions and mitochondrial function in enterocytes in response to
high fat feeding
Although we did not see differences in the percent of mitochondria in close association
with CLDs in enterocytes from chronically high fat fed Dgat1-/- compared to WT mice using
transmission electron microscopy (TEM), the function of potential interactions between these
organelles in enterocytes is unknown. In other cell types there is evidence that CLDmitochondria contact allows for efficient transfer of fatty acids to the mitochondria for oxidation
[10, 11]. To assess this further in enterocytes, we will first determine if these organelles are in
fact in direct contact with each other using electron tomography. This microscopy technique
involves the reconstruction of a tilt series of two-dimensional images to obtain three-dimensional
structural information about the sample [12]. Using this technique will allow for confirmation of
direct contact between mitochondria and CLDs. Based on the initial TEM analysis, we would
predict to observe direct CLD-mitochondria contact in enterocytes from both models.
To follow up on the altered mitochondrial morphology that was observed more frequently
in enterocytes from chronically high fat fed Dgat1-/- compared to WT mice, we could assess
mitochondrial function in these models. Although intestinal fatty acid oxidation is low in both
fed and fasted states [13, 14], increases in fatty acid gene and protein levels have been observed
in response to chronic high fat feeding in mice [15, 16], suggesting fatty acids may be a
relatively more important fuel source when their intake is high. In order to determine if there is
impaired mitochondrial function in chronically high fat fed Dgat1-/- compared to WT mice, we
could isolate mitochondria from enterocytes in these models and assess mitochondrial respiration
in the presence of fatty acyl-CoA using an extracellular flux analyzer. In addition, reactive
oxygen species (ROS) production, as an indicator of oxidative stress, could also be assessed in
intestinal tissue using 2’, 7’-dichlorofluorescein diacetate (H2DCFDA). This compound is an

193
indicator of ROS levels in cells because it yields a fluorescent compound when it becomes
oxidized. In addition, it would also be interesting to assess mitochondrial respiration and ROS
production in the small intestine of lean mice as an additional control in order to determine if
high fat feeding has an impact on enterocyte mitochondrial function.
6.2.3 Assessing the effects of additional nutrient and hormonal stimuli on intestinal lipid
mobilization
Together with our collaborators, we have established methods for the collection and
preservation of duodenal biopsy samples in response to a dietary challenge for subsequent TEM
and proteomic analyses. These methods can be used and adapted for assessing the effects of
other nutrient and even hormonal stimuli on intestinal lipid storage and mobilization. It would be
interesting to look at the effect of oral fat exposure on lipid stored in the intestine from a
previous meal. Both sham feeding [17] and the consumption of subsequent high fat meals [18]
have been shown to induce a peak in plasma CM-TAG levels that is derived from the previous
meal, however changes that occur within the small intestine in response to oral fat exposure have
not yet been assessed. Based on the blood lipid results, we would expect to see a decrease in
intestinal lipid stores and potentially increases in proteins involved in the mobilization and
secretion of this stored lipid. In addition, glucagon-like peptide 2 (GLP-2) has also been shown
to stimulate CM-TAG secretion [19], and would be another stimulus of interest to assess further
with these methods. Since it was reported that GLP-2 stimulates the release of a ‘pre-formed’
apoB pool, as opposed to promoting the synthesis of new CMs, it would interesting to see if lipid
is primarily mobilized from the CM secretory pathway within enterocytes, as opposed to from
CLDs.
6.2.4 Glucose-regulated proteins in the duodenum
The identification of differentially present proteins in human duodenal biopsies in response
to glucose compared to water consumption provided a list of potential glucose regulated proteins
in the small intestine. In addition, the ability of glucose consumption to mobilize lipid stored in
the intestine from a previous meal suggests that some of these potential glucose regulated
proteins may be involved in regulating glucose-stimulated lipid mobilization from the small
intestine. One particular protein of interest to follow up on is syntaxin-binding protein 5. This
protein was identified in the duodenum in response to water but not glucose consumption.
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Interestingly, syntaxin-binding protein 5 has been shown to be a negative regulator of insulin
secretion in pancreatic beta cells, and glucose has been shown to inhibit this protein and induce
its degradation in order to promote insulin secretion [20]. Since there is evidence that this protein
is glucose regulated in another cell type, it would be interesting to determine if it is regulated
similarly within enterocytes. In addition, whether or not this regulation impacts the mobilization
of intestinal lipid stores would be interesting to investigate further. Furthermore, it would also be
of interest to confirm that the differentially present proteins with known roles in lipid metabolism
identified in this study are in fact regulated by glucose.
These potential glucose regulated proteins were identified using a proteomic approach and
isolated from the entire duodenal tissue sample, so the first steps for further investigation would
be to confirm their presence, relative protein levels, and localization within the small intestine.
Since we showed that glucose mobilized intestinal lipid stores in both mice and humans, mice
could be used as a model for these assessments. Protein levels could be assessed in response to
the same dietary challenge (1 hour after oral glucose or water consumption and 6 hours after an
acute dietary fat load) via Western blot and protein localization could also be assessed within
mouse intestinal tissue using immunofluorescence microscopy. To further confirm that the
proteins of interest are glucose regulated, their protein levels and localization within the intestine
could be assessed in response to glucose compared to water consumption in the absence of a
dietary fat challenge.
Additional follow-up on a protein like syntaxin-binding protein 5 could be performed by
altering the expression of this gene in an enteroid model or by using a genetic mouse model, as
described in section 6.2.1. Assessing if intestinal lipid storage and secretion are altered in
response to dietary fat alone, as well as in response to glucose consumption several hours after a
dietary fat load in these models, would help to determine whether or not this protein plays a
crucial role in regulating dietary fat absorption. This type of approach would help to increase
knowledge about the molecular players involved in regulating glucose stimulated lipid
mobilization from the small intestine.
6.2.5 Unanswered questions about enterocyte CLDs
Although this dissertation work provides novel insight into potential regulators of
intestinal lipid storage, there are still several unanswered questions about CLDs in enterocytes. A
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long term goal of our studies is to determine to function(s) of CLDs within enterocytes and their
contribution to the process of dietary fat absorption. By investigating potential regulators of
intestinal lipid storage and mobilization, we have provided evidence that these lipid stores can
provide substrate for CM secretion. However we also know that TAG stored within CLDs can be
used for other cellular fates, including serving as a substrate for synthesis of other complex lipid
species (i.e. phospholipids), acting as signaling molecules, or being oxidized [21]. Therefore,
determining the relative proportion of TAG stored within CLDs that is used for particular fates
within the cell, as well as how this is impacted by dietary and hormonal factors, is of interest.
Another question that remains unanswered is what proportion of re-esterified TAG gets
packaged into CLDs prior to secretion within CMs. We tend to think of CLDs as a temporary
storage pool for lipid in response to consuming high amounts of dietary fat, which helps to
control the amount and rate at which TAG is secreted into circulation. However, it is not actually
known whether CLDs are only synthesized once a certain amount of lipid is present within
enterocytes. Although it may seem like an inefficient process, it is also possible that all reesterified TAG is initially packaged into CLDs and has to subsequently be hydrolyzed and reesterified at the ER membrane before being packed onto CMs for secretion. Furthermore, it is
still unknown how the composition of dietary fat impacts intestinal lipid storage and
mobilization. This is something that has been studied in terms of its effects on blood lipid levels,
however the effects it has on CLD morphology and metabolism have not yet been characterized.
Since we have confirmed in this work that oral glucose is a stimulus that can mobilize
intestinal lipid stores, this raises the questions of how and why intestinal lipid stores are
regulated by a nutrient other than fat. As there is also evidence that consumption of a subsequent
high fat meal [18] and oral fat exposure [17] can stimulate mobilization of lipid stored in the
intestine, it is possible that this is a general response to nutrient consumption that serves to
prepare the intestine to respond to the incoming nutrient load. This could be further investigated
by assessing and comparing the effects of additional nutritive and non-nutritive stimuli on lipid
stored in the intestine from a previous meal. In addition, whether this effect is regulated through
neural and/or local mechanisms within the intestine is something that requires further
investigation.
Overall, it is clear that additional work is needed to understand the function and
regulation of intestinal lipid storage. Being able to gain further insight into the role of CLDs in
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enterocytes and the regulation of intestinal lipid mobilization will help provide novel dietary and
therapeutic strategies for the treatment of hypertriglyceridemia and related metabolic diseases.
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